Observational research in childhood respiratory diseases by Sarna, Mohinder
 
1 
 
 
Observational Research in Childhood Respiratory Diseases 
  
 
 
 
 
Mohinder Sarna 
BSc, MAppEpid. 
 
A Thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2019 
School of Medicine 
 
 
 
 
  
 
2 
ABSTRACT 
Acute respiratory infections (ARIs) are common during the first two years of life, when 
infants and young children experience six to eight ARIs annually. In this age group, 
ARIs are the most commonly managed problems in general practice. Between 3 and 
6% of infants are hospitalised in their first year of life with a severe ARI illness. 
Information about the epidemiology of ARI in children is based on historic community-
based studies, cohorts of hospitalised patients, emergency department or primary 
healthcare presentations, and more recently from birth cohort studies principally 
involving children at high-risk of asthma. However, these studies do not completely 
identify the burden of mild-to-moderate ARIs in the community. 
 
Recent community-based cohort studies have used sensitive polymerase chain 
reaction (PCR) assays. However, they have had one or more methodological 
limitations, including subject selection, length of study, non-representative sample 
populations, variable sampling frequency, and the lack of a control population. 
Furthermore, frequent detection of respiratory viruses in asymptomatic individuals 
questions their clinical and public health significance. Studies reporting the causal 
effect of individual respiratory viruses in ARI are needed to help address this question. 
 
The Observational Research in Childhood Infectious Diseases (ORChID) study was a 
four year prospective, community-based, longitudinal birth cohort study of ARIs in 158 
healthy children from birth to two years of age. ORChID sought to minimise some of 
the methodological limitations of previous studies. Parents completed a daily symptom 
diary and collected weekly nasal swabs, which were tested against 17 respiratory 
viruses. Healthcare-seeking behaviour was recorded in a separate ‘burden’ diary. 
I found that young children experienced 0.56 (95% confidence interval (CI): 0.54, 0.59) 
ARIs per child-month. This equated to almost five cumulative months of respiratory 
symptoms during the first two years. Forty-eight percent of ARIs where a burden diary 
was completed initiated a visit to a family doctor. ARIs were associated with increasing 
age, the winter season, and childcare attendance. 
Studies examining respiratory viruses in neonates have largely been from neonatal 
units or neonates presenting to hospital with respiratory symptoms. I was able to show 
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that respiratory virus infections were common (0.25 episodes per neonatal period, 
95% CI: 0.18, 0.34), with diverse human rhinovirus (HRV) genotypes dominating 
(21/29; 72% of neonates with positive swabs). Almost 50% of respiratory virus 
infections in this period were asymptomatic. This subclinical shedding of all respiratory 
virus types complicates estimates of the true community burden of viral ARI in infants 
and young children. 
To explore this further, I investigated the relative contribution of individual respiratory 
viruses to ARIs by calculating the virus-specific attributable fractions in exposed (AFE) 
children of ARIs and lower respiratory tract infections (LRTIs). The overall incidence 
of virus infections was 978 (95% CI: 930, 1029) per 100 child-years in the first two 
years of life. Viruses were detected in 75% of ARI episodes, while 23% of weekly 
swabs were positive for viruses during asymptomatic periods. RNA viruses, including 
HRV, influenza, parainfluenza, respiratory syncytial virus (RSV), human 
metapneumovirus (HMPV), and human coronaviruses NL63 and OC43 were 
associated with a significantly increased risk of ARI symptoms. Support for causality 
was strongest for RSV (AFE 68%, 95% CI: 45%, 82%), and HMPV (AFE 69%, 95% 
CI: 43%, 83%) in children with LRTIs. In contrast, amongst the DNA viruses tested, 
only adenoviruses (AFE 29%, 95% CI; 12%, 42%) were significantly associated with 
an increased risk of ARI symptoms. Of HRV species, only HRV-C had a significant 
AFE result for LRTIs (AFE 22% (95% CI: 5%, 22%). 
I went on to examine the timing of detection for each of the 17 respiratory viruses 
tested for in the ORChID infant cohort. Determining timing of first virus detection 
episodes (fVDEs) for different respiratory viruses in infants and young children 
identifies risk periods and informs preventive interventions, including vaccination. The 
median age for first HRV infections was 2.9 months (25th–75th centiles: 1.6, 5.1), while 
for all other respiratory viruses combined the median age was >13.9 months. Overall 
52% of first HRV detections were symptomatic, compared with 57-83% with the other 
first virus detections. Thus, infants and young children do not always experience 
respiratory symptoms with their first viral detection episode, and for some viruses, 
such as RSV, these commonly occur when maternal vaccines may no longer offer 
protection. 
Collectively, these findings highlight the important community-managed disease 
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burden caused by respiratory viruses in early childhood. They also provide a wealth of 
information about the relationship between respiratory virus infection and symptoms of 
respiratory illness. The ORChID study uses modern molecular-based techniques over 
four respiratory seasons to address questions about respiratory virus acquisition and 
infection. 
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Definitions 
An acute respiratory episode (ARI) episode was defined by the presence of 
respiratory symptoms and/or signs of the upper and/or lower respiratory tracts listed 
below. 
Upper respiratory tract infection (URTI): parent-reported runny nose/nasal 
congestion, dry cough, or doctor-diagnosed acute otitis media (AOM). 
Lower respiratory tract infection (LRTI): parent-reported rattly breathing, moist 
cough, shortness of breath, wheeze, or doctor-diagnosed pneumonia. 
If wheeze was a component of a child’s LRTI, it was sub-categorised as a ‘wheezy 
episode’.  
ARIs were sub-categorised hierarchically as either a LRTI or URTI, respectively. 
Fever as a symptom was accepted if the parent ticked the fever symptom box or if 
they recorded axillary temperatures >37.5°C. For the purposes of demarcating ARIs, 
a new episode was considered to have commenced if there were ≥3 symptom-free 
days since the last day with symptoms. Daily symptoms were recorded until the child’s 
second birthday. 
New virus detection episode (VDE): when a new virus (different virus or new 
species/subtype of the same genus or species respectively) was detected in a swab 
by PCR testing, or the same virus was detected after at least two negative intervening 
swabs, or the same virus was detected at least 30 days from the last positive swab. 
Symptomatic new VDE: when respiratory symptoms were reported within seven days 
either side of detecting a new virus detection episode in the weekly nasal swab. 
First viral detection episode (fVDE): when a respiratory virus not detected 
previously was first found in a child’s weekly nasal swab specimen. 
Symptomatic fVDE: when respiratory symptoms were reported within seven days 
either side of first detecting the virus of interest in the weekly nasal swab. 
Symptomatic fVDEs were sub-categorized hierarchically as LRTI or URTI episodes 
respectively. 
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Thesis Introduction, Aims, and Structure 
Introduction to the Thesis Topic 
Acute respiratory infections (ARIs) are common in young children during the first two 
years of life, when infants and young children experience six to eight ARIs each year, 
and are the most frequently managed problems in general practice. Complications are 
common, and between 3 and 6% of young children are hospitalised with more severe 
disease. Much of what is known about the epidemiology of ARIs in young children is 
based on historic community-based studies, cohort studies of hospitalised patients, 
emergency department (ED) or primary healthcare presentations, and more recently 
from birth cohort studies that have involved mainly children with one or both parents 
being atopic and thus considered to be at high-risk of asthma. Findings from these 
studies may not identify the true community burden of mild-to-moderate disease in 
otherwise healthy children in the contemporary, modern community. 
The discovery of novel viruses and the ability to detect them and other known viruses 
using sensitive molecular-based methods has led the way for several cohort studies 
being conducted using polymerase chain reaction (PCR) assay testing of specimens. 
However, these cohort studies have had several limitations, including subject 
selection, length of study, non-representative sample populations, variable sampling 
frequency, and the lack of a control population. Furthermore, with the detection of 
respiratory viruses in both asymptomatic individuals as well as children with ARI 
symptoms, the clinical and public health significance of respiratory viruses is often 
uncertain, as detection may represent persistent shedding from a recent illness or 
either a nascent or genuine subclinical infection. Studies reporting the causal effect of 
individual respiratory viruses in ARI are needed to help address this question. 
Research Aims 
The broad aims of this research are to: 
  Describe the community-based epidemiology of respiratory viruses in the first 
two years of life, including the incidence, symptoms, management, and 
associated risk factors of ARIs; 
  Determine the relative contributions of individual respiratory viruses to ARI in 
the first two years of life; and 
  Determine the pathogenicity of newly discovered respiratory agents, including 
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the new HRV-C species, by comparing the timing and duration of detection in 
respiratory specimens with the presence of symptoms.  
 
The specific hypotheses to be tested include that:  
 Collectively, HRVs, and the six recently described respiratory viruses from four 
virus families (HMPV, HCoV-NL63, HCoV-HKU1, HBoV-1, HPyV-WU, HPyV-
KI) are more frequently detected during ARIs in the first two years of life than 
the long-established viruses (RSV, PIVs, INFV, HAdVs) identified from hospital-
based studies. 
 Respiratory pathogens are more likely to be associated with symptoms when 
first acquired. 
 Established respiratory viruses are individually more likely to be associated with 
symptoms than the recently described novel DNA viruses HPyV and HBoV-1. 
 Most respiratory pathogen shedding is transient, ceasing within 2-4 weeks of 
initial detection. 
 HRV-C is more likely to be associated with lower respiratory tract infections 
(LRTIs) than other HRV species. 
The Observational Research in Childhood Infectious Diseases (ORChID) study was a 
four year prospective, community-based longitudinal, dynamic birth cohort study of 
ARI episodes in children from birth to two years of age. ORChID was designed to 
address some of the methodological limitations of previous studies. It employed 
prospective serial sampling, sensitive molecular testing, and intensive clinical follow-
up in a community-based healthy infant birth cohort, all of whom were born at term. 
Data were collected on respiratory symptoms daily, and healthcare seeking behavior. 
Weekly nasal swabs were tested against 17 novel and established respiratory viruses.  
Thesis Structure 
This thesis is divided into seven chapters. 
Chapter 1 provides a literature review of the impact of ARIs, risk factors associated 
with ARIs, the aetiology of common respiratory viruses, and a summary of the findings 
of community-based studies to date. 
Chapter 2 outlines the basic methods employed in the study. 
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Chapters 3–6 report the findings of research studies based around specific questions. 
Each of these chapters presents a published manuscript. 
Using data from the ORChID Study, in Chapter 3 I initially collated symptom data to 
report on the burden of community-based ARIs in the first two years of life. I 
demonstrate that ARIs are a common cause of early childhood morbidity in the 
community, where they are almost exclusively managed. While mainly self-limiting and 
of a viral nature, antibiotics are still commonly prescribed for ARIs with almost half the 
children receiving these agents after visiting their family doctor. The most common 
reason for prescribing antibiotics was for acute otitis media (AOM). 
Combining symptom and nasal swab testing results, in Chapter 4 I first explored 
respiratory virus acquisition in neonates, and explored possible risk factors for ARI 
during this period. I found that respiratory viruses are detected frequently during 
infancy and are without symptoms in 45% of instances (13 of 29 neonates). Subclinical 
shedding by all respiratory virus types complicates estimates of the true community 
burden of viral ARI in infants. 
I then investigated the relative contribution of individual respiratory viruses to ARIs by 
calculating the virus-specific attributable risk of ARIs and LRTIs in Chapter 5 over the 
two year study period. Asymptomatic detection of both RNA and DNA respiratory 
viruses occur commonly. The virus-specific attributable risk of ARIs and LRTIs, a 
neglected key metric for interpreting molecular diagnostic tests in ambulatory clinical 
settings, provides quantitative estimates of the relative proportion of virus-associated 
ARIs, including the more serious LRTIs, in the community, yielding important insights 
for prioritising public health interventions. 
In Chapter 6 I looked at the timing of first infections of respiratory viruses, and the 
proportions that were symptomatic, in further detail. I asked whether specific factors 
were associated with symptomatic first infections. This analysis identified age, season 
and the number of children in the household as potential risk factors to symptomatic 
infection, although these varied by virus type. 
In Chapter 7, I summarise the thesis findings as a whole, discuss the implications of 
the findings, and how they will inform future research and public health policy.
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Chapter 1 – Introduction 
The impact of viral acute respiratory infections 
Acute respiratory infections (ARIs) are the most commonly experienced illnesses 
throughout life (1). Viruses are the most frequent causes of ARIs, either on their own 
or in synergy with bacterial pathogens. Previous research has estimated the childhood 
incidence of community-managed ARIs in Australia ranges from 3.2–5.8 cases of ARIs 
per child-year (2-4), with the highest incidence rates reported in the first two years of 
life (5, 6). While most ARIs result in mild, self-limited symptoms, complications such 
as acute otitis media (AOM) and sinusitis are common, especially in those younger 
than two years of age. Consequently, in countries such as the United Kingdom, ARIs 
account for 59% of general practitioner (GP) consultations in this age group (7). 
Furthermore, it is estimated that 3–6% of children younger than one year of age are 
hospitalised with lower respiratory infections (LRTI), including bronchiolitis, croup, 
pneumonia, or secondary bacterial pneumonia (7, 8), making up to 25% of all 
hospitalisations in this age group. These infections are a considerable burden on the 
health system (9). The majority of cases of ARIs are managed solely in the community 
(6) and these impose considerable costs upon families and society (10, 11). 
In Australia, the disease burden in Aboriginal and/or Torres Strait Islander children is 
also greater than in non-Indigenous Australians. Hospitalisation rates of acute lower 
respiratory infection amongst Aboriginal and/or Torres Strait Islander children are 
nearly six times that of non-Indigenous children (12). Antecedent respiratory viral 
infection has been shown to increase nasopharyngeal bacterial density and 
progression to AOM with perforation in Indigenous children (13), who have some of 
the highest rates of AOM with perforation globally. 
Early onset of ARIs accompanied by wheezing have been associated with subsequent 
recurrent wheezing illnesses in infants and young children, and a diagnosis of asthma 
later in childhood. Indeed, ARIs are probably the most frequent causes of asthma 
exacerbations in older children and adults. When ARIs involve the lower respiratory 
tract and are severe in infants and young children, they can be associated with 
impaired lung function, non-smoking-related chronic obstructive lung disease (COPD) 
in adulthood, and when severe, bronchiectasis (15-20). 
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Available information on the epidemiology of viral ARIs in children has largely been 
based on cohorts of hospitalised patients (21, 22), findings reflecting the most severe 
infections. These illnesses are not representative of mild-to-moderate disease 
managed in the community, and can under-estimate the underlying true community 
disease burden (23-25), an important consideration in planning future preventive 
strategies. 
Respiratory illnesses are also the most commonly managed problems in general 
practice in Australia. An early epidemiological report on the nature of primary care 
consultations in general practice in Australia showed that nearly 50% of consultations 
in children younger than five years of age were for ARIs (26). A recent analysis of 
Australian GP activity described 26 of 100 encounters in this age group for common 
respiratory tract infections: upper respiratory tract infection (URTI), 
bronchitis/bronchiolitis, tonsillitis, and pneumonia (27). Others have shown that in this 
age group almost half of ARI episodes resulted in a medical consultation (10, 28) and 
their management had considerable impact upon healthcare services (29). 
Extrapolation of Australian data published in a Bettering the Evaluation And Care of 
Health (BEACH) survey suggest that 1.7 per 100 encounters in Australians of all ages 
attending primary care were for URTI alone and 6.2 encounters for cough (30). 
However, there are few published reports that provide detailed and up-to-date data 
regarding the rate and impact of respiratory events in the community, beyond the 
scope of those managed by GPs, particularly in young children. 
Studies estimating the impact of respiratory illness have largely focused on direct 
hospitalisation and in-patient costs (31-34) or on evaluating the cost-effectiveness of 
introducing a vaccine (35, 36). They also vary in their method of analysis, including 
which cost drivers are used, making comparisons difficult. In general, the inclusion of 
societal and indirect costs such as productivity losses from lost work time caring for a 
sick child increases the overall cost of ARIs (10, 35, 37, 38). Children are also active 
transmitters of respiratory viruses to other family members (39-42). Palmer et al. (41) 
showed that employees with at least one child with an influenza-like illness (ILI) missed 
more days at work due to illness in another household member than employees 
without a child. A more recent study showed that parent work absenteeism was higher 
for parents with children in the 0 to 3 year age group compared to those with older 
children (43). 
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Risk factors for ARIs 
Several risk factors associated with the development of ARIs have been identified by 
observational studies of natural infection, challenge inoculations in human volunteers, 
and in vitro experimental models.  
Numerous studies have reported high rates of illness in children younger than five 
years of age. In addition to being active transmitters of infectious agents in households 
(39), children attending childcare are at higher risk of experiencing ARIs (44) and AOM 
(45). De Hoog et al. (45) also found that children who enter childcare in the first year 
of life have URTIs and AOM at an earlier age, leading to higher use of healthcare 
resources compared to non-attendees. However, an eight year study examining short- 
and long-term risk of infections as a function of group childcare attendance observed 
that although participation in large group childcare before 2.5 years of age was 
associated with increased infections at that time, it appeared to protect against 
infections during the elementary school years (46). Family household size and 
composition have also been identified as risk factors. Members of larger families (42), 
and children in families where younger children have older siblings (47), are at greater 
risk of developing an ARI.  
Examination of pre- and post-natal factors has identified preterm birth on its own or in 
combination with other factors to be a significant risk factor for more severe disease 
from several viruses (48-50). This is presumably from a combination of reduced levels 
of protective maternal antibodies and small lower airway diameters that are easily 
obstructed. ARIs have also been reported to be more severe in children with 
underlying complex chronic comorbidities, or immunosuppression (49, 51, 52). The 
risk of developing severe disease from respiratory syncytial virus (RSV) infection was 
higher in preterm infants with or without chronic neonatal lung disease, congenital 
heart disease, immunodeficiency, chromosomal, neuromuscular or other underlying 
chronic disorders (53). The study by Simoes (48) also identified that for up to half of 
hospitalised patients, severe LRTI from RSV infection was associated with being male, 
being aged younger than six months, being born early in the RSV season, attending 
childcare, exposure to household crowding and older siblings, absence of breast‐
feeding, tobacco smoke exposure (48), and race/ethnicity (54). Race/ethnicity on its 
own has been shown to be an independent risk factor in Indigenous populations in 
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several countries (54-56). Being born in the six months before the annual respiratory 
virus season has also been identified as a risk factor in RSV and human 
metapneumovirus (HMPV) infections in other studies (49, 54). 
Childhood wasting remains the leading risk factor for lower respiratory infection 
mortality in children younger than five years in underprivileged populations worldwide, 
estimated to be responsible for 61.4% of lower respiratory infection deaths in 2016 
(95% UI: 45.7, 69.6) (57). The higher burden of disease in these populations is likely 
due to a combination of factors, including malnutrition and overcrowding. 
Exposure to environmental tobacco smoke (ETS) is a well-recognised risk factor for 
both acute and chronic respiratory illness. Maternal smoking and ETS exposure 
influence lung development and are associated with both URTI and LRTI, wheezing, 
and asthma (58). There is evidence linking the effects of ETS exposure to impaired 
early-life immune function, resulting in an imbalance in Th1 and Th2 responses, which 
may increase susceptibility to allergic diseases and childhood ARIs (58). Exposure to 
ETS is also associated with more severe respiratory disease. ETS has been found to 
increase the risk of severe RSV disease as measured by hospitalisation and hypoxia 
in both infants and children (aOR 2.2, 3.8), and a 20% increased need for ICU 
admission and 12% increased risk of intubation in children with influenza compared to 
children without ETS exposure (58). 
The effect of breastfeeding on mortality and morbidity from respiratory infections was 
assessed in a systematic review published by the World Health Organization (59). 
Breastfeeding reduced the risk of hospitalisation for respiratory infection by 57% 
[pooled relative risk (RR): 0.43 (95% CI: 0.33, 0.55)]. Studies that compared breastfed 
with non-breastfed children reported the highest protective effect [pooled RR: 0.33 
(95% CI: 0.24; 0.46)] against hospitalisation for respiratory infection. Mortality from 
LRTIs was also reduced among breastfed children [pooled RR: 0.30 (95% CI: 0.16; 
0.56)]. Furthermore, breastfeeding also reduced the prevalence or incidence of LRTIs 
[pooled RR: 0.68 (95% CI: 0.60; 0.77)] (59).  
Importantly, this systematic review examined data from both low and high income 
countries. These results were robust, observed in high and low-income countries and 
across different respiratory infection-related outcomes.  
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Aetiology of respiratory viruses 
Large epidemiological studies in the 1950s and 1960s demonstrated the importance 
of viruses in ARIs, despite employing relatively insensitive classical cell-based 
techniques available for viral detection at the time (60, 61). Historically, known 
respiratory viruses in childhood have included RSV, influenza viruses (INFV), 
parainfluenza viruses (PIV), human coronaviruses (HCoV) OC43 and 229E, 
adenoviruses (HAdV), and HRV-A and B species. 
In the last two decades, several novel human respiratory viruses have been identified 
using either modern molecular techniques or improved culture methodologies. These 
viruses are now detected in routine diagnostic or research specimens using sensitive 
nucleic acid amplification tests (NAAT), such as PCR assays. These include HMPV 
(62), novel HCoVs NL63 and HKU1 (63, 64), human bocavirus-1 (HBoV-1) (65), and 
newly discovered human polyomavirus species (HPyV) (66, 67). A new species of 
HRV (HRV-C) has also been discovered, previously not detected as this new clade 
had been non-cultivable using traditional cell-culture techniques (68).  
While there are other viruses responsible for respiratory symptoms in children, I have 
focused here on the respiratory viruses commonly associated with ARIs, and were 
therefore selected for study in the Observational Research in Childhood Infectious 
Diseases (ORChID) study cohort. Questions remain over their relative importance in 
disease managed within the community, and for some even their role as respiratory 
pathogens remains controversial. 
RNA viruses 
Respiratory Syncytial Virus (RSV) 
RSV is an enveloped, non-segmented, negative strand RNA virus of the family 
Paramyxoviridae with two antigenic subtypes, A and B. RSV is well-recognised as an 
important viral respiratory pathogen in infancy and early childhood. It is the most 
frequent cause of acute LRTI in this age group (69), and the most common reason for 
infants to be hospitalised in the first year of life (70, 71).Globally in 2015, 33.1 million 
(95% UI: 21.6, 50.3) episodes of RSV-LRTI (28% of all LRTI) resulted in approximately 
3.2 million (95% UI: 2.7, 3.8) hospital admissions, and 59, 600 (95% UI: 48,000, 
74,500) in-hospital deaths in children aged younger than five years (72). The most 
recent estimates from 2016 place RSV as a leading contributor of LRTI deaths in this 
 
32 
age group (57), notwithstanding deaths from bacterial pneumonia may be 
underestimated given the insensitivity of blood cultures. Estimates of RSV 
hospitalisation rates for children younger than five years of age in Australia have used 
a variety of methods and have ranged from 2.2 (73) to 4.9 (31) per 1000 child-years, 
with an average annual cost (calculated between 2001 and 2010) of more than AUD$9 
million in New South Wales alone (31).  
Infection with RSV occurs early in life and it is a generally held belief that between 
50% and 70% of infants are infected in the season they are first exposed to RSV (74). 
In the seminal Houston Family Study, 97% of children had serological evidence of 
infection by the end of their second season, 40% of them developed signs of LRTI 
(wheezing or croup), and 2–3% of these presented with severe symptoms and 
required hospitalisation (74). However, studies from Asia, Europe, and Latin America 
have observed lower RSV seroprevalence rates of 36–70% by age two years (75-78), 
while in Kenya a birth cohort project similar in design to the Houston study found 73% 
had RSV by two years of age (79).  
RSV typically has a winter seasonal peak in temperate climates, but seasonality differs 
between temperate and tropical climates. In tropical climates, a seasonal peak is less 
well-defined (55, 80) and may even be bimodal (81). In subtropical climates, such as 
South-East Queensland, the peak is in mid-to-late autumn (March-April), tapering in 
late winter (June-August) (82). Incidence can be influenced by the severity of the 
annual epidemic, which varies from year to year, and opportunity for individual 
exposure, such as older siblings and childcare attendance (83).  
Well-recognised risk factors for severe LRTI with RSV infection have been mentioned 
previously (see page 29/30 for further details), and include being born preterm, 
underlying chronic cardiopulmonary disorders, trisomy 21, and being infected in the 
first six weeks of life. 
Nevertheless, most infants hospitalised with RSV infection are otherwise healthy and 
were born at term. It is thought that hospitalised infants have more severe disease 
because they have pre-existing smaller airways, immature immune systems, and/or 
lack protective maternal antibodies (84, 85). In a two year prospective study examining 
the viral aetiology of acute wheezing illnesses in hospitalised children in Finland, RSV 
was more prevalent in infants whereas picornaviruses dominated in older children 
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(86), presumably because as otherwise healthy infants become older, their airways 
grow, immune systems mature, and the symptoms of RSV disease lessen (74, 79). 
Findings from the Dutch WHISTLER birth cohort study showed decreased lung 
function at birth predisposed to severe RSV disease, and to post-RSV wheezing in 
term infants (84). RSV infection in young children is also more likely to be associated 
with respiratory symptoms (22) than asymptomatic detection. 
Monoclonal antibodies such as palivizumab are currently offered to high-risk infants. 
Long-acting monoclonal antibodies and candidate antenatal vaccines undergoing 
trials in pregnant women to reduce the risk of RSV infection in young infants are also 
currently underway (87). A successful vaccine would go some way to determine 
whether RSV has an aetiological role in asthma. 
Influenza virus (INFV) 
INFVs are negative sense, enveloped, single-stranded, segmented RNA viruses of the 
family Orthomyxoviridae. Subtypes A, B, and C are known to infect humans. INFVs 
undergo frequent antigenic mutations that contribute to variability from year-to-year. 
INFV has a sharp seasonal pattern in temperate climates. Data from the Global 
Burden of Disease Study shows globally, influenza was the second most common 
aetiology among LRTI episodes (39.1 million episodes, 95% UI: 30.5, 48.4). In children 
under five years of age, the incidence of seasonal influenza was estimated to be 9.1 
LRTIs per 1000 people (95% UI: 5.4, 14.8). 
In Australia, influenza hospitalisation rates are highest in children aged 0-5 months 
(152 per 100,000 in 2013), followed by children 6-23 months of age (98 per 100,000 
in 2013) (14).  
Children have the highest attack rates of influenza. In otherwise healthy children, 
influenza is typically a mild to moderate illness and, in most children, resolves without 
complications (88). Although the vast majority of children are treated as outpatients 
(outpatient visits are 10–250 times more common than hospitalisations (88)), infants 
can experience a more severe clinical course and are frequently admitted to hospital 
for INFV-associated illnesses. The highest hospitalisation rates for seasonal INFV 
infections are in the first year of life (71, 89). 
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Influenza infections can be complicated by secondary infections, which add 
considerably to the burden of influenza. There is some evidence for the role of INFV 
in facilitating bacterial transmission and disease (90). Clinically, AOM is the most 
frequent INFV-associated complication (91). Another significant, though less common, 
complication of influenza is pneumonia (92). Such secondary infections are less 
frequent where protein-polysaccharide conjugate pneumococcal and Haemophilus 
influenzae type b vaccines are routinely administered to children (93). Influenza-
related clinical deterioration is more likely in children with asthma (94). 
Influenza infection in children has consequences beyond direct medical outcomes. 
Children shed influenza virus longer and in larger amounts than adults and thus play 
a major role in the transmission of influenza in families and society. Influenza also 
translates into a societal burden evident as a child’s absenteeism from childcare or 
school, and parental work loss because of influenza in their children (95, 96). In a 
prospective study in Finland, the frequency and duration of parental work loss because 
of child influenza were highest among children younger than three years of age, 
among whom the mean duration of parental absenteeism in families in which a parent 
had to stay at home was 3.2 days (95). 
Asymptomatic detection of INFV is not uncommon. Estimates of the asymptomatic 
fraction have ranged from 20–50% (97-99) and in a 2015 meta-analysis of 4–28% 
(100). Two studies have reported influenza viral RNA shedding in asymptomatic 
persons to be age and symptom related. In a household transmission study of INFV 
in Nicaragua, children younger than 6 years of age had a longer duration of pre-
symptomatic INFV shedding than adults (101).The duration of post-symptomatic INFV 
shedding was longest in children 0–5 years old, followed by children 6–15 years of 
age, and then adults. In a community-based study in Hong Kong where healthy 
household contacts of symptomatic persons with INFV were followed up, viral RNA 
shedding occurred in pauci-symptomatic and asymptomatic cases, but was shorter 
and declined more rapidly than observed for symptomatic cases (102). 
For children aged six months to <5years of age, influenza vaccination in Australia is 
recommended, but currently only funded as part of the National Immunisation Program 
for all Indigenous children (14), (103). 
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Parainfluenza virus (PIV) 
PIVs are single-stranded, negative sense, enveloped RNA viruses of the 
Paramyxoviridae family containing four distinct antigenic types, PIV 1–4. PIVs are a 
common cause of ARIs in children, with clinical manifestations ranging from afebrile 
URTIs to severe LRTI symptoms (104). The most characteristic and clinically 
important syndrome associated with PIV-1 and PIV-2 is croup 
(laryngotracheobronchitis). 
Morbidity data from prospective studies conducted in the latter half of the twentieth 
century in diverse populations of different ages and the types of illness surveyed (105-
108) show the number of cases of croup and LRTI increase dramatically from the age 
of four months to six years. One study in the US found that PIVs accounted for 74% 
of isolates in cases of croup presenting to a paediatric practice over an 11 year period 
(109). The use of PCR detection in samples from children in the household and 
childcare settings (3, 110) has contributed to our understanding of PIV epidemiology 
by documenting the presence of prolonged shedding (up to 35 days), multiple 
infections and re-infections, and asymptomatic disease. PIVs have been studied 
specifically in children with asthma (111) and bronchiolitis (112). Data from the New 
Vaccine Surveillance Network show that 7% of all hospitalisations for fever and/or ARI 
in children younger than 5-years of age in the United States can be attributed to PIV 
(113). Half of these resulted from PIV-3 infection, with most of the remainder caused 
by PIV-1. 
Human rhinoviruses (HRV) 
HRV are non-enveloped, single, positive-stranded RNA viruses within the family 
Picornaviridae containing three species (A, B, C). HRVs are the most common cause 
of ARIs (114) and the most frequently detected of all respiratory viruses in all ages. 
HRV infections are associated with a wide range of clinical presentations, both URTIs 
(the ‘common cold’, AOM, rhinosinusitis) and LRTIs (2, 69, 115). HRV infections have 
been linked to bronchitis, bronchiolitis in infants, and childhood pneumonia, as well as 
to acute exacerbations of more chronic pulmonary disorders in older children and 
adults, such as asthma and COPD (116). 
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HRVs exhibit enormous diversity, with currently about 160 recognised subtypes. A 
large number of distinct types circulate each year with little cross-immunity, and while 
some predominate in a given season, they are replaced by others in subsequent years 
(117). HRVs are frequently transmitted from children to other family members and 
multiple virus types have been shown to circulate simultaneously in families (39) and 
in childcare (118). Cross-sectional PCR detection rate data do not comprehensively 
represent HRV circulation patterns because sequential infections by different strains 
occur and may appear as unbroken symptomatic episodes during a single observation 
period (117). 
HRVs are second only to RSV for being detected in infants hospitalised with 
bronchiolitis. In a three year prospective study, Calvo and colleagues investigated the 
frequency of 16 respiratory viruses in 318 children hospitalised with bronchiolitis (69). 
RSV was found in 61% of cases of bronchiolitis and HRV in 17%. High-risk birth cohort 
studies have identified HRV, ahead of RSV and INFVs as the major upper and lower 
respiratory pathogens in the first year of life (2, 120, 121). For severe respiratory 
infections requiring hospitalisation, RSV dominates in infants and HRV in children 
older than 12 months of age (122). 
Studies in hospitalised patients and atopic cohorts suggest HRV-associated wheeze 
in early childhood results in an increased risk for the later development of asthma, 
especially if already sensitised to aeroallergens (17, 123, 124). Children hospitalised 
for HRV-positive bronchiolitis used long-term asthma controller medication more often 
than those hospitalised for HRV-negative bronchiolitis during the first year after 
hospitalisation. HRV-associated wheezing illness was also associated with more 
courses of systemic corticosteroids during follow-up (125). 
Results in healthy cohorts are scarcer, but one study on a healthy unselected birth 
cohort has shown that HRV and other viruses were associated with lower respiratory 
symptoms during infancy, as well as a high pre-symptomatic respiratory system 
resistance. Lung function was measured shortly after birth and before two months of 
age in 140 healthy infants. HRV presence during infancy was not associated with 
childhood wheezing, but wheeze during a HRV episode was an indicator of children 
at high risk for ongoing childhood wheeze, partly because of reduced neonatal lung 
function and airway compliance leading to airflow limitation (126). 
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The clinical significance of the different HRV species has been the subject of much 
debate. HRV-A and HRV-C species have been linked to more severe illness than 
HRV-B, especially in children (127-129), however this finding has not been consistent 
across studies (118, 128, 130, 131). Several studies have shown HRV-C viruses to be 
detected in infants with wheezing or persistent cough (132), or more often associated 
with severe exacerbations of asthma requiring intensive care admissions than other 
species (133-135). An observation in a West Australian cohort study was that infants 
who wheezed with infection by one HRV strain did not always wheeze with a second 
or third infection (2), suggesting that some strains may be more “wheezogenic” than 
others. HRV genotype-specific analysis of nasal lavages from high-risk infants enrolled 
in the COAST study has shown that HRV-A or -C clades of viruses cause more severe 
respiratory illnesses in infants (136). However, it is important to note that many of 
these studies were among children presenting for ambulatory or hospital-based 
medical care or in high-risk cohorts at risk of developing wheeze. 
A further consequence of sensitive PCR testing has been the frequent detection of 
HRV in specimens from asymptomatic individuals, the role and clinical significance of 
which has been debated. HRV RNA has been detected before, during and after 
symptomatic infection, and in subclinical infection (137). Indeed, HRV has usually 
been the most frequent viral finding whether a person was symptomatic or not. Several 
studies have independently identified HRV RNA in 12% to 35% of asymptomatic 
subjects (138-140).  
Considering their ubiquity, relatively low numbers of co-detections of other respiratory 
viruses occur with HRV strains (3, 117, 141). While up to 50% of HRV detections are 
found concurrently with another virus (117), higher rates of up to 80% co-detection 
can be found with some other viruses (142). 
HRV shedding after an acute illness appears to be of short duration (143). More recent 
studies have shown HRV infections to disappear within 4–5 weeks (39, 144). A later 
study by the same authors showed that persistence of the same HRV type beyond 2 
weeks was observed in only 5% of infections (122). However, prospective studies with 
repeated sampling combined with genotyping are few and essential to fully describe 
HRV epidemiology, to distinguish between shedding from a previous subclinical 
illness, and to define infection with different genotypes in an unbroken illness episode. 
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A limited number of longitudinal birth cohort studies have prospectively evaluated HRV 
infections in infants and young children but these have had limitations in size (145-
147), frequency of sampling (144, 148), and limited asymptomatic sampling (118, 144, 
149) and follow-up (144, 150). Furthermore, few studies sequenced serial HRV 
detections in the same child to distinguish between genotypes (118, 144, 145, 150-
152). Studies that employed molecular genotyping to characterise strains did not 
identify persistent HRV shedding by a single strain and it seems instead the finding of 
generic “persistent” infections or prolonged shedding is from strain replacement and 
sequential infections caused by a succession of HRV strains (39, 137, 153). 
Human metapneumovirus (HMPV) 
HMPV is an enveloped, single-stranded, negative sense RNA virus in the family 
Paramyxoviridae. First identified in 2001 in RSV-negative children with bronchiolitis 
(154), HMPV is closely related to RSV and appears to have a similar seasonality and 
clinical spectrum associated with RSV infection, although HMPV infections occur in 
patients that are slightly older (155).  
Overall annual rates of hospitalisation associated with HMPV infection were 1 per 
1000 children less than five years of age, 3 per 1000 infants less than six months of 
age , and 2 per 1000 infants six to eleven months of age in a six year surveillance of 
three US counties (156). The estimated annual burden of outpatient visits was 55 clinic 
visits and 13 ED visits per 1000 children (156). A more recent meta-analysis estimated 
the prevalence of hospitalised ARI to be 6.4% (95% CI: 5.3-7.3) (157). Average annual 
incidence of HMPV in Queensland was 7.1% in respiratory samples from patients with 
acute LRTI collected for 4 years (158). 
Infection with HMPV can range from a mild URTI (159), URTI with AOM (159), through 
to bronchiolitis, croup, or pneumonia (158, 160). Serological studies have shown that 
by age fiveyears, almost all children have been infected by HMPV (154), although 
children younger than two years of age are most at risk of severe disease (155, 158). 
Its association with wheeze and asthma has been highlighted in several studies (161-
163). Clinical evidence suggests that HMPV is associated with acute exacerbations of 
asthma in both children and adults (164). Animal models have demonstrated that 
airway hyper-responsiveness and inflammation are triggered following HMPV 
infection, and HMPV is able to persist in vivo by inhibiting innate immune responses 
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and causing aberrant adaptive responses. Asymptomatic and subclinical infection 
appear to be uncommon (154, 156). Screening of 400 samples from infants without 
respiratory symptoms revealed no positive samples in one study (154) and 1.3% in 
another (156). 
Human coronaviruses (HCoV) 
HCoVs are enveloped, single-stranded, negative sense RNA viruses in the family 
Coroniviridae and were first described in the 1960s with the discovery of species 229E 
and OC43 (165-167). Together with HRVs, they are regarded as important ‘common 
cold’ agents. Increased interest in HCoVs followed the severe acute respiratory 
syndrome (SARS-HCoV) epidemic in 2003 and was rekindled with the emergence of 
the Middle East Respiratory Syndrome (MERS-HCoV) virus in 2012 (168). In the early 
part of this century, two other HCoVs, NL63 (63) and HKU1 (64) were also identified. 
Infection from these four non-SARS/MERS HCoV species occur in the first five years 
of life (169), and can cause URTIs (common cold) and LRTIs (ranging from croup 
(170), bronchiolitis (171), and pneumonia (172)). However, a systematic review found 
no association between HCoV infection and acute asthma exacerbations (173). 
The newly discovered species appear to be present in higher rates than the two older 
species in both hospitalised and healthy children (174). Most of the evidence of their 
involvement in severe disease comes from reports from hospital-based studies using 
PCR platforms (171, 175-177). Furthermore, HCoVs are frequently encountered with 
other viruses (178), which complicates determining the primary aetiology. It is thus 
difficult to say what proportion of ARIs that result in hospitalisation are in fact caused 
by these viruses. In a comparison of all HCoV types in a community cohort and a 
children’s hospital in the same community over two years, children in the community 
generally had mild illness with few medically attended cases and were older. In 
hospitalised children, young age and chronic complex conditions were associated with 
severity of illness (179). 
DNA viruses 
Adenoviruses (HAdV) 
HAdVs are non-enveloped, double-stranded DNA viruses within the family 
Adenoviridae and important pathogens in young children. They are most frequently 
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associated with febrile URTIs with pharyngitis, pharyngoconjunctivitis, or coryza, but 
can occasionally cause pneumonia. HAdVs have also been independently associated 
with acute otitis media with perforation in Indigenous children (13). They account for 
5–10% of ARIs in infants and young children (180), and have been implicated in up to 
10% of childhood pneumonia (181, 182). HAdVs are especially prevalent in childcare 
centres and households with young children. Longitudinal studies performed in 
families and paediatric facilities showed that species C HAdV infections occur early in 
life and are often endemic (183, 184). 
These studies identified a large number of asymptomatic infections with species C and 
demonstrated a high frequency of faecal shedding of viruses (180). Infants and young 
children have the highest attack rates of endemic HAdV infections. Although most 
HAdV illnesses are acute and self-limited, infection may be prolonged, and 
asymptomatic infections are common. HAdVs have been isolated from at least 50% 
of surgically removed tonsils, from the kidney, and also from lymphocytes, suggesting 
that infection may remain latent for a very long time, possibly for life (185). Prolonged 
viral shedding following HAdV infection and ubiquitous environmental contamination 
have been implicated in disease transmission (186). 
Human bocavirus (HBoV) 
HBoV-1 was first identified in 2005 (65) in nasopharyngeal aspirates (NPAs) collected 
from children with ARI episodes. It is a small non-enveloped, single-stranded DNA 
virus in the family Parvoviridae, genus Bocavirus. 
HBoV-1 is most commonly found in young children aged 6–24 months with ARIs and 
appears to be acquired early in life (51). HBoVs have also been detected in children 
diagnosed with community-acquired pneumonia in Brazilian children (187, 188). 
Studies have shown that HBoV-1 may persist in the respiratory tract for a longer time 
than other respiratory agents, resulting in frequent detection of low load HBoV-1 
carriage by PCR (189, 190). HBoV-1 DNA may be detectable in the nasopharynx of 
immunocompetent individuals for at least six months after infection (191, 192). 
Consequently, high rates of co-detection of HBoV-1 with other viruses (40–80%) and 
high prevalence rates (5-44%) in asymptomatic children (190, 191, 193-196) have 
been noted and its role as a pathogen has been questioned. Additional prospective 
studies are required to determine the actual pathogenic role of HBoV-1. 
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Nonetheless, there is some evidence to show that HBoV-1 is pathogenic and 
associated with ARI symptoms. The strongest evidence to date comes from studies 
where symptomatic ARIs have occurred in association with HBoV-1 as a single 
pathogen in respiratory secretions, associated with high viral loads, viraemia (195, 
197), and seroconversion (198, 199). The study by Ricart et al. (197) also found that 
viral load was positively correlated with length of hospitalisation, but inversely 
correlated with days of respiratory effort before admission to hospital with acute 
bronchiolitis (suggesting a more rapid development of symptoms with higher viral 
loads). Other studies that have included asymptomatic controls have shown an 
association between the presence of the virus and symptomatic illness in PCR studies 
of children (196, 200, 201). HBoV-1 viral load was also associated with the presence 
of ARI symptoms, a metric along with HBoV-1 capsid messenger RNA that has been 
reported previously to be associated with disease severity (202). Capsid protein VP1 
is thought to exert a direct pathogenic effect on human airway cells (203). Thus, a 
combination of tests involving serology, quantitative PCR of blood and respiratory 
secretions, and transcriptional assays will be needed to accurately diagnose HBoV-1 
infection (204). 
Human polyomaviruses (HPyV) 
The Polyomaviridae constitute a family of small DNA viruses that infect a variety of 
hosts. In the last decade 11 new human polyomaviruses have been identified, 
including the phylogenetically related KI-HPyV and WU-HPyV (65, 67), the latter two 
identified in the respiratory tract specimens of children with acute respiratory 
symptoms. 
Sero-epidemiological studies have shown that primary exposure occurs early in life 
(205), with seroprevalence in children under the age of two years for KI-HPyV at 
around 40% and WU-HPyV varying between 45-83%. Seroprevalence of KI-HPyV and 
WU-HPyV is high in the adult population (55-90% and 69-98%, respectively) (206, 
207). 
In healthy, non-immunocompromised children, KI-HPyV and WU-HPyV seem to have 
a minor aetiological role in ARIs, most often manifesting as mild respiratory illness or 
asymptomatic infections, and thus their pathogenic role has been questioned (208, 
209). Attributing causality remains problematic. Studies that have included 
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asymptomatic controls have detected viral sequences at similar or higher frequencies 
in controls compared with ARI cases (11% vs. 7% WU/KI) (208), (4.2% vs 7% WU) 
(210) (0% vs 2.2% KI, 6% vs 7% WU) (211). KI-PyV and WU-PyV have also been co-
detected with other viruses in specimens from symptomatic subjects (66, 212, 213), in 
some cases in the order of 70–80% (212). In a vaccine trial in Filipino children with 
lower respiratory disease, the prevalence and co-detection rates for KI-HPyV and WU-
HPyV were 4.2% and 84%, and 5.3% and 74% respectively (214). 
Epidemiological studies 
In addition to the seminal, community-based epidemiological studies conducted in 
families during the 1950s and 1960s (see page 29), hospital-based studies have also 
contributed to our understanding of the epidemiology of more severe viral ARIs in 
infants. These studies have emphasised RSV and, to a lesser extent, seasonal INFV, 
as the most common reasons for infants to be hospitalised in the first year of life (70, 
71), as well as more recently emphasised the roles of HRV, PIV, and HMPV (69, 215-
218). 
The advent of sensitive PCR testing combined with the collection of a less invasive 
clinical specimen such as an anterior nose swab and home-based self or parent 
collection provides the opportunity to conduct more intensive community-based 
studies. These studies’ design features offer several potential advantages, including 
timely and easy collection of specimens during acute episodes of ARI, removing the 
need for trained staff to collect specimens. These characteristics combine to make 
large, community-based studies logistically and financially more achievable, and 
provide the means to collect previously unavailable detailed information about 
infections in the community. 
In the last two decades, a number of prospective community-based birth cohort studies 
on respiratory viruses have been conducted (Table 1), in both infants at high-risk of 
asthma and healthy infants, although very few have employed the above 
methodologies, viz parent-collected symptom and swab information (rather than 
health care workers) (219). Birth cohort studies of high-risk infants have investigated 
the role of respiratory viruses in the development of wheezing illnesses, as well as 
provided valuable insights into asthma risk factors and the natural history of wheezing 
and asthma through childhood and beyond (2, 121, 220, 221). These studies have 
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identified HRV, ahead of RSV and INFVs, as the major upper and lower respiratory 
pathogens in the first year of life. 
However, in many cases cohort studies of ARIs in healthy children have had one or 
more methodological limitations, including follow-up restricted to a single year or 
respiratory season, and in so doing failing to account for seasonal or year-to-year 
variability in respiratory virus activity (222-224). Other limitations include non-
representative sample populations, variable sampling frequency (146, 225), testing 
confined to a single or limited number of pathogens (146, 224), or lacking a control 
population or control specimen sampling strategy (3, 42, 222, 223, 226). Several 
cohort studies have recruited through clinics or hospitals on presentation of an ARI 
(227), or looked at specific clinical outcomes (140, 160, 225, 227, 228). 
Well-designed prospective community-based cohort studies of ARI in unselected, 
healthy children with longitudinal follow-up and intensive sampling have been few 
(148, 151, 229), and understandably so, as they are not without challenges. Cohort 
studies of long duration with intensive follow-up are biased towards smaller families of 
higher socioeconomic status (2, 230). 
However, these longitudinal study designs can establish temporal associations and 
offer the ability to correctly classify infections as symptomatic or asymptomatic, 
account for background prevalence, and afford the opportunity to examine viral 
shedding. Clinical follow-up can be correlated with virological and demographic data, 
and other risk determinants.  
Birth cohort studies extend this further and provide valuable insight into incipient and 
‘first’ infections acquired from birth and thereafter, persistence, and true asymptomatic 
infections. As demonstrated in a birth cohort study on norovirus, for viruses that 
commonly infect and re-infect, sometimes sub-clinically, similar to respiratory viruses, 
longitudinal data are crucial for understanding the relationship between primary, 
secondary, and subsequent infections and the development of disease (231).  
 44 
Table 1: Summary of prospective observational community-based birth cohort studies of respiratory viruses published this 
century 
Reference Study 
selection 
Cohort 
size 
Enrolment 
age/follow-up 
Sampling/Symptom 
collection details 
Main findings 
High-risk cohorts       
Lemanske, 2005 
(121) (US) 
One allergic parent 285 infants Birth–12 months Nasal mucus specimens at scheduled 
visits (regardless of symptoms) and at 
onset of ARI; Daily symptom diaries 
Symptomatic HRV illnesses during infancy 
biggest risk factor for development of 
preschool wheezing. 
Legg, 2005 (220) 
(UK) 
One atopic, asthmatic 
parent 
88 infants Birth–5 months Nasal lavage at each ARI; daily 
diaries for ARI only 
Picornaviruses most frequently detected; 
RSV infection associated with diagnosis of 
bronchiolitis. 
Kusel, 2006 (2) 
(Australia) 
One atopic parent 263 infants Birth–12 months NPA at each ARI; 2 control NPAs; 
daily symptom diaries 
69% ARI virus-positive: HRV (49%) and RSV 
(11%) most common; RSV strongly 
associated with LRI requiring hospitalisation 
Kusel, 2007 (28) 
(Australia) 
Children at high 
atopic risk 
198 children Birth–5 years Postnasal aspirates; all episodes of 
ARI 
Viruses (69%) of aspirates; HRV (48%), RSV 
(11%). RSV/RV associated with wheezy LRI 
(OR, 4.1 (1.3-12.6). 
Jartti, 2008 (137) 
(US) 
One allergic parent 285 infants Birth–12 months Nasal mucus specimens at scheduled 
visits (regardless of symptoms) and at 
onset of ARI; Daily symptom diaries 
HRV infections occur early, pervasively, and 
repetitively in high-risk infants. Infants with 
prolonged or recurrent respiratory illnesses 
have series of infections rather than persistent 
infection with one virus strain. 
Jackson, 2008 (123) 
(US) 
One allergic parent 259 children Birth–6 years of age Nasal mucus specimens at scheduled 
visits (regardless of symptoms) and at 
onset of ARI; Daily symptom diaries 
Viral wheezing illnesses in infancy and early 
childhood caused by HRV infections are most 
significant predictors of subsequent 
development of asthma at age 6 years. 
Bisgaard, 2010 
(221) (Denmark) 
Children of asthmatic 
mothers  
411 children 4 weeks–3 years NPA during wheezy episodes and at 
planned visits without LRI symptoms; 
Daily symptom diaries 
Wheezy episodes associated with bacterial 
and viral infections 
Healthy cohorts       
van Benten, 2003 
(232) (The 
Netherlands) 
Antenatal recruitment 126 infants Birth–12 months Nasal brush samples during routine 
visits every 6 months and during 
URTI 
HRV most prevalent (40%) in URTI, rhinitis, 
followed by RSV (20%), HCoV (10%). HRV 
may affect maturation of immune system and 
development of allergic disease. 
von Linstow, 2008 
(190) (Denmark) 
Antenatal recruitment 228 infants Birth–12 months Nasal swab sampling and symptom 
diaries at monthly visits 
HBoV-1 detected 8% in swabs from ARTI, 9% 
from asymptomatic children.  
von Linstow, 2008 
(233) (Denmark) 
Antenatal recruitment 228 infants Birth–12 months No sampling conducted; Daily 
symptom diaries, monthly visits 
6 episodes/child/year; Determinants of ARI: 
age, winter, household size, childcare, 
presence of siblings 
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Reference Study 
selection 
Cohort 
size 
Enrolment 
age/follow-up 
Sampling/Symptom 
collection details 
Main findings 
Healthy cohorts       
Regamey, 2008 
(226) (Switzerland) 
Antenatal recruitment 
2 hospitals 
197 infants Birth–12 months Nasal swab on onset and 3 weeks 
later; Weekly standardised phone 
interviews 
First ARI at 6 months; HRV, HCoV 55% <6 
months; 25% ARI had wheeze; 97% acute 
rhinitis 
Ede, 2009 (234) 
(US) 
Nursery or primary 
care paediatric clinic 
180 infants Birth-12 months Nasopharyngeal secretions during 
ARI and AOM 
Increase in respiratory virus activity not due to 
pandemic virus, but spectrum of viruses did 
change during pandemic. HRV most common 
in URI (55%), RSV in LRTI (64%) 
van der Zalm, 2009 
(222) (The 
Netherlands) 
Postnatally recruited 
through council 
register  
305 infants Birth–12 months Nose and throat swabs on onset of 
illness; Daily questionnaires 
High prevalence of respiratory pathogens in 
infants in first year of life; HRV most prevalent. 
RSV infections the most severe compared 
with HRV, but HRV highest overall burden of 
disease. 
van der Zalm, 2009 
(139) (The 
Netherlands) 
Postnatally recruited 
through council 
register 
18 children Birth–7 years old Nose swabs taken biweekly; Daily 
questionnaires 
Respiratory pathogens frequently detected in 
asymptomatic children. Younger children 
more likely symptomatic, as are multiple 
detections. 
Fairchok, 2010 (110) 
(US) 
2 large childcare 
centres; children with 
LRTI 
119 children Birth–30 months Nose swab 48 hours of onset of 
illness; Daily diary 10 days following 
onset of illness 
Viruses identified in twice as many ARIs as 
previously reported in childcare cohort. 
HMPV, HCoV infections less frequent and 
severe than RSV, HAdV, HRV infections. 
van der Zalm, 2011 
(145) (The 
Netherlands) 
Postnatally recruited 
through council 
register 
18 children Birth–7 years old Nose swabs taken biweekly; testing 
HRV only; Daily questionnaires 
Total lung resistance associated with HRV-
associated wheeze. HRV-associated wheeze 
might be first sign to recognize infants with 
reduced neonatal lung function 
Houben, 2011 (224) 
(The Netherlands) 
Antenatal recruitment 
from 2 large hospitals 
298 infants Birth–12 months  Nose/throat swabs, daily symptom 
diaries (RSV LRTI only) 
Predictors for RSV LRTI (14% of children): 
childcare, siblings, high education, birth 
weight >4 kg, birth Apr-Sep. First year 
wheezing in 62% of children with RSV LRTI 
Mackay, 2013 (235) 
(Australia) 
Antenatal recruitment 234 infants Birth–12 months Nose and throat swabs on onset of 
illness; Daily symptom diaries 
HRV only. No clinical impact attributable to 
HRV species and genotypes. 
Martin, 2013 (236) 
(US) 
3 childcare centres on 
military base 
225 children 5 weeks–30 months Nasal swab at enrolment, then onset 
of illness; Daily symptom diary for 10 
days following illness 
High proportion (47%) attending childcare had 
multiple viruses; multiple viruses associated 
with less severe illness 
van der Gugten, 
2013 (237) (The 
Netherlands) 
Postnatally recruited 
through council 
register 
140 infants Birth–12 months Monthly samples; Daily symptom 
diaries; lung function measured <2 
months of age 
HRV during infancy not associated with 
wheezing, wheeze during HRV episode 
indicator of kids at high risk for wheeze 
because of reduced lung function 
 
  
 46 
 
Reference Study 
selection 
Cohort 
size 
Enrolment 
age/follow-up 
Sampling/Symptom 
collection details 
Main findings 
Zomer-Kooijker, 
2014 (15) (The 
Netherlands) 
Postnatally recruited 
through council 
register 
417 infants Birth–12 months Nose/throat swabs (RSV only), daily 
diaries 
Median neonatal respiratory compliance 
lower, resistance higher in hospitalised RSV 
patients. Lower birth lung function 
predisposes to severe RSV disease and post-
RSV wheeze. 
Anders, 2015 
(238)(Vietnam) 
Antenatal recruitment 
from four hospitals 
1,478 infants Birth-12 months NPS during ARI, clinic-based 
surveillance, hospital admissions, 
self-reports 
HRV, RSV, INFV-A, HboV-1 most frequently 
detected viruses. ARI-associated 
hospitalisations associated with longer stays, 
frequent ICU admission. 
Howard, 2015 (151) 
(Peru) 
Household study 500 children Children <3 years of age Weekly nasal swabs, weekly 
questionnaires 
INFV, HMPV, PIV and RSV detections in 
children with an ARI usually indicate causal 
relationship. RSV Ct lower during ARI.  
Chonmaitree, 2015 
(225) (US) 
Nursery or primary 
care paediatric clinic 
362 infants Birth-12 months Nasopharyngeal secretions during 
ARI and AOM 
Viruses detected in 76% of URTI and 27% 
asymptomatic monthly specimens; latter 
associated with young age, male sex, low viral 
load, single detections, specific viruses. 
Mack, 2016 
(147)(Switzerland) 
Antenatal recruitment 
from four hospitals 
41 infants Birth-12 months Weekly telephone interviews and 
weekly nasal swabs 
HRVs highly prevalent in the first year; 51% 
asymptomatic. Respiratory symptoms during 
HRV infection associated with age, maternal 
atopy, premorbid lung function 
Toivonen, 2016 
(149) (Finland) 
Antenatal recruitment, 
public hospitals 
923 children Birth–24 months Nasal swabs during ARI and at 
2,13,24 months; Daily diaries and 
clinic visit data 
HRV detected in 59% ARI, associated with 
50% of AOM, 41% of wheezing illnesses, 49% 
of antibiotic treatments, and 48% of outpatient 
office visits for ARI. 9% of asymptomatic 
children were HRV-positive. 
Kumar, 2017 (239) 
(India) 
Enrolment through 
major hospital 
310 infants Birth-12 months NPAs at each ARI.  63% ARI virus-positive, 18% viral 
coinfections. HRV most common virus, 
followed by RSV, PIV, HCoV.  
Martin, 2018 (118) 
(US)  
3 childcare centres on 
military base 
225 children 5 weeks–30 months Initial nasal swab, then onset of ARI; 
Daily symptom diary 10 days post ARI  
Heterotypic co-circulation of many HRV 
genotypes. 
Uddin, 2018 
(240)(Nepal) 
Pregnant women 
from 2 community-
based, vaccine trials 
3,505 infants Birth-6 months Weekly household visits, midnasal 
swabs during ARI 
8% of infants had an HCoV-ARI in first six 
months. HCoV incidence higher in non-
neonates. 46% coinfections with another 
virus.  
Abbreviations: AOM: acute otitis media; ARI: acute respiratory infections; aRSV: asymptomatic RSV; Ct: cycle threshold; GP: general practice; HAdV: human adenoviruses; 
HCoV: human coronaviruses; HRV: human rhinovirus; ILI: influenza-like illness; INFV: influenza virus; LRTI: lower respiratory tract infection; NPA: nasopharyngeal aspirate; 
NPS: nasopharyngeal swab; NTS: nose/throat swab; OME: Otitis media with effusion; PIV: parainfluenza viruses; RSV: respiratory syncytial virus; URTI: upper respiratory tract 
infection 
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Determining pathogenicity in the molecular era: asymptomatic detections and 
causation 
The use of PCR technology has become increasingly common in routine diagnostics 
and epidemiological studies of respiratory viruses. PCR is fast, sensitive, and 
successful at detecting viruses, including those that are fastidious or do not grow in 
standard cell culture. These contemporary detection methods identify nucleic acid 
rather than an infectious virus, which can prove problematic when interpreting positive 
results. The dogma of a positive result identifying the agent of a disease relates to 
traditional diagnostic methods of viral culture and serology, and may not necessarily 
hold true with a positive PCR result detecting target sequences of nucleic acids. 
Koch’s postulates associate infection with disease, and may not be immediately 
relevant for newly identified viruses, many of which have not been cultured. Modified 
Koch’s postulates were proposed by Fredricks and Relman (241) to help address this 
problem and include virus identification by molecular detection techniques (Appendix 
2). 
A positive PCR finding in a person who is deemed asymptomatic may reflect: 
 mild, but unrecognised or falsely attributed symptoms to another infection, 
 a nascent, incubating infection with testing prior to developing symptoms,  
 past, resolved infection (i.e. residual viral genetic material following infection 
without active replication), or  
 a genuine subclinical infection (acute, persistent, or reactivation of latent 
infection) without associated signs and symptoms. 
All respiratory viruses have been detected in studies with asymptomatic subjects, or 
longitudinal study designs with asymptomatic periods, both individually or co-detected 
with other viruses, making the clinical significance of a positive result difficult to 
interpret. Understanding the aetiological role of viruses in illness requires not only 
appropriate study designs, but suitable approaches to the analysis and interpretation 
of virus detection data. 
Cross-sectional designs cannot describe the causal chain of infection. Other 
approaches to assess the role of detected pathogens in cases have been to compare 
their infection status to control subjects without the disease. This case-control 
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analytical approach has limitations as it assumes 100% specificity among subjects 
who test positive for the pathogen. 
One approach to estimating the aetiological role of a pathogen is to calculate an 
‘attributable fraction’ in the exposed population (AFE). The AFE provides information 
about the percentage of cases amongst exposed individuals that can be attributed to 
the exposure. However, while the AFE approach addresses the limitations inherent 
with the case-control approach, it is a population level metric and cannot inform on the 
individual aetiology. The option for estimating aetiology for an individual case is to 
assign the group aetiological fraction for pathogens detected in that case, regardless 
of the findings for other pathogens detected (242).  
Summary 
Viral ARIs remain the most common illnesses experienced by children, particularly in 
the first two years of life. Information about the epidemiology of ARIs in children is 
based on historic community-based family studies, cohorts of hospitalised patients, 
ED, or primary healthcare presentations, and more recently mainly from birth cohort 
studies in children at high-risk of asthma. However, findings from these studies do not 
identify the contemporary burden of mild-to-moderate disease in otherwise healthy 
children that are overwhelmingly managed in the community, resulting in an overall 
under-estimate of disease burden. Contemporary published data on the nature and 
duration of ARIs in children in the community, and how these illnesses are managed, 
are limited. Intermittent wheeze triggered by ARIs in the first one to two years of life 
have also been implicated in the later development of asthma in susceptible 
individuals. Taken together, ARIs in children result in substantial costs to the families, 
society, and the healthcare system.  
Since 2001, modern molecular-based techniques have discovered several new 
human viruses in patients with respiratory symptoms. The use of sensitive PCR 
assays has highlighted the detection of respiratory viruses in asymptomatic subjects, 
the co-detection of multiple viruses in respiratory secretions, and virus persistence 
following recovery from illness. The clinical significance of positive PCR findings 
therefore can be difficult to interpret because of few prospective, unselected healthy 
infant birth cohort studies where serial sampling and comprehensive molecular-based 
testing of respiratory secretions for pathogens is conducted before, during and after 
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respiratory episodes. Epidemiological studies conducted to date have had one or more 
limitations in study design preventing them from adequately addressing these 
questions. Furthermore, none of these cohort studies tested for all the newly 
discovered respiratory viruses. Few prospective studies examining the aetiological 
role of HRV in ARIs have conducted sequence-based typing of serial HRV detections 
to distinguish between species and genotypes.  
The Observational Research in Childhood Infectious Diseases Study 
The ORChID study was designed to address some of these methodological limitations. 
The ORChID study was a four year prospective, community-based longitudinal birth 
cohort study of ARIs in children during the first two years of life (243), modelled on a 
previous cohort study conducted by Lambert et al. in Melbourne in 2003/2004 (3). 
Parents consented antenatally for their newborn infants to be recruited into the study 
shortly after birth at one of two metropolitan hospitals in Brisbane if they met the 
inclusion criteria (born healthy and at term (36–42 weeks) without congenital 
abnormalities or underlying chronic disorders). Brisbane is a subtropical city of more 
than 2 million inhabitants in Southeast Queensland, Australia. 
Parents completed a daily symptom diary designed in a tick-box format that captured 
a set of pre-defined respiratory symptoms. Parents were also trained to take weekly 
nasal swabs from their child irrespective of symptoms, which were tested against a 
panel of 17 novel and established respiratory viruses. Illness episodes were 
documented further in a ‘burden diary’, which recorded healthcare-seeking behaviour, 
antibiotic prescriptions, and laboratory investigations. Full details of the methods 
employed in the study are outlined in Chapter 2. 
The progressive two year recruitment and follow up until the second birthday means 
the study spanned multiple seasons, allowing for analysis of year-to-year variation in 
respiratory virus activity. Regular serial sampling in a healthy, unselected cohort 
allowed temporal relationships between respiratory virus detection and respiratory 
illness to be explored, improving the understanding of the role of respiratory viruses in 
illness. The longer follow-up period with this cohort and more frequent sampling 
increased the likelihood of sampling so-called ‘asymptomatic’ or genuine subclinical 
infections, as well as gave an indication of the duration of virus detection before, 
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during, and after symptomatic illness. As infants were swabbed from birth, the study 
design also allowed an examination of the prevalence, type, and timing of first 
infections with various viruses, including whether they were symptomatic, and the 
proportion of infants and their samples that were positive for viruses over the first two 
years of life. 
Aims  
The broad aims of this research are to: 
  Describe the community-based epidemiology of respiratory viruses in the first 
two years of life, including the incidence, symptoms, management and 
associated risk factors of ARIs; 
  Determine the relative contributions of individual respiratory viruses to ARI in 
the first two years of life; and 
  Determine the pathogenicity of newly discovered respiratory agents, including 
the new HRV-C species, by comparing the timing and duration of detection in 
respiratory specimens with the presence of symptoms.  
Hypotheses 
The hypotheses to be tested are: 
1. Collectively, HRVs, and the six recently described respiratory viruses from four 
virus families (HMPV, HCoV-NL63, HCoV-HKU1, HBoV-1, HPyV-WU, HPyV-
KI) are more frequently detected during ARIs in the first two years of life than 
the long established viruses (RSV, PIVs, INFV, HAdVs) identified from hospital-
based studies. 
2. Respiratory pathogens are more likely to be associated with symptoms when 
first acquired. 
3. Established respiratory viruses are more likely to be individually associated with 
symptoms than the recently described novel DNA viruses HPyV and HBoV-1. 
4. Most respiratory pathogen shedding is transient, ceasing within 2-4 weeks of 
detection. 
5. HRV-C is more likely to be associated with LRTIs than other HRV species. 
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Significance 
At the commencement of this PhD, the role of some recently identified respiratory 
viruses was unclear. The prevalence of viruses in asymptomatic samples also posed 
a challenge in determining their role in infection. The clinical significance of HRV-C 
was a subject of ongoing debate. Findings from the ORChID study presented in this 
PhD have gone some way to address these information gaps in understanding 
respiratory virus epidemiology in early childhood.
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Chapter 2 – Methods 
Study population 
The ORChID study (clinicaltrials.gov: NCT01304914) was conducted in the 
subtropical city of Brisbane, Australia (latitude 27° South, average monthly maximum 
temperature range 22-30°C, maximum rainfall in December-February, population 2.2 
million) from September 2010 to October 2014. This was a dynamic cohort study, 
which enabled participants to leave the study temporarily (such as during family 
holidays) and re-join at a later date. 
Recruitment was from antenatal clinics and was progressive over two years, which 
allowed infants born between September 2010 and October 2012 to be enrolled evenly 
throughout the study period to account for seasonal and year-to-year variation in 
respiratory virus activity. Parents provided written consent for their newborn infants to 
be recruited into the study shortly after their birth at one of two metropolitan hospitals 
(one private and one government-funded). Exclusion criteria for enrolment and 
ongoing participation included gestational age at birth of less than 36 weeks, major 
congenital abnormalities, chronic heart, respiratory (excluding asthma), 
gastrointestinal, neurological, or immunological disorders, parents unable to converse 
in English, living outside the Brisbane metropolitan region, or planning to move from 
the area within the next two years (243). Consequently, symptom data and nose swab 
specimen collection spanned more than four years from September 2010 to October 
2014. 
Demographic, social and clinical characteristics  
Following the infant’s recruitment into the study, parents provided their demographic, 
social and health characteristics as well as pregnancy and birth details. Telephone 
interviews were conducted every three months to update immunisation, feeding, and 
childcare attendance details. Childcare was categorised according to Australian 
Bureau of Statistics definitions as formal (regulated care outside the child’s home) or 
informal (non-regulated care provided by family or friends) (244). The duration of 
exclusive breastfeeding was defined as the period of time from birth to introducing milk 
formula or solids, whichever was first. 
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Symptom data collection 
We provided diary cards listed with pre-defined respiratory symptoms or diagnoses, 
to be completed daily, and returned by mail at the end of each month (Appendix 3). 
Parents were trained to recognise and record respiratory signs/symptoms, including 
runny nose/nasal congestion, distinguishing between a wet and dry cough and rattly 
breathing, and breathing difficulties, including wheezing, so as to minimise inaccuracy 
of reporting. The diary cards were designed in a tick-box format, modified from a prior 
study investigating influenza vaccine effectiveness (245) and used previously in a 
Melbourne cohort study (3). Parents were provided with a digital thermometer to 
measure temperature. Diagnoses of AOM and pneumonia were validated by a doctor’s 
visit and where appropriate following review of the hospital ED or admission medical 
records (6). 
Classification of acute respiratory infections 
ARI episode was defined by respiratory symptoms and/or signs of the upper and/or 
lower respiratory tracts listed below (3, 6). 
URTI: parent-reported runny nose/nasal congestion, dry cough, or doctor-diagnosed 
AOM (6). 
LRTI: parent-reported rattly breathing, moist cough, shortness of breath, wheeze, or 
doctor-diagnosed pneumonia (6). 
If wheeze was a component of a child’s LRTI, it was sub-categorised as a ‘wheezy 
episode’.  
ARIs were sub-categorised hierarchically as either a LRTI or URTI, respectively. 
Fever as a symptom was accepted if the parent ticked the fever symptom box or if 
they recorded axillary temperatures >37.5°C. For the purposes of demarcating ARIs, 
a new episode was considered to have commenced if there were >3 symptom-free 
days since the last day with symptoms (3). Daily symptoms were recorded until the 
child’s second birthday. 
ARI burden diary 
Parents were asked to further document healthcare-seeking behaviour (visits to a 
family physician, an ED presentation, or a hospital admission) and antibiotic usage in 
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a separate ‘burden impact diary’ (Appendix 4) (3). Burden diaries were requested for 
all LRTIs, AOM and any URTI resulting in both nasal symptoms (nasal discharge or 
congestion) and cough. To minimise inconvenience we did not seek burden diaries for 
children with nasal symptoms alone as we reasoned under these circumstances 
impact would be minor and parents were unlikely to seek medical advice. Burden 
diaries were mailed back to study staff by parents with symptom diary cards at the end 
of each month. When reviewing hospital ED presentation or admission notes, the 
recorded principal diagnosis was accepted as the reason for consultation, regardless 
of whether the child had an ARI at the time. 
Details of specimen collection, processing, PCR assays, quality control 
measures, and assay parameters used to identify respiratory viruses 
Specimen collection 
We supplied parents with swabs, a specimen collection instruction sheet, sealable 
bags, pre-addressed envelopes, and labelled stickers at the commencement of the 
study and at regular intervals (Appendices 5 and 6). All swabs were collected using a 
plastic-shaft, rayon-budded swab in a transport tube with a foam pad reservoir soaked 
with viral transport medium (Virocult MW950, Medical Wire & Equipment, Wiltshire, 
England). A single swab was used to sample both nostrils. Parents were taught by 
trained research staff to collect anterior nose swabs from their infant, beginning around 
the time of birth and then weekly thereafter. Parents were also reminded of correct 
swab technique when contacted by telephone for other information or if there were 
issues with the quality of swabs submitted. Immediately post-birth, parents also 
provided their own nasal swab specimens and reported respiratory symptoms within 
the previous two weeks. 
The specimens were mailed at ambient temperature directly to the research laboratory 
by standard surface mail, taking a median of 3 (interquartile range 2-4) days and where 
they were processed and stored at -80°C until further analysis (243, 246). Swabs were 
batch-tested for HRV, RSV-A, RSV-B, INFV-A, INFV-B, PIV-1, PIV-2, PIV-3, HMPV, 
HCoV-OC43, NL63, 229E, HKU1, HAdV, WU-HPyV, KI-HPyV, and HBoV-1, using 
previously validated real-time PCR assays (243).  
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Quality Control measures 
Prior to nucleic acid extraction, a known amount of whole equine herpesvirus (EHV) 
spiked into each sample assessed nucleic acid extraction quality and presence of PCR 
inhibitors (247). Any extract having a >3 cycle-threshold (Ct) difference to that of the 
expected value by EHV real-time PCR assays was considered to have failed quality 
control and the sample was re-extracted. 
 
Specimen quality was assessed by testing for a marker of human genomic DNA, 
endogenous retrovirus-3 (ERV-3) (248). In addition, Ct values were used as semi-
quantitative markers of viral load as in real-time PCR assays they are inversely 
proportional to the amount of specific virus nucleic acid present in the specimen (246). 
We have demonstrated previously that among specimens with an ERV-3 Ct value >38, 
respiratory virus detection declined significantly (odds ratio 0.35, 95% CI: 0.27, 0.44 
when ERV-3 was undetectable) (249). Thus, virus-negative swabs with an ERV-3 Ct 
value >38 were deemed to be of poor quality and removed from parts of the analysis, 
such as incidence calculations. 
Swab quality was monitored throughout the study and the number of ERV-3 negative 
specimens ranged from 19.6% to 44.6% in the first 8 months of the study (250). 
Analysis of ERV-3 positive and respiratory virus positive specimens showed that ERV-
3 positive sample rates increased with age and varied by season (249), with ERV-3 
positive rates in the first six months of age as a reference. Following a cluster of 
specimens that were negative for ERV-3, study nurses contacted parents and 
reminded them of the optimal swab technique they had been shown at enrolment. 
After this feedback, the number of ERV-3 specimens declined. 
Nucleic Acid Extraction 
Each swab was resuspended in 2mL of phosphate buffered saline from which 200µL 
was used for nucleic acid extraction. After being spiked with EHV, samples were 
extracted on the QIAxtractor automated high-throughput extraction platform using DX 
reagents according to the manufacturer’s instructions (Qiagen, Australia). Total DNA 
and RNA were eluted into 150µL of elution buffer. 
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Detection of Viruses by Real-Time PCR 
DNA viruses 
All real-time PCR assays targeting DNA templates (EHV, ERV-3, HAdV, KI-HPyV, 
WU-HPyV, HBoV-1) used an identical set of master mix and cycling conditions. In 
brief, 8pmol of each primer, 3·2pmol of the respective probe(s), and 2µL of template 
were made in a 20µL final reaction volume using the Bioline Sensi Mix II Probe PCR 
mix kit (Bioline, Australia), and followed cycling conditions of: activation at 94°C for 2-
minutes, followed by 45 cycles of 95°C for 15-seconds and 60°C for 60-seconds.  
RNA viruses 
For RNA viruses, real-time, one-step reverse-transcription PCR (RT-PCR) assays 
were used following a common protocol for all but INFV and HRV assays. In brief, 
8pmol of each primer, 3·2pmol of the respective probe(s), and 2µL of template were 
made in a 20µL final reaction volume using the Bioline SensiFAST Probe One-Step 
RT-PCR kit (Bioline, Australia), and followed cycling conditions of: 45°C reverse 
transcriptase incubation for 20-minutes, 95°C activation for 2-minutes, followed by 45 
cycles of 95°C for 15-seconds and 60°C for 60-seconds. The single deviation from the 
common RT-PCR protocol in the INFV A/B reaction was use of asymmetric amounts 
of INFV A and B probes (6·4pmol and 3·2pmol, respectively). 
HRV typing 
A concentration of 16pmol of each primer, as well as magnesium chloride additive of 
the same concentration, were used along with 2pmol of the respective probe in the 
HRV assay. The cycling conditions for the RT-PCR were as follows: 45°C reverse 
transcriptase incubation for 20-minutes, 94°C activation for 2-minutes, followed by 55 
cycles of 95°C for 15-seconds to denature and 60°C for 60-seconds for the annealing 
step. Reactions were performed on ABI 7500 and Viia7 instruments (Life 
Technologies, Australia), as well as the Qiagen Rotorgene Q (Qiagen Australia).  
Samples testing positive for HRV were genotyped by sequencing the variable region 
of VP4/VP2 genes using a nested PCR assay with two sets of primers (251-253). 
Samples that could not be amplified twice by the VP4/VP2 assay were further 
investigated by amplifying a 390 nucleotide fragment from the 5'UTR segment (254). 
PCR products were purified (QIAquick PCR purification kit, Qiagen, Australia) and 
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submitted for DNA sequencing to the Australian Equine Genetics Research Centre 
(The University of Queensland, Brisbane, Australia).  
All detections with Ct values ≤40 were considered positive for the target respiratory 
virus. Details of probe and primer sequences for each respiratory virus tested are listed 
in Table 2.
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Table 2: Details of primer and probe sequences by virus 
Reaction 
Mix 
Virus Target Gene Primer, Probe sequences (5'-3') Source 
1 Human 
rhinovirusa 
5' UTR CY+AGCC+TGCGTGGY 
GAAACACGGACACCCAAAGTA 
FAM-TCCTCCGGCCCCTGAATGYGGC-BHQ1 
Lu, 2008. (251) 
Arden, 2010. (252) 
2 Influenza A Matrix  CTTCTAACCGAGGTCGAAACGTA 
GGTGACAGGATTGGTCTTGTCTTTA 
Q670-TCAGGCCCCCTCAAAGCCGAG-BHQ2 
Whiley, 2005. (255) 
Influenza B Matrix  GCATCTTTTGTTTTTTATCCATTCC 
CACAATTGCCTACCTGCTTTCA 
FAM-TGCTAGTTCTGCTTTGCCTTCTCCATCTTCT-
BHQ1 
Lambert, 2008. (256) 
3 RSV-A Nucleocapsid AGATCAACTTCTGTCATCCAGCAA  
TTCTGCACATCATAATTAGGAGTATCAAT 
FAM-CACCATCCAACGGAGCACAGGAGAT-BHQ1 
van Elden, 2003. (257)  
RSV-Bb Nucleocapsid AAGATGCAAATCATAAATTCACAGGA 
TGATATCCAGCATCTTTAAGTATCTTTATAGTG 
YAK-TATGTCC+AGG+TTAGGAAG+G+G+AA-BBQ 
van Elden, 2003. (257) 
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Reaction 
Mix 
Virus Target Gene Primer, Probe sequences (5'-3') Source 
4 Parainfluenza-1 Hemagglutinin-
neuraminidase 
TTTAAACCCGGTAATTTCTCATACCT 
CCCCTTGTTCCTGCAGCTATT 
FAM-
TGACATCAACGACAACAGGAAATCATGTTCTG-
BHQ1 
Lambert, 2008. (256) 
Parainfluenza-2 Nucleocapsid AGAGTTCCAACATTCAATGAATCAGT 
CTCAAGAGAAATGTCATTCCCATCT 
YAK-CCTCTGTATTGCTCATGCATAGCACGGA-
BBQ 
Lambert, 2008. (256) 
Parainfluenza-3 Nucleocapsid CGGTGACACAGTGGATCAGATT 
AGGTCATTTCTGCTAGTATTCATTGTTATT 
Q670-TCAATCATGCGGTCTCAACAGAGCTTG-
BHQ2 
Lambert, 2008. (256) 
5 Human 
coronavirus-
HKU1 
Polymerase CCTTGCGAATGAATGTGCT 
TTGCATCACCACTGCTAGTACCAC 
FAM-TGTGTGGCGGTTGCTATTATGTTAAGCCTG-
BHQ1 
Dare, 2007. (258) 
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Reaction 
Mix 
Virus Target Gene Primer, Probe sequences (5'-3') Source 
6 Human 
coronavirus-
OC43 
Nucleocapsid CGATGAGGCTATTCCGACTAGGT 
CCTTCCTGAGCCTTCAATATAGTAACC 
Q670-TCCGCCTGGCACGGTACTCCCT-BHQ2 
van Elden, 2004. (259) 
Human 
coronavirus-
NL63 
Polyprotein 1a ACGTACTTCTATTATGAAGCATGATATTAA 
AGCAGATCTAATGTTATACTTAAAACTACG 
YAK-ATTGCCAAGGCTCCTAAACGTACAGGTGTT-
BBQ 
Gunson, 2005. (260) 
Human 
coronavirus-
229E 
Nucleocapsid CAGTCAAATGGGCTGATGCA 
AAAGGGCTATAAAGAGAATAAGGTATTCT 
FAM-CCCTGACGACCACGTTGTGGTTCA-BHQ1 
van Elden, 2004. (259) 
7 Human 
metapneumovir
us 
Nucleocapsid  CATATAAGCATGCTATATTAAAAGAGTCTC 
CCTATTTCTGCAGCATATTTGTAATCAG 
FAM-TGYAATGATGAGGGTGTCACTGCGGTTG-
BHQ1 
Maertzdorf, 2004. 
(261) 
8  Adenovirus Hexon  GCCACGGTGGGGTTTCTAAACTT 
GCCCCAGTGGTCTTACATGCACATC 
FAM-TGCACCAGACCCGGGCTCAGGTACTCCGA-
BHQ1 
Heim, 2003. (262) 
9 Human 
bocavirus-1 
VP1  GGCAGAATTCAGCCATACTCAAA 
TCTGGGTTAGTGCAAACCATGA 
FAM-
AGAGTAGGACCACAGTCATCAGACACTGCTCC-
BHQ1 
Tozer, 2009. (263) 
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Reaction 
Mix 
Virus Target Gene Primer, Probe sequences (5'-3') Source 
10 Human 
polyomavirus 
WU  
NCCR GCCGACAGCCGTTGGATATA 
TTTCAGGCACAGCAAGCAAT 
FAM-AGGGTCACCATTTTTATTTCAGATGGGCA-
BHQ1 
Antonsson, 2012. 
(264) 
Human 
polyomavirus KI 
NCCR 
 
GAACTTCTACTGTCCTTGACACAGGTA 
GGATTAGAACTTACAGTCTTAGCATTTCAG 
Q670-ACCCTTTGTAGGCCAAAGGAGAGTGAAGG-
BHQ2 
Antonsson, 2012. 
(264) 
Human 
polyomavirus KI 
STAg  CACAGGTGGTTTTCTATAAATTTTGTACTT 
GAAGCAGTGGGATGTATGCATTC 
YAK-TGCATTGGCATTCGTGATTGTAGCCA-BBQ 
Antonsson, 2012. 
(264) 
11 Endogenous 
retrovirus-3 
ENV gene CATGGGAAGCAAGGGAACTAATG 
CCCAGCGAGCAATACAGAATTT 
FAM-TCTTCCCTCGAACCTGCACCATCAAGTCA-
BHQ1 
Yuan, 2001. (248) 
 Equine 
Herpesvirus 
Glycoprotein B 
gene 
GATGACACTAGCGACTTCGA 
CAGGGCAGAAACCATAGACA 
Q670-TTTCGCGTGCCTCCTCCAG-BHQ2 
Bialasiewicz, 2009. 
(247) 
+ indicates Locked Nucleic Acid (LNA) base (eg: +A is a LNA Adenine analogue) 
aRhinovirus pan assay; bModified probe from published version presented 
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Cohort characteristics 
Of 891 potential participants approached, 165 (18.5%) eligible singleton infants from 163 
families were enrolled (two families’ enrolled two siblings) (Figure 2). Seven were 
excluded subsequently; one from ineligibility (born <36 weeks) and six for failing to provide 
any swabs. Of the remaining children, 158 provided 11,192 swabs. For consistency, we 
censored the end of the study period at the child’s second birthday, at which point a total 
of 11,125 swabs (Figure 2; 68.3% of maximum expected; median 84.5, range 1-104) were 
submitted. Four families submitted swabs but no symptom diaries before withdrawing 
early from the study. In this analysis of clinical information, 154 children provided 87,547 
child-days of symptom diaries (77.9% of maximum expected days; median 726 (range 1-
730 days)) with 67% followed until at least 23 months (Figure 3). One or more respiratory 
symptoms were recorded on 16,877 (19.3%) days, and corresponded to 1,641 discrete 
ARI episodes. Demographic and social characteristics are reported in Table 3. Compared 
to the general population of Brisbane and the state of Queensland, study children were 
from smaller families of advantaged backgrounds (Table 4). Enrolled families were more 
likely to have children that attended childcare and less likely to smoke. 
 
Figure 1: Recruitment of participants into the Observational Research in Childhood 
Diseases Study, September 2010-September 2012. 
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Figure 2: Submission of nasal swabs and symptom diaries from participants in the 
Observational Research in Childhood Infectious Diseases Study 
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Figure 3: Proportion of swab and/or diary return for 158 participants in the 
Observational Research in Childhood Infectious Diseases Study 
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Table 3: Characteristics of children enrolled in the Observational Research in 
Childhood Infectious Diseases Study. 
Characteristic (n=158 unless stated) Frequency (%) or Mean (+SD) 
Sex (male) 75 (47.5%) 
Gestational age (weeks) 39.8 (±1.3) 
Birth weight (g) 3530.8 (± 430.4) 
Delivery  
 Vaginal 107 (67.7%) 
Birth order (maternal)  
 First born 106 (67.1%) 
Parental mean age  
 Mother (years) (n=157) 31.8 (± 4.6) 
Family history of asthma or eczema  
 Mother 50 (31.6%) 
 Father 44 (27.8%) 
 Sibling 15 (9.5%) 
 First degree relative with asthma or 
 eczema 
83 (52.5%) 
Smoke exposure at birth  
 Mother (n=156) 5 (3.2%) 
 Other householder (n=155)a 17 (11.0%) 
Maternal educational status (n=157)  
 Primary school 5 (3.2%) 
 High school 15 (9.6%) 
 Diploma/Certificate 38 (24.2%) 
 University or higher university degree 99 (63.1%) 
Household income (n=155)b  
 Lowest quarter 0 
 Lower quarter 17 (11.0%) 
 Higher quarter 52 (33.5%) 
 Highest quarter 86 (55.5%) 
Child Immunisation status to 18 months (n=154)c 
 Fully immunised 141 (91.6%) 
Exclusive breastfeeding  
 At birth (n=149) 142 (95.3%) 
 At 3 months (n=142) 97 (68.3%) 
 At 6 months (n=133) 5 (3.8%) 
Childcare  
 At 6 months (n=133) 33 (24.8%) 
 At 9 months (n=123) 48 (39.0%) 
 At 12 months (n=115) 72 (62.6%) 
 At 15 months (n=110) 87 (79.1%) 
aIncludes 2 single parent households; bIncome categories based on Australian Bureau of Statistics 
income quartiles (Quartile 1: <$26,000; Quartile 2: $26,000-$67,499; Quartile 3: $67,500-$114,999; 
Quartile 4: ≥$115,000); c11/154 (7.1%) infants did not receive a full course of rotavirus vaccines because 
they presented for immunisation outside of required age limits; c2 children had chickenpox diagnosed 
before the varicella vaccine could be administered at the scheduled age of 18 months, but were up-to-
date for all other vaccines; another 2 children withdrew early and information was unavailable on their 
later immunisations. Influenza vaccines are not part of the national Australian infant immunisation 
schedule. Only 7 children received the influenza vaccine in the first two years of life. Abbreviations: SD: 
standard deviation.
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Table 4: Comparison of socio-demographic characteristics of the ORChID Study 
cohort and the general population of Brisbane or the State of Queensland, 2011. 
 ORChID cohort Brisbane/Queensland 
Sex (% male) 75 (47.5%) 51.3%a 
Aboriginal/Torres Strait Islander 
status 
2 (1.3%) 3.4%b 
Caesarean delivery 51 (32.3%) 34.2%c 
Maternal age (years) 31.8 (±4.6) 29.3c 
No. of children in the household   
  Average children per family 1.5 (±0.8) 1.9a 
Household income   
  <$26,000 0% 14.3%d 
  $26,000-$67,499 10.5% 31.2% 
  $67,500-$114,999 35.8% 23.7% 
  ≥$115,000 53.7% 30.8% 
Smoking exposure   
  Mother smokes 5 (3.2%) 14.8%e 
  Other householder smokes 17 (11.1%)  
Immunisation   
  Fully immunised to 18 months 141 (91.6%) 92.8%f 
Childcare   
  At 12 months 72 (62.6%) 47.6%g 
aAustralian Bureau of Statistics 2011 Census of Population and Housing Basic Community Profile 
(Catalogue number 2001.0) - Brisbane (UCL301001). Table B04. Data presented are an average for 
children 0-2 years of age. 
http://www.censusdata.abs.gov.au/census_services/getproduct/census/2011/quickstat/UCL301001?o
pendocument&navpos=220. Accessed 28 May 2017. 
bAustralian Bureau of Statistics 2011 Census of Population and Housing Basic Community Profile 
(Catalogue number 2001.0) - Brisbane (UCL301001). Table B07. Data presented are an average for 
children 0-4 years of age. 
http://www.censusdata.abs.gov.au/census_services/getproduct/census/2011/quickstat/UCL301001?o
pendocument&navpos=220. Accessed 24 October 2017. 
cSource: ‘Australian mothers and babies 2011’ report. Australian Institute of Health and Welfare. 
http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129545698. Data presented are for 
deliveries in Queensland. Accessed 28 May 2017. 
dAustralian Bureau of Statistics report 6523.0 Household Income and Income Distribution, Australia, 
2011–12. Table 2; http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/6523.02011-
12?OpenDocument. Accessed 28 May 2017. 
eAustralian Bureau of Statistics report 43640DO001: Australian Health Survey 2011-2012. Tables 1-
17 – Queensland, Table 7.2 – Smoker status. Data presented are for current female smokers aged 
25-34 years in Queensland; 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4364.0.55.0012011-12?OpenDocument. 
Accessed 28 May 2017. 
fAustralian Immunisation Register. Data presented are for 2011 Queensland State summary of 
percentage of fully immunised children 24-<27 months; 
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/acir-ann-cov-hist-
data.htm. Accessed 28 May 2017. 
gAustralian Bureau of Statistics report 44020DO001_201106 Childhood Education and Care, Australia, 
June 2011, Table 1 and 6; http://www.abs.gov.au/ausstats/abs@.nsf/mf/4402.0. Accessed 28 May 
2017 
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Chapter 3 – The burden of community-managed acute respiratory 
infections in the first two years of life 
 
This chapter is presented as a published original article: 
Sarna M, Ware RS, Sloots TP, Nissen MD, Grimwood K, Lambert SB. The burden of 
community-managed acute respiratory infections in the first 2-years of life. Pediatric 
Pulmonology 2016; 51(12):1336-46. DOI 10.1002/ppul.23480. 
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ABSTRACT 
Introduction: 
Contemporary information on acute respiratory infections (ARIs) in children is based 
on hospital cohorts, primary healthcare presentations, and high-risk birth cohort 
studies. We describe the burden and determinants of symptomatic episodes of ARIs 
in unselected healthy children in the first two years of life. 
Methods:  
One hundred and fifty-four children from subtropical Brisbane, Australia participated 
in a longitudinal, community-based birth cohort study. A daily tick-box diary captured 
pre-defined respiratory symptoms. Parents also completed a burden diary, recording 
family physician and hospital visits, and antibiotic use. 
Results: 
Participants contributed 88,032 child-days (78.2% of expected), of which 17,316 
(19.7%) days were symptomatic during 1,651 ARI episodes: incidence rate 0.56 ARIs 
per child-month (95% CI: 0.54, 0.59). Runny nose (14,220 days; 6.0 days median 
duration) and dry cough (6,880 days; 4.0 days median duration) were reported most 
frequently. Overall, 955 burden diaries recorded 455 family physician visits (1-8 visits 
per ARI) and 48 hospital presentations, including six hospital admissions. Antibiotics 
were prescribed on 209 occasions (21.9% of ARI episodes where burden diary 
submitted). Increasing age, non-summer seasons, and attendance at childcare were 
associated with an increased risk of ARI. 
Conclusions:  
ARIs are a common cause of morbidity in the first two years of life, with children 
experiencing 13 discrete ARI episodes and almost five months of respiratory 
symptoms. Most ARIs are managed in the community by parents and family 
physicians. Antibiotic prescribing remains common for ARIs in young children. Secular 
societal changes, including greater use of childcare in early childhood, may have 
maintained the high ARI incidence in this age group. 
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INTRODUCTION 
Respiratory symptoms are exceedingly common, occurring at every age, and often 
caused by infections. ARIs occur throughout life, but are most frequent during the first 
two years (114). Most early childhood ARIs are caused by viruses and are self-limiting 
in nature, involving mainly the upper respiratory tract where symptoms of nasal 
discharge or congestion predominate. Nevertheless, secondary bacterial infections 
from pathogens such as Streptococcus pneumoniae and Haemophilus influenzae can 
often occur in this age group and may lead to AOM and sinusitis complicating the 
original illness (265, 266). Although less common than URTIs, infections involving the 
lower respiratory tract may affect as many as one-third of infants in the first year of life 
(267). As with URTIs, the majority of LRTIs are caused primarily by viruses (268), but 
3-5% of infants are hospitalised because of bronchiolitis, croup, virus-associated 
wheezing, or secondary bacterial pneumonia (269). Information about the 
epidemiology of ARIs in children is based on historic community-based studies (60, 
61), cohorts of hospitalised patients (119, 270), Emergency Department (23) or 
primary healthcare presentations (271), and more recently from birth cohort studies in 
children at high-risk of asthma (2, 221). However, findings from these latter groups 
may not identify the burden of mild-to-moderate disease in healthy children managed 
in the community, while hospital-derived data can under-estimate the disease burden 
from illnesses, such as influenza and pertussis within the community (88, 272). 
An early Australian study reported ARIs were the most commonly managed problems 
in primary care, making up nearly 50% of consultations in children aged <5 years (26). 
A recent analysis of Australian family physician activity described 26 per 100 
encounters in this age group were for common respiratory tract infections (URTI, 
bronchitis/bronchiolitis, tonsillitis, and pneumonia) (27). Others have shown that in this 
age group almost half the ARI episodes resulted in a medical consultation (3, 28) and 
their management had considerable impact upon healthcare services (29). 
Several risk factors have been associated with the development of ARIs in various 
settings, including well-established determinants such as age (114), household size 
(114), exposure to other children, especially siblings (114) (28) or group child care 
attendance (28), environmental exposures, particularly tobacco smoke (273), a family 
history of atopy (273), and more recently gestational age at birth (274). Contemporary 
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published data on the nature and duration of symptoms in children with ARIs in the 
community are limited (3, 222, 233). We describe the incidence, symptoms, 
management and determinants of ARIs in a community-based birth cohort of healthy 
Australian children in their first two years of life, information that will guide strategies 
to minimise disease transmission and over-use of antibiotics in ARI, and help predict 
the future impact of novel respiratory vaccines. 
 
MATERIALS AND METHODS 
Details of the study population, demographic and symptom data collection, the ARI 
burden diary, and classification of ARIs have been outlined in Chapter 2. 
Analysis 
Summary statistics are presented as mean (standard deviation, SD) or median 
(interquartile range, IQR) for continuous variables and frequency (percentage) for 
categorical variables. ARI mean incidence rates (IR), averaged over the two year 
period, and associations between participant characteristics and new episodes of ARI, 
were calculated using Poisson regression. The association between potential risk 
factors, including age, sex, type of delivery, gestational age at birth, season, family 
history of asthma or eczema, tobacco smoke exposure, household size, maternal 
education status, mode of feeding, and type of childcare attendance were examined 
using both univariable and multivariable analyses. Breastfeeding and childcare 
attendance were analysed as time-varying variables using mixed-effects Poisson 
regression with child entered as a random effect. Multivariable models were adjusted 
for all of the above risk factors and were calculated using mixed effects regression. All 
models included the natural logarithm of time-at-risk-of-ARI as an offset. Time-at-risk 
began with the first recorded symptom diary day completed and ended at age 24 
months or when the child was lost to follow-up or left the study. This was a dynamic 
study and families could also leave the study for a short duration (e.g. for a holiday) 
and re-enter at a later date. Days forming part of an ARI and the next three days were 
excluded from the calculation of time-at-risk. Effect estimates are presented as 
incidence rate ratios (IRRs) with 95% CI. Data were analysed using Stata v12 for 
Windows (StataCorp, Texas, USA). 
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RESULTS 
Of 891 potential participants approached, 165 (18.5%) infants from 163 families were 
enrolled between September 2010 and November 2012 (Figure 2). Eleven participants 
were excluded from this analysis due to pre-term birth (n=1) or because they did not 
supply symptom data (n=10). Symptom diary information was received for 154 
children from 152 families. The number of children for whom symptom information was 
received at 6, 12, 18, and 24 months was 139 (90.3%), 122 (79.2%), 110 (71.4%), and 
100 (64.9%) respectively. In total 88,032 child-days of follow-up were recorded (78.2% 
of total expected days; median 731; range 7-759). 
Cohort characteristics 
Two-thirds of the children were first-born and more than half came from advantaged 
families (Table 5). Immunisation coverage was high. The median duration of exclusive 
breast-feeding was 19 (range 0-30) weeks. In 19 (12.3%) households, 23 adults (five 
mothers) were active smokers at birth. Two children (1.2%) were Aboriginal, consistent 
with the proportion of the Indigenous population in Brisbane. Eighty-one (52.6%) 
families had a first-degree relative (mother, father or sibling) with a history of asthma 
or eczema. By age 15 months, 79% of children were in some form of childcare. 
Overall, 1,651 ARIs were recorded, providing a mean IR of 0.56 ARI per child-month 
(95% CI: 0.54, 0.59); 1,370 (83.0%) as URTIs (mean IR=0.47 URTI per month, 95% 
CI: 0.44, 0.49) and 281 (17.0%) as LRTIs (mean IR=0.10 LRTI per month, 95% CI: 
0.09, 0.11) (Figure 4). Fever was reported in 320 (19.4%) ARIs, a dry cough in 584 
(42.6%) URTIs, while a moist cough was present in 234 (83.3%) and wheezing in 93 
(33.1%) LRTI episodes (Table 7). AOM was reported in 56 children (36.4%, mean 
IR=0.04 ARI with AOM per child-month (95% CI: 0.03, 0.05). These episodes of AOM 
complicated 76 (5.5%) URTIs and 40 (14.2%) LRTIs respectively. The longest duration 
of continuous respiratory symptoms in any individual child was 192 days. We did not 
observe any clustering of events in the different years. 
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Table 5: Characteristics of children enrolled in the Observational Research in 
Childhood Infectious Diseases Study who returned symptom diaries 
Characteristic (n=154 unless stated) frequency (%) or mean (+SD) 
Gender (male) 74 (48.1%) 
Gestational age (weeks) 39.8 (±1.3) 
Birth weight (g) 3514.5 (± 511) 
Delivery  
  Vaginal 105 (68.2%) 
  Caesarean 49 (31.8%) 
Birth order (maternal)  
  First born 103 (66.9%) 
Parental mean age  
  Mother (years) (n=153) 31.7 (± 4.6) 
  Father (years) (n=152) 34.2 (± 6.2) 
Family history of asthma or eczema  
  Mother 49 (31.8%) 
  Father 42 (27.3%) 
  Sibling 15 (9.7%) 
  First degree relative with asthma or eczema 81 (52.6%) 
Smoke exposure at birth  
  Mother (n=152) 5 (3.3%) 
  Other householder (n=149) 18 (12.1%) 
Maternal educational status (n=153)  
  High school 14 (9.2%) 
  Diploma/Certificate 38 (24.8%) 
  University or higher university degree 96 (62.7%) 
Household income (n=151)a  
  Lowest 0 
  Lower 17 (11.1%) 
  Higher 51 (33.8%) 
  Highest  83 (55.0%) 
Child Immunisation status (n=154)b  
  Fully immunised 137 (89.0%) 
Exclusive breastfeeding  
  At birth  (n=149) 142 (95.3%) 
  At 3 months (n=142) 97 (68.3%) 
  At 6 months (n=133) 5 (3.8%) 
Childcare  
  At 6 months (n=133) 31 (23.3%) 
  At 9 months (n=123) 48 (39.0%) 
  At 12 months (n=115) 72 (62.6%) 
  At 15 months (n=110) 87 (79.1%) 
aIncome categories based on Australian Bureau of Statistics income quartiles (Quartile 1: <$26,000; 
Quartile 2: $26,000-$67,499; Quartile 3: $67,500-$114,999; Quartile 4: >$115,000). b10/154 (6%) 
subjects did not receive a full course of rotavirus vaccines because they presented for immunisation 
beyond the required age constraints; three subjects withdrew early and information was unavailable on 
their later immunisations. Influenza vaccines are not part of the national Australian infant immunisation 
schedule. Thus, only seven children received the influenza vaccine in the first two years of life. 
Abbreviations: SD: standard deviation  
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Frequency, type and duration of symptoms and ARI 
Respiratory symptoms were recorded on 17,316 (19.7%) days, equivalent to 4.7 
months over the first two years of life. The most common and persistent symptoms 
were nasal discharge/congestion and dry cough (Table 6 and Table 7). Overall, 826 
days (0.9%) of fever associated with an ARI were reported in 107 (69%) children, with 
temperatures ranging from 37.5-41.0°C. 
 
Table 6: Frequency of symptoms. Total number of child-days on record = 88,032. 
Characteristic No. child-
days 
% 
Days acute respiratory 
infections 
17,316 
19.7 
Days upper respiratory tract 
infection 
12,324 
14.0 
Days lower respiratory tract 
infection 
4,992 
5.7 
Symptom   
Fever associated with acute 
respiratory infection 
826 0.9 
 
Nasal discharge/congestion 14,220 16.2 
Dry cough 6,880 7.8 
Moist cough/pulmonary congestion 2,091 2.4 
Shortness of breath 109 0.1 
Wheeze 409 0.5 
Diagnoses (doctor-diagnosed)   
Otitis media 712 0.8 
Pneumonia 13 <0.1 
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Table 7: Duration of respiratory symptoms and acute respiratory infection episodes 
Duration of 
illness 
1-3 days  4-7 days  8-14 days 15-21 days  22-28 days >28 days 
n % n % n % N % n % n % 
ARIa (n=1,651) 427 25.9 451 27.3 456 27.6 151 9.1 72 4.4 94 5.7 
URTI 
(n=1,370) 414 30.2 410 29.9 347 25.3 101 7.4 45 3.3 
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3.9 
LRTI (n=281) 13 4.6 41 14.6 109 38.8 50 17.8 27 9.6 41 14.6 
Number of days with symptom/diagnosis for URTIsb   
Fever (n=215) 174 80.9 37 17.2 4 1.9 0 0 0 0 0 0 
Nasal discharge 
(n=1,233) 
386 31.3 374 30.3 321 26.0 77 6.2 35 2.8 40 3.2 
Dry cough 
(n=584) 
223 38.2 166 28.4 121 20.7 36 6.2 18 3.1 20 3.4 
Otitis media 
(n=76) 
19 25 40 52.6 15 19.7 2 2.6 0 0 0 0 
Number of days with symptom/diagnosis for LRTIs   
Fever (n=105) 74 70.5 28 26.7 2 1.9 1 1.0 0 0 0 0 
Moist cough 
(n=234) 
50 21.4 84 35.9 70 29.9 13 5.6 8 3.4 9 3.8 
Shortness of 
breath (n=31) 
18 58.1 10 32.3 3 9.7 0 0 0 0 0 0 
Wheeze (n=93)  53 57.0 22 23.7 16 17.2 2 2.2 0 0 0 0 
Pneumonia (n=3) 2 66.7 0 0 1 33.3 0 0 0 0 0 0 
Otitis mediac 
(n=40) 
13 32.5 15 37.5 8 20 2 5 2 5 0 0 
aAbbreviations: ARI: acute respiratory infection; LRTI: lower respiratory tract infection; URTI: upper respiratory tract infection; b within an ARI,  
symptoms may overlap and/or be sequential, thus duration of symptoms does not correspond to duration of ARI ;ccomplicating the LRTI episode 
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Management 
Overall, 955 completed burden diaries were submitted for 1,007 ARIs (94.8%) that 
met the threshold for burden diary completion. Noting that a burden diary was not 
required for all URTIs, diaries captured 688 (50.2%) URTIs and 267 (95.0%) LRTIs. 
Episodes of URTI where a burden diary was not required (isolated nasal congestion 
or cough) had a median duration of 4 (IQR 2-7) days compared with 10 (IQR 5-16) 
days for those submitting a diary. For ARIs covered by burden diaries, a family 
physician visit occurred with 455 (47.6%) episodes, 300 for URTIs and 155 for LRTIs 
(Table 8). Additional family physician visits (range 1-7) were required in 169 (17.7%) 
ARI episodes. A further 34 consultations were made with other healthcare 
professionals, most commonly paediatricians, n=10 (Table 8). Antibiotics were 
prescribed at least once for 209 (21.9%) ARI episodes (median 1.0, range 1-4 
courses), which represented 45.9% of ARIs prompting a family physician visit, most 
commonly for AOM (98, 46.9%). Two children with pneumonia were administered 
antibiotics and managed by their family physician. Children with a LRTI were more 
likely to be prescribed antibiotics than children with an URTI (unadjusted odds ratio 
(OR) = 2.0 (95% CI: 1.5, 2.8). 
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Figure 4: Incidence rate of acute respiratory infection episodes per child-month by age and type of respiratory infection 
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The 955 episodes included 48 hospital presentations resulting in 6 (0.6%) 
hospitalisations (IR 0.002 admissions per month, mean length of stay 1.3 (range 0-3) 
days) (Table 8). All 6 hospitalisations were for LRTI: croup (2), pneumonia (1), acute 
wheezy episode treated with albuterol and prednisolone (1), bronchiolitis (1), and 
bronchiolitis with bilateral AOM (1). Two children also underwent elective grommet 
insertions for recurrent AOM. There were significant differences in seeking healthcare 
for LRTIs vs URTIs, including family physician visits (unadjusted OR=1.6 (95% CI: 1.2, 
2.1)), and hospital presentations (unadjusted OR=4.3 (95% CI: 2.3, 8.2)). 
 
Table 8: Healthcare-seeking behaviour by type of acute respiratory infection 
 Type of respiratory infection 
Healthcare-seeking 
behaviour 
URTIa  
(n=688)  
LRTI  
(n=267) 
Totalb 
(n=955) 
Family physician visits 300 (43.6%) 155 (58.1%) 455 (47.6%) 
Other healthcare professional 22 (3.2%) 12 (4.5%) 34 (3.6%) 
Hospital    
   Presentations 19 (2.8%) 29 (10.9%) 48 (5.0%) 
   Admissions 0 (0.0%) 6 (2.2%) 6 (0.6%) 
Antibiotics 126 (18.3%) 83 (31.1%) 209 (21.9%) 
aAbbreviations: URTI: upper respiratory tract infection, LRTI: lower respiratory tract infection; bsymptom 
information not available for four burden diaries 
 
Risk factors  
Increasing age, non-summer seasons, and childcare attendance were independent 
risk factors for ARI (Table 9). We did not observe an association between family history 
of atopy and LRTI or wheezing episodes. We also did not see an association between 
household size, tobacco smoke exposure, gestational age at birth, and ARI. The rate 
of ARI increased progressively during the first six months of life, then stabilised for the 
rest of the study period (Figure 3). The mean age at first ARI was 6.7 months (95% 
CI: 6.5, 7.0); children aged 15 months had the highest rates of ARI at 1.05 ARI per 
child-month (Figure 3). A seasonal peak in the rate of ARI per child-month was 
observed between the months of May to September, which in Australia encompass 
late fall, winter, and early spring seasons (Figure 5). 
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Figure 5: Number of acute respiratory infection episodes and rate of acute 
respiratory infection per child-month by type of infection and month of the yeara, 
September 2010 – October 2014. 
 
aThis combines all months of the study. All numerator ARIs and denominator child-days were 
summed for each month of the year over four years 
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Table 9: Number of children, child-months, acute respiratory illness episodes, days exposed, and association between 
participant characteristics and acute respiratory infections 
Explanatory variables No. of 
children 
No. of 
child-
months 
No. of ARI Incident rate per 
child-month (95% 
CI) 
Unadjusted 
Incidence  
rate ratio  
(95% CI) 
Adjusted 
Incidence  
rate ratioa  
(95% CI) 
Age (months)       
  0-<3  154 406.7 129 0.3 (0.3, 0.4) Referent rate Referent rate 
  3-<6 141 353.1 183 0.5 (0.4, 0.6) 1.6 (1.3, 2.0) 1.8 (1.4, 2.3) 
  6-<12 135 541.9 465 0.9 (0.8, 0.9) 2.7 (2.2, 3.3) 2.9 (2.2, 4.0) 
  12-<24 117 905.9 865 1.0 (0.9, 1.0) 3.0 (2.5, 3.6) 2.6 (1.9, 3.6) 
Sex       
  Male 74 1017.9 720 0.7 (0.7, 0.8) Referent rate Referent rate 
  Female 80 1189.6 922 0.8 (0.7, 0.8) 1.1 (1.0, 1.2) 1.1 (0.9, 1.4) 
Type of delivery       
  Vaginal 105 1465.0 1141 0.8 (0.7, 0.8) Referent rate Referent rate 
  Caesarean 49 742.5 501 0.7 (0.6, 0.7) 0.9 (0.8, 1.0) 0.8 (0.6, 1.0) 
Gestational age       
   Term (39w0d-41w6d)  119 1746.5 1327 0.8 (0.7, 0.8) Referent rate Referent rate 
   Late pre-term/early term 
   (36w0d-38w6d) 
35 461.0 315 0.7 (0.6, 0.8) 0.9 (0.8, 1.0) 1.0 (0.8, 1.4) 
Season       
  Summer 142 600.9 319 0.5 (0.5, 0.6) Referent rate Referent rate 
  Autumn 138 549.6 452 0.8 (0.7, 0.9) 1.6 (1.4, 1.9) 1.6 (1.4, 1.8) 
  Winter 138 497.3 478 1.0 (0.9, 1.0) 2.0 (1.7, 2.3) 1.9 (1.6, 2.2) 
  Spring 143 559.7 393 0.7 (0.6, 0.8) 1.4 (1.2, 1.6) 1.3 (1.1, 1.5) 
Family history       
  No family history 73 1021.1 741 0.7 (0.7, 0.8) Referent rate Referent rate 
  Either parent asthma/eczema 78 1142.5 870 0.7 (0.7, 0.8) 1.0 (0.9, 1.1) 1.0 (0.8, 1.3) 
  First degree relative 
asthma/eczemab 
81 1186.4 901 0.8 (0.7, 0.8) 1.0 (0.9, 1.2) 1.0 (0.8, 1.3) 
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aadjusted for age, sex, type of delivery, gestational age, season, family history, tobacco smoke exposure, household size, maternal education status, mode of 
feeding, and childcare attendance; bmother, father or sibling; cformal and informal childcare attendance were combined because of the small number of children 
attending informal childcare alone; abbreviations: ARI: acute respiratory infection. Discrepancies in the numbers of children in Table 1 and Table 4 are either 
because of no ARIs before leaving the cohort and/or missing data. 
Explanatory variables No. of 
children 
No. of 
child-
months 
No. of ARI Incident rate per 
child-month (95% 
CI) 
Unadjusted 
Incidence  
rate ratio  
(95% CI) 
Adjusted 
Incidence  
rate ratioa  
(95% CI) 
Tobacco smoke exposure       
  No exposure 130 1885.5 1406 0.7 (0.7, 0.8) Referent rate Referent rate 
  Either parent smokes 19 244.9 171 0.7 (0.6, 0.8) 0.9 (0.8, 1.1) 0.8 (0.6, 1.2) 
Household size       
  No other children in 
household 
100 1495.6 1052 0.7 (0.7, 0.7) Referent rate Referent rate 
  More than one child in 
household 
54 712.0 595 0.8 (0.8, 0.9) 1.2 (1.1, 1.3) 1.2 (0.9, 1.5) 
Maternal education status       
  High school 14 186.2 141 0.8 (0.6, 0.9) 1.0 (0.8, 1.2) 0.9 (0.6, 1.4) 
  Diploma/Certificate 38 526.7 353 0.7 (0.6, 0.7) 0.9 (0.8, 1.0) 0.8 (0.6, 1.1) 
  University/higher university 
degree 
96 1443.3 1099 0.8 (0.7, 0.8) Referent rate Referent rate 
Mode of feeding       
   Formula 142 1739.4 1447 0.8 (0.8, 0.9) Referent rate Referent rate 
   Breast milk 146 467.6 195 0.4 (0.4, 0.5) 0.5 (0.4, 0.5) 1.2 (0.9, 1.6) 
Childcare attendance       
  No childcare 153 1238.4 679 0.5 (0.5, 0.6) Referent rate Referent rate 
  Informal childcare only 48 343.2 197 0.6 (0.5, 0.7) 1.3 (1.0, 1.5) 0.9 (0.7, 1.1) 
  Formal and/or informal 
childcarec 
90 625.5 766 1.2 (1.1, 1.3) 2.6 (2.3, 3.0) 1.9 (1.6, 2.3) 
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DISCUSSION 
In this community-based cohort we found that during their first two years of life, healthy 
Australian children living in a subtropical city had on average 13 discrete symptomatic 
episodes of ARI. Further, these combined episodes amounted to a cumulative total of 
almost five months of any respiratory symptoms in the first two years of life. Just 17% 
of all episodes were LRTIs, including 6% with recorded symptoms of wheezing. 
Parents consulted their family physician for almost half (48%) of the ARIs captured by 
a burden diary and an antibiotic was prescribed in 46% of these episodes. Increasing 
age, non-summer seasons, and attendance at childcare were independent risk factors 
for ARI. 
Our incidence estimate is consistent with other reports of an annual mean 5.0-6.3 ARI 
episodes per child during their first 1-2 years of life (222, 233, 266, 275). However, this 
contrasts with a lower annual mean incidence of 4.2 ARI episodes in a community-
based, high-risk birth cohort in Perth, Western Australia (28). The lower IR in that study 
probably reflects study design, which required parents to contact research staff within 
24-hours of ARI onset and staff to make visits within 48-hours of notification. Lower 
rates have also been reported in similar study designs involving high-risk infant cohorts 
where mild infections went under-reported (275). Furthermore, a smaller proportion of 
Western Australian cohort participants attended childcare (32%), which could also 
explain lower ARI incidence (28). Other studies have focused primarily on LRTIs 
requiring medical attention and hospitalisation (21) or extrapolated from other data 
sources such as Emergency Department presentations (276). 
Nasal discharge/congestion and cough were the major ARI symptoms in both 
frequency and duration, whereas fever and wheeze were less common and resolved 
quickly. A recent systematic review of ARI in children attending primary care (277) 
estimated that 90% of healthy children with nasal symptoms from ARI will recover 
within two weeks, longer than the 7-10 days cited by current guidelines (278, 279). 
Our observations on symptom duration are similar for nasal discharge/congestion, 
although in our cohort 90% of cough also resolved by two weeks rather than the 
estimated 25 days from the systematic review (277). This information is relevant to 
both parents and clinicians to help set more realistic expectations for ARI episodes 
and for parents to decide when to re-consult for persistent symptoms.  
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Many children in our study were first-born and from well-educated, affluent families; 
factors thought to decrease the rate of infection in a household. Secular changes in 
Australia have led to an increase in the proportion of households where both parents 
are employed outside the home, and their children are more likely to attend childcare 
at an earlier age than other sectors of the population (244). A slightly higher proportion 
(80-85%) of our cohort attended some form of care by the age of 15-24 months, 
compared to 74% of children in the Australian population (244), with childcare 
attendance an independent risk factor for ARI (11, 29). We did not observe a 
relationship between ARI and either tobacco smoke exposure or household size, 
however our power to detect such associations was small because of the low number 
of household smokers in our cohort and two-thirds of participants were first-born. In 
contrast to recent studies reporting a continuum of increasing risk of adverse 
respiratory outcomes with increasing prematurity (274), we did not see an association 
between gestational age at birth and ARI, although our eligibility criteria excluded early 
pre-term children (<36 weeks gestation) and only two children in our cohort were born 
late pre-term/early term (36w0d-37w6d). Consistent with other paediatric studies, age, 
greater respiratory virus activity outside summer months, and childcare attendance 
were independently associated with an increased risk of ARI in our cohort (2, 3, 60, 
114, 233, 269). 
Of ARI episodes captured in a burden diary, nearly half required a medical 
consultation, with significantly higher likelihood of consultation for LRTIs. Thus, studies 
estimating ARI from primary care visits alone could underestimate disease burden by 
50% or more. Studies with parent-completed diaries are able to capture mild-to-
moderate disease in the community that may not generate a doctor’s visit (3). When 
an ARI-related medical consultation occurred in our cohort, almost half were 
prescribed an antibiotic, more likely for AOM than for other URTIs, so that by the end 
of the study more than half the cohort had been prescribed an antibiotic on at least 
one occasion. This degree of antibiotic exposure is comparable with other Australian 
studies (3, 28, 280) and within the broad range of prescribing found within Europe 
(222, 233, 281), the United Kingdom (282), and in the United States of America (283). 
A European study observed that while the frequency of infection episodes did not differ 
between countries, antibiotic prescribing habits were determined by other factors, such 
as physician attitudes and socio-economic factors (281). This was highlighted by a 
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recent cross-sectional survey of common ARI management in young children in 
Australian family practice (27). It found highest antibiotic prescribing rates for URTI 
were from older male doctors who were also less likely to educate parents about these 
infections. While antibiotic prescribing in our cohort was higher for LRTI than for URTI, 
few cases of pneumonia were diagnosed and thus educating parents and physicians 
on the self-limiting and viral nature of most ARIs remains a priority for promoting good 
antimicrobial stewardship. 
Strengths and limitations   
Our study had a good retention rate for an intensive two year study with daily data 
collection, providing 78% of total expected person-days of follow-up recorded and 95% 
of expected burden diaries submitted. We captured burden diary information for 50% 
of URTIs. The remaining URTIs where data were not collected were mild events 
involving either nasal symptoms or dry cough in isolation, and unlikely to impact upon 
resources at the family level. The prospective study design with parent-reported diary 
cards gives a comprehensive account of ARIs, including minor symptoms. Although 
we did not validate symptom information captured in the daily diaries (other than 
doctor-diagnosed AOM and pneumonia), we minimised inaccuracy of reporting by 
training parents how to recognize symptoms and complete the diary before they 
commenced the study. Furthermore, this study design has been used before 
successfully (3) and this and other studies have shown that parents can be trained to 
recognize and document symptoms of interest (3), often as reliably as health 
professionals (284, 285). While visits by trained healthcare workers to validate all 
symptoms would have been ideal, a study of this magnitude and scale would have 
been logistically challenging and resource intensive to conduct without parent 
participation. We used relatively specific case definitions for both URTI and LRTI 
without the inclusion of non-specific constitutional symptoms, which may be unreliable 
in this age group. It is possible therefore that some minor respiratory symptoms may 
have been missed when more non-specific symptoms, such as fever, irritability, and 
poor feeding dominated the clinical picture. Our cohort were from families of more 
advantaged backgrounds, which is common in longitudinal cohort studies (28, 230) 
given the long-term, intensive nature of the study. However, our findings of the 
exposures within the cohort on the outcomes of interest remain valid and provide 
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estimates on ARI burden and management in an Australian subtropical urban 
community.  
Conclusions 
Our study adds to current knowledge about ARIs in the first two years of life as a 
common cause of early childhood morbidity in the community. Most are URTIs and 
their symptom duration, particularly nasal symptoms of the common cold, can be much 
longer than commonly published estimates. When healthcare assistance is sought, 
family physicians are consulted most often, with very few children requiring 
hospitalisation. Nevertheless, antibiotics are still commonly prescribed for ARIs. 
Secular societal changes and the increasing use of childcare in early childhood may 
have impacted on the incidence of ARIs in this age group. Future studies examining 
the aetiologies of these ARIs are underway and will help guide prevention strategies. 
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Chapter 4 – Respiratory viruses in neonates 
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ABSTRACT 
Introduction: 
Acute viral respiratory infections are important causes of morbidity and mortality in 
infants worldwide. However, little is known about these infections in the first four weeks 
of life (the neonatal period). The few studies describing respiratory viruses in neonates 
are predominantly from neonatal units or neonates presenting to hospital with 
respiratory symptoms, and are unlikely to be widely generalisable. Respiratory virus 
infection in this age group, even if asymptomatic, may influence future respiratory 
health. Hence we describe the respiratory viruses detected in neonates in a 
community-based birth cohort. 
Methods: 
One hundred and fifty-seven children from subtropical Brisbane, Australia, participated 
in a longitudinal, community-based birth cohort study. Parents completed a daily tick-
box diary capturing pre-defined respiratory symptoms, and collected weekly nasal 
swabs, which were tested for 17 respiratory viruses by polymerase chain reaction 
assays. The association between potential risk factors and new virus infections was 
assessed using Poisson regression. 
Results: 
An average of 0.25 (95% CI: 0.18, 0.34) respiratory virus infections per neonatal period 
were detected in 157 full-term infants. Human rhinoviruses of diverse subtypes 
dominated and almost 50% were asymptomatic.  Virus shedding was transient (5-14 
days) and serial HRV detections were as likely to result from new genotype acquisition 
as continued detection of the original infection. Being the first-born child was 
associated with a reduced incidence of infection (IRR 0.5; 95% CI: 0.2, 0.9, p=0.02). 
There was no evidence of transmission between parents harbouring respiratory 
viruses around the time of delivery and their newborn infants. 
Conclusions:  
Respiratory viruses are common and often unrecognised in healthy neonates. HRV 
predominates. This early exposure to HRV means preventative strategies against 
HRV need to begin early.  
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INTRODUCTION  
Despite acute viral respiratory infections being important causes of morbidity and 
mortality in infants worldwide, little is known about these infections in the first four 
weeks of life (referred henceforth as the neonatal period). The few studies describing 
respiratory viruses in neonates are unlikely to be widely generalizable as they are 
predominantly from neonatal units (286, 287) or neonates presenting to hospital with 
respiratory symptoms (288, 289). While several community-based birth cohort studies 
tested for respiratory viruses (144, 146), few collected samples before four weeks of 
age and then only tested for a limited number of viruses (290). It is important to 
understand respiratory virus exposure in this age group as early infection, even if 
asymptomatic, may influence future respiratory health (291). Hence we describe the 
respiratory viruses detected in neonates in a community-based birth cohort. 
 
MATERIALS AND METHODS 
Details of the study population, demographic and symptom data collection, 
classification of ARIs, anterior nose swab sample collection, transport, processing, and 
testing, have been outlined in Chapter 2. 
Analysis 
A new virus detection occurred when a new virus species or another HRV genotype 
was detected. We defined each swab as representing seven days of study-time, with 
a maximum of 28 days per neonate. The association between potential risk factors 
(sex, mode of delivery – vaginal vs Caesarean, first-born status, season, parental 
history of asthma or eczema, household tobacco smoke exposure, and breastfeeding) 
and new virus infections was assessed using Poisson regression. As categories of 
season and breastfeeding were not mutually exclusive for individual neonates, these 
two variables were analysed using mixed-effects Poisson regression with neonate 
included as a random effect. All models were offset using the natural logarithm of 
study-time. Effect estimates are expressed as incidence rate ratios with 95% CI. A 
failure curve of first virus detections was constructed from life tables. Data were 
analysed using Stata v12.0 (StataCorp, Texas, USA).  
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RESULTS 
Viruses detected and symptoms in neonates 
Overall, 157/164 enrolled and eligible (74 males, 47.1%) neonates provided 574 nasal 
swab specimens (range 1-5 per neonate), yielding 552 weeks of data (87.9% of 
maximum expected). One infant did not provide any swabs in the neonatal period. Of 
the 43 virus-positive swabs from 29 (10 male) neonates (Figure 6), new infections 
were detected in 34 swabs (incidence rate 0.25 virus infections per neonatal period; 
95% CI: 0.18, 0.34). The earliest virus detection was at two days of age and the age 
at first detected infection was consistent throughout the neonatal period (Figure 7).  
HRV was observed in 21/29 (72.4%) neonates with positive detections. Overall, HRV 
was found in 31 weekly swabs, including from all 4 neonates with viruses detected in 
the first-week of life. HCoV was detected in 4 neonates (5 swabs) and PIV-3 virus in 
2 neonates (2 swabs), with 1 neonate each having RSV-A (3 swabs), INFV-B virus (1 
swab), and HMPV (1 swab). No co-detections were identified. 
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Figure 6: Nature, timing and symptoms associated with respiratory viruses 
detected in 29 healthy, full-term neonates during the neonatal period  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  *No symptom diary was completed for subjects 11, 37 and 126 
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Figure 7: Time to detection of first respiratory virus (n=157)* 
 
*one infant did not provide any swabs during the neonatal period 
 
Thirteen neonates had 14 symptomatic episodes associated with virus detection 
(Figure 6). The earliest symptomatic virus detections were in the first week of life, on 
days 6 and 7 (both HRV-A), and associated symptoms commenced on days 9 and 11, 
respectively. Eleven showed upper respiratory symptoms of nasal 
discharge/congestion (four also had a dry cough), including subject 66 who 
experienced two discrete respiratory episodes (corresponding to two different strains 
of HRV-A). The remaining two infants exhibited lower respiratory symptoms: subject 
67 had wheezing (HCoV-229E detected on day-13), while subject 161 had wheezing 
accompanied by fever and a wet cough (HCoV-HKU1 detected on days-14 and 21, 
and HRV on day-28). Subjects 4, 51, 67, 134, 142, 161 sought medical advice, with 
subject 51 diagnosed with otitis media at 22 days of age. None were hospitalised. In 
contrast, 13 neonates had asymptomatic viral detections. This included subject 71 with 
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influenza-B on day-16, and subject 25 shedding RSV-A between days 9-26. Symptom 
diary data were unavailable for three neonates with single HRV detections.  
Being the first-born child was associated with a reduced incidence of infection (IRR 
0.5; 95% CI: 0.2, 0.9, p=0.02) (Table 10). In contrast, no associations were observed 
between other risk factors (sex, mode of delivery, season, parental history of 
asthma/eczema, household tobacco exposure, or exclusive breastfeeding) and virus 
infection as a neonate.  
HRV typing  
Of the 31 HRV-positive samples (21 neonates), nine (29.0%) were sequenced, but 
could not be assigned a specific HRV genotype (unclassified novel VP4/VP2 
sequences) based on a GenBank database search (http:www.ncbi.nlm.nih.gov), while 
4 (12.9%) HRV detections could not be sequenced, usually because of insufficient 
viral RNA template loads. Of the 18 samples able to be typed, 11 (61.1%) were HRV-
A, 2 (11.1%) were HRV-B, and 5 (27.8%) were HRV-C. Overall, there were 17 different 
subtypes amongst the 27 HRVs able to be sequenced. Apart from HRV-B52 and HRV-
C02 (each detected in 2 unrelated neonates), clustering of HRV genotypes was 
confined to individuals. Repeat detection of homologous genotypes for 1-2 weeks was 
observed in 4 neonates (subjects 29, 66, 120, 139). In contrast, 4 subjects (44, 51, 66, 
120) had either different HRV genotypes or different unclassified HRV sequences in 
subsequent swabs. 
Viruses detected and symptoms in parents  
Two-hundred-and-thirty-nine (127 mothers) parents submitted swabs. Nine (three 
mothers) parents (3.8%, 95% CI: 1.9%, 7.5%) of eight neonates had respiratory 
viruses detected, 8 with HRV and 1 with influenza-A virus, with no co-detections. Five 
parents with HRV reported nasal discharge/congestion, while one other complained 
of fever, myalgia, and lassitude. Of the eight neonates with infected parents, subject 
51 had different HRV genotypes detected on days 18 and 25, subject 100 had a 
different HRV genotype detected on day-28, and subject 71, whose parents had HRV, 
became infected with influenza-B. The remaining 5 neonates remained asymptomatic 
and virus-negative. No transmission events between parents and infants were 
detected. 
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Table 10: Number of children and swabs, and association between participant characteristics and new virus detections of 
the ORChID community-based birth cohort in the neonatal period. 
Characteristics Total no. of  
children  
N=157 
No. of positive  
children 
N=29 
Total no. of 
Swabs 
N=574 
New virus 
detections, N=34 
n (%) 
Unadjusted  
incidence rate 
ratio 
(95% CI), p value 
Sex        
Males 74 10 273 (47.6%) 11 (32.4%) reference 
Females 83 19 301 (52.4%) 23 (67.6%) 1.8 (0.9, 3.8), 0.09 
Mode of delivery      
Vaginal  106 20 385 (67.1%) 24 (70.6%) reference 
Caesarean 51 9 189 (32.9%) 10 (29.4%) 0.8 (0.4, 1.7), 0.60 
Birth order      
Not first-born 105 14 185 (32.2%) 17 (50.0%) reference 
First-born 52 15 389 (67.8%) 17 (50.0%) 0.5 (0.2, 0.9), 0.02 
Seasona      
Summer 52 10 171 (29.8%) 10 (29.4%) reference 
Autumn 35 5 102 (17.8%) 7 (20.6%) 0.9 (0.3, 2.9), 0.92 
Winter 47 6 147 (25.6%) 9 (26.5%) 0.9 (0.3, 2.5), 0.81 
Spring 34 8 154 (26.8%) 8 (23.5%) 0.8 (0.3, 2.2), 0.64 
Parent with asthma/eczema 
No 79 16 284 (49.5%) 15 (44.1%) reference 
Yes 138 25 290 (50.5%) 19 (55.9%) 1.2 (0.6, 2.3), 0.63 
Household tobacco exposure 
No 21 2 509 (88.7%) 29 (85.3%) reference 
Yes 140 25 65 (11.3%) 5 (14.7%) 1.4 (0.5, 3.5), 0.53 
Breastfeedinga,b       
Received milk 
formula 
21 2 66 (11.8%) 2 (6.5%) reference 
Received breastmilk  140 25 493 (88.2%) 29 (93.5%) 1.5 (0.4, 6.1), 0.55 
aTotal number of children does not add up to 157 because an infant could be in more than one category 
bData from 559 swabs from 152 neonates; one neonate had new infection in both categories
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DISCUSSION 
In a community-based, urban Australian birth cohort of 157 healthy, full-term infants with 
high exclusive breastfeeding rates and little household tobacco exposure, we detected a 
mean of 0.25 (95% CI: 0.18, 0.34) new respiratory virus infections per neonatal period. 
These infections occurred consistently throughout the neonatal period. Being an only 
child, and presumably less exposed to other children, was associated with a reduced risk 
of virus detection. HRVs representing diverse genotypes predominated and almost half of 
all episodes associated with respiratory virus detections were asymptomatic. Virus 
shedding was transient (5-14 days) and serial HRV detections were as likely to result from 
new genotype acquisition as continued detection of the original infection. Finally, although 
numbers were small, there was no evidence of transmission between parents harbouring 
respiratory viruses around the time of delivery and their newborn infants.  
It is possible that the frequent subclinical viral detections we observed were due to some 
protection against symptomatic illnesses afforded by maternal trans-placental and 
breastmilk antibodies (292). Indeed, neonates who appear healthy may be important 
sources of virus transmission. Early exposure to HRV could also have implications for 
infants with a family history of atopy or asthma. High-risk birth cohort studies have found 
a close relationship between HRV infections in infancy and subsequent asthma 
development, particularly with HRV-A and C species (124). Recently, a cross-sectional 
study of the Danish asthma birth cohort (COPSAC2010) detected viruses (predominantly 
HRV) in 12% of neonates at four weeks of age (291). Some of the infected neonates 
exhibited an exaggerated type-2 mucosal immune response, suggesting early HRV 
exposure may trigger aberrant immune programing in susceptible individuals and promote 
subsequent development of asthma and allergic sensitization (124, 291). Any preventive 
intervention will therefore need to begin early. 
HRV genotype diversity occurs in neonates as well as in infants and young children (150). 
Moreover, even during single acute respiratory infection episodes, continued HRV 
presence in neonates is most likely from sequential infections by different HRV genotypes 
rather than continued shedding of the original genotype. In HRV-positive infants with 
sequential detections, we observed a change of genotype 50% of the time. These findings, 
and those from other reports (144, 150), emphasise the importance of nucleotide 
sequencing when studying HRV infections.  
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Our study’s strengths include the prospective collection of swabs at birth and then weekly 
thereafter, allowing respiratory viruses to be detected during the neonatal period. Parent 
swabs and symptom history also enabled us to examine possible transmission from parent 
to newborn, which appeared limited, although this observation was constrained by the 
small number of positive swabs. It is also possible that parents may have missed 
identifying mild respiratory and non-specific symptoms in their newborn infants. Finally, 
and similar to other community-based HRV studies (150), 41.9% of sequences from HRV 
detections either failed to align with HRV reference prototype sequences or could not be 
genotyped, usually because of low viral RNA template loads. Nevertheless, the ORChID 
study design, with its weekly sampling and HRV-sequencing, was able to demonstrate 
sequential detection by the same and different HRV genotypes. 
In conclusion, respiratory virus infections were common in neonates and many were 
asymptomatic. HRV predominated and our future studies will assess the association 
between early HRV exposure and ensuing frequency and severity of respiratory infections, 
as well as with later respiratory health, mucosal immunity, and lung function. 
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Chapter 5 – Viruses causing lower respiratory symptoms in children 
younger than two years of age: findings from the ORChID birth cohort 
 
This chapter is presented as a published original article: 
Sarna M, Lambert SB, Sloots TS, Whiley DM, Alsaleh A, Mhango L, Bialasiewicz S, Wang 
D, Nissen MD, Grimwood K, Ware RS. Viruses causing lower respiratory symptoms in 
children younger than 2-years of age: findings from the ORChID birth cohort. Thorax; 
2018; 73(10):969-79. DOI: 10.1136/thoraxjnl-2017-210233. 
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ABSTRACT 
Introduction: 
Viral acute respiratory infections (ARIs) cause substantial child morbidity. Sensitive 
molecular-based assays aid virus detection, but the clinical significance of positive tests 
remains uncertain as some viruses may be found in both acutely ill and healthy children. 
We describe disease-pathogen associations of respiratory viruses and quantify virus-
specific attributable risk of ARIs in healthy children during the first two years of life. 
Methods: 
One hundred fifty-eight term newborn babies in Brisbane, Australia, were recruited 
progressively into a longitudinal, community-based, birth cohort study conducted between 
September 2010 and October 2014. A daily tick-box diary captured predefined respiratory 
symptoms from birth until their second birthday. Weekly parent-collected nasal swabs 
were batch-tested for 17 respiratory viruses by PCR assays, allowing calculation of virus-
specific attributable fractions in the exposed (AFE) to determine the proportion of virus-
positive children whose ARI symptoms could be attributed to that particular virus. 
Results: 
Of 8100 nasal swabs analysed, 2646 (32.7%) were virus-positive (275 virus co-detections, 
3.4%), with human rhinoviruses accounting for 2058/2646 (77.8%) positive swabs. 
Viruses were detected in 1154/1530 (75.4%) ARI episodes and in 984/4308 (22.8%) 
swabs from asymptomatic periods. Respiratory syncytial virus (AFE: 68% (95% CI: 45%, 
82%)) and human metapneumovirus (AFE: 69% (95% CI: 43%, 83%)) were strongly 
associated with higher risk of lower respiratory symptoms. 
Conclusions: 
The strong association of respiratory syncytial virus and human metapneumovirus with 
ARIs and lower respiratory symptoms in young children managed within the community 
indicates successful development of vaccines against these two viruses should provide 
substantial health benefits. 
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INTRODUCTION 
Viral ARIs are a common cause of morbidity in children, either on their own or in synergy 
with bacterial pathogens (293). Virus-positive ARIs early in life are associated with 
developing wheeze and asthma during childhood and adolescence (114). Community-
based studies from the 1950-1960s examining the aetiology of ARIs by traditional 
laboratory detection methods remain the template for understanding childhood respiratory 
virus epidemiology (60). Advances in molecular diagnostics, including polymerase chain 
reaction (PCR) testing, have improved virus detection in those with ARIs (294). However, 
this increased test sensitivity has also resulted in viruses being detected in asymptomatic 
individuals (151, 294). The clinical significance of finding respiratory viruses is not always 
straightforward, and a better understanding of the proportion of infections that are 
symptomatic for individual viruses is needed. 
The AFE provides information about the percentage of cases amongst exposed 
individuals that can be attributed to the exposure. In our study, the AFE measures the 
percentage of ARIs in virus-positive children attributable to that particular virus. The AFE 
does not inform on the aetiology at an individual level, but is a key population level metric 
for interpreting positive specimen results. It assists with estimation of the true burden of 
disease, thus guiding preventative strategies for respiratory infections, such as 
immunisation. Virus-specific AFE estimates for ARI in children are reported infrequently, 
with most studies reporting AFEs having important methodological limitations. Except for 
one community study (151), these investigations recruited either highly-selected 
hospitalised children or outpatients as study cases (182, 295, 296), or used controls from 
outpatient clinics (182, 295). A meta-analysis of 23 studies that calculated virus-specific 
AFEs included 22 studies employing hospital-based case ascertainment and only three 
using community-based controls (22). Other studies comparing symptomatic and 
asymptomatic groups calculated odds ratios (ORs) (147, 225, 297), or relative risks (298), 
without calculating AFEs. Moreover, several studies focussed solely either on specific 
viruses (147, 297) or outcomes (182, 225, 297, 298). 
Longitudinal, community-based studies employing sensitive molecular-based assays with 
regular and frequent sampling, irrespective of illness, are best suited to explore the 
relationship between respiratory virus detections and ARI symptoms, especially as they 
represent most ARI episodes. The aim of our study was to examine the disease-pathogen 
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associations of respiratory viruses in young children participating in a community-based 
birth cohort project (243) and to calculate their virus-specific AFE values. 
 
MATERIALS AND METHODS 
Details of the study population, demographic and symptom data collection, classification 
of ARIs, anterior nasal swab sample collection, transport, processing, and testing, have 
been outlined in Chapter 2. 
 
Definitions 
New virus detection episode (VDE): when a new virus (different virus or new 
species/subtype of the same genus or species respectively) was detected in a swab by 
PCR testing, or the same virus was detected after at least two negative intervening swabs, 
or the same virus was detected at least 30 days from the last positive swab. 
Symptomatic new VDE: when respiratory symptoms were reported within seven days 
either side of first detecting the virus of interest in the weekly nasal swab. 
 
Analysis 
The incidence rate of new single VDEs per 100 child-years was calculated using Poisson 
regression. To account analytically for the differing lengths of time children remained in 
the study, the natural logarithm of the number of swabs returned was included in the model 
as an offset. Swabs were removed from incidence rate calculations for individual viruses 
when the participant was not at risk of a new VDE (a positive consecutive swab following 
the initial positive swab, and two swabs after the last positive swab, as per our definition 
of a new VDE), or the swabs were of lesser quality (to avoid under-estimating incidence 
rates) (249). When calculating incidence rates for ‘any virus’ we assumed children were 
at risk of being positive for new viruses in every swab. 
The virus-specific risk and AFE of single VDEs in cases of ARI and LRTI were estimated 
using a generalised linear model with binomial family and log link. Robust variance 
estimates were calculated using sandwich estimators to account for repeated measures 
within children. We analysed LRTIs separately as children with these infections are more 
likely to visit family physicians, present to hospital and receive antibiotics (6). The AFE 
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was calculated as 100% *(1-RR-1), where RR (risk ratio) is the proportion of children 
positive for a virus with ARI symptoms, divided by the proportion of children negative for 
the virus who have ARI symptoms (Table 11).  
 
Table 11: Calculation of attributable fraction in the exposed 
The AFE calculates the proportion of symptomatic acute respiratory infections (ARI) in 
virus-positive individuals that can be attributed to the virus. 
Swab status Acute respiratory 
infection 
No symptoms Total population 
Virus-positive a b a+b 
Virus-negative c d c+d 
Total a+c b+d a+b+c+d 
 
The risk of having symptoms given that a child is virus-positive = a/(a+b) 
The risk of having symptoms given that a child is virus negative = c/(c+d) 
The risk ratio of having symptoms if a child is virus-positive compared to if they are 
virus-negative is a/(a+b)/c/(c+d) 
Attributable fraction in the exposed is 100% * (a/a+b)-(c/c+d) 
              (a/a+b) 
 
The AFE can also be written in terms of the risk ratio (RR): AFE = 100% * (1-RR-1), where 
RR is the proportion of children positive for a virus with ARI symptoms, divided by the 
proportion of children negative for the virus who have ARI symptoms. 
For example, 
 AFE = 0% - the risk of having symptoms when virus-positive is equal to the risk of 
having symptoms when virus-negative – that is, the presence of the virus is not 
associated with the presence of symptoms; 
 AFE = 50% - 50% of symptomatic episodes when virus-positive were attributable 
to the presence of the virus; 
 AFE = 100% - the risk of having symptoms when virus-negative = 0. 
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Only virus-negative swabs of lesser quality (Ct >38) were excluded in these analyses of 
association, as swab quality of positive swabs did not modify the association between 
VDEs and ARI symptoms (Table 12). 
The association between potential risk factors (age, sex, type of delivery, gestational age 
at birth, season, family history of asthma or eczema, tobacco smoke exposure, household 
size, maternal education status, mode of feeding, category of childcare attendance), and 
symptomatic and asymptomatic virus detection was examined using mixed-effects logistic 
regression with the child entered as a random effect to account for repeated 
measurements within children. Both univariable and multivariable analyses were 
conducted. Breastfeeding and childcare attendance were analysed as time-varying 
variables. Multivariable models included all the above risk factors with no forward or 
backward selection. Only virus-negative lesser quality swabs were excluded in these 
analyses. As it was not possible to determine individual virus contributions to ARI 
symptoms during virus co-detections, samples with more than one virus detected were 
analysed descriptively (Table 17). Data were analysed using Stata v12.1 (StataCorp, 
Texas, USA). 
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Table 12: Acute respiratory infections, lower respiratory tract infections and asymptomatic single new virus detections, risk 
ratios, and attributable fractions by respiratory virus in children from the ORChID birth cohort with virus positive detections 
with cycle-threshold values >38 excluded (n=7,856). 
 Acute respiratory infections Lower respiratory tract infections 
Virus Risk ratioa 
(95% CI) 
Attributable fraction in 
the exposed (%) 
Risk ratioa 
(95% CI) 
Attributable fraction in 
the exposed (%) 
Single new detections    
All HRV 1.5 (1.4, 1.7) 33 (29, 41) 1.1 (1.0, 1.2) 9 (0, 17) 
HRV-A 1.6 (1.5, 1.7) 37 (32, 42) 1.2 (1.0, 1.6) 19 (-3, 36) 
HRV-B 1.2 (1.0, 1.5) 18 (-1, 33) 0.8 (0.4, 1.6) -19, -130, 39) 
HRV-C 1.6 (1.4, 1.7) 38 (30, 40) 1.4 (1.1, 1.7) 28 (12, 41) 
INFV-A 1.7 (1.2, 2.3) 41 (17, 57) 1.6 (0.4, 5.7) 38 (-150, 82) 
INFV-B 1.0 (0.5, 2.8) 0 (-1, 64) 0 0 
PIV-1 1.8 (1.3, 2.5) 44 (23, 60) 2.5 (0.8, 7.8) 60 (25, 87) 
PIV-2 n/c n/c n/c n/c 
PIV-3 1.6 (1.3, 2.0) 38 (23, 50) 2.0 (1.2, 3.3)  50 (17, 70) 
RSV-A 1.4 (1.1, 1.7) 29 (9, 41) 3.0 (2.0, 4.5) 67 (50, 78) 
RSV-B 1.8 (1.4, 2.2) 44 (29, 55) 3.1 (1.8, 5.4) 68 (44, 81) 
HCoV-OC43 1.6 (1.3, 2.0) 38 (23, 50) 2.3 (1.4, 3.7) 57 (29, 73) 
HCoV-NL63 1.7 (1.4, 2.1) 41 (29, 52) 1.7 (0.9, 3.3) 41 (11, 70) 
HCoV-229E 0.9 (0.3, 2.5) -11 (-233, 60) 1.2 (0.2, 7.7) 17 (-4, 87) 
HCoV-HKU1 1.1 (0.7, 1.6) 9 (-43, 38) 0.8 (0.2, 2.9) 25 (-4, 66) 
HMPV 1.6 (1.2, 2.1) 38 (17, 52) 3.2 (1.7, 6.0) 69 (41, 83) 
HAdV 1.5 (1.2, 1.8) 33 (17, 44) 1.0 (0.4, 2.4) 0 (-15, 58) 
WU-PyV 1.3 (0.9, 1.8) 23 (-11, 44) 1.4 (0.6, 3.5) 29 (-67, 71) 
KI-PyV 0.8 (0.6, 1.2) 25 (-67, 17) 1.2 (0.6, 2.2) 17 (-67, 55) 
HBoV-1 1.3 (1.0, 1.6)  23 (0, 38) 1.3 (0.8, 2.2) 23 (-25, 55) 
Any virus 1.6 (1.5, 1.7) 38 (33, 41) 1.4 (1.2, 1.5) 29 (17, 33) 
aadjusted for clustering using sandwich estimators to account for within-infant correlation between observations; bIndividual rhinovirus species do not add up to ‘All rhinovirus’ 
detections because of a combination of more than one rhinovirus species detected within the same ARI episode, or single new virus detection episodes where HRV positive 
specimens could not be sequenced. Abbreviations: n/c: not calculable as there were no cases in the asymptomatic group. HRV: human rhinovirus, INFV: influenza virus, PIV: 
parainfluenza virus, RSV: respiratory syncytial virus, HCoV; human coronavirus, HMPV: human metapneumovirus, HAdV: human adenovirus, WU-PyV: WU polyomavirus, KI-
PyV: KI polyomavirus, HBoV-1: human bocavirus-1.
 
102 
RESULTS 
Cohort characteristics 
Of 891 potential participants approached, 165 (18.5%) eligible singleton infants from 163 
families were enrolled (two families enrolled two siblings) (Figure 8). Seven were excluded 
subsequently; one from ineligibility (born <36 weeks) and six for failing to provide any 
swabs. Of the remaining children, 158 provided 11,125 swabs (Figure 8; 68.3% of 
maximum expected; median 84.5, range 1-104) from birth until their second birthday, and 
154 children provided 87,547 child-days of symptom diaries (77.9% of maximum expected 
days; median 726 (range 1-730 days)) with 67% followed until at least 23 months (Figure 
3). One or more respiratory symptoms were recorded on 16,877 (19.3%) days, and 
corresponded to 1,641 discrete ARI episodes. Demographic and social characteristics are 
reported in Table 3). 
 
Virus detections   
When calculating incidence rates, of the 11,192 total swabs submitted by all children, 
3,025 (27.2%) lesser-quality swabs (346 virus-positive and 2,679 virus-negative) were 
removed from the analyses, as were 67 swabs submitted after the child’s 2nd birthday, 
leaving 8,100 swabs from 157 children (Figure 8). Overall, 2,646/8,100 (32.7%) swabs 
were positive for respiratory viruses (Table 13), of which 1,520 were new VDEs.  
The incidence of new VDEs increased in the first 9 months of life, with symptomatic 
episodes dominating after six months of age (Figure 8). There was an overall incidence 
rate of 978 new VDEs per 100 child-years (95% CI: 923, 1,029, Table 13). More than one 
virus was detected in 275/8,100 (3·4%) specimens. HRV was the most commonly 
detected virus (2,058/2,646 detections, 77·8% of all detections, mean rate of 1,002 new 
VDEs per 100 child-years, 95% CI: 942, 1,066), followed by HBoV-1 (60 new VDEs per 
100 child-years, 95% CI: 49, 73), and KI polyomavirus (56 new VDEs per 100 child-years, 
95% CI: 45, 69) (Table 13). 
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Figure 8: Submission of nasal swabs and symptom diaries from participants in the ORChID Study. 
 
 
Ct = cycle-threshold; ERV-3=endogenous retrovirus-3 
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Figure 9: Incidence rate of new virus detection episodes per child-month by age 
and type of infection (N=151). 
 
      All new VDE    new symptomatic VDE      new 
asymptomatic VDE 
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Table 13: Respiratory viruses detected in 8,100 high-quality nasal swabs collected from 157 children from the ORChID birth 
cohort in the first two years of life. Incidence rates/100 child-years presented overall, and for the first and second years of life 
separately. 
Virus 
Virus positive 
swabs 
New virus 
detections 
N=1,520a 
New VDE/100 child-
years  
(Overall year mean) 
New VDE/100 child-
years  
(1st-year) 
New VDE/100 child-
years  
(2nd-year) 
 n (%) n (%) Mean (95%CI) Mean (95% CI) Mean (95% CI) 
All HRVb 2,058 (25.4) 1,012 (66.6) 1,002 (942, 1066) 770 (703, 842) 1354c (1245, 1472) 
HRV-A 702 (8.7) 440 (28.9) 323 (295, 355) 258 (224, 297) 409 (361, 464) 
HRV-B 154 (1.9) 97 (6.4) 64 (53, 78) 60 (45, 79) 69 (52, 92) 
HRV-C 635 (7.8) 495 (32.6) 363 (332, 396) 295 (259, 336) 448 (398, 505) 
INFV-A 12 (0.1) 12 (0.8) 7.7 (4.4, 13.6) 4.7 (1.8, 12.5) 11.5 (5.7, 22.9) 
INFV-B 2 (0.0) 2 (0.1) 1.3 (0.3, 5.2) 1.2 (0.2, 8.3) 1.4 (0.2, 10.1) 
PIV-1 7 (0.1) 7 (0.5) 4.5 (2.2, 9.5) 2.3 (0.6, 9.3) 7.2 (3.0, 17.2) 
PIV-2 4 (0.0) 4 (0.3) 2.6 (1.0, 6.9) 1.2 (0.2, 8.3) 4.3 (1.4, 13.3) 
PIV-3 59 (0.7) 56 (3.7) 36.5 (28.1, 47.4) 27.1 (18.0, 40.8) 47.8 (34.0, 67.3) 
RSV-A 69 (0.9) 58 (3.8) 37.9 (29.3, 49.0) 30.7 (20.9, 45.1) 46.4 (32.8, 65.6) 
RSV-B 22 (0.3) 20 (1.3) 12.9 (8.3, 20.1) 8.2 (3.9, 17.2) 18.7 (10.9, 32.2) 
HCoV- OC43 51 (0.6) 42 (2.8) 27.3 (20.2, 37.0) 18.8 (11.5, 30.7) 39.1 (26.8, 57.0) 
HCoV-NL63 56 (0.7) 40 (2.6) 26.0 (19.1, 35.5) 18.8 (11.5, 30.7) 37.7 (25.6, 55.3) 
HCoV-229E 14 (0.2) 9 (0.6) 5.8 (3.0, 11.2) 4.7 (1.8, 12.5) 7.2 (3.0, 17.2) 
HCoV-HKU1 34 (0.4) 28 (1.8) 18.2 (12.5, 26.3) 10.5 (5.5, 20.3) 27.4 (17.5, 43.0) 
HMPV 27 (0.3) 23 (1.5) 14.9 (9.9, 22.4) 12.9 (7.1, 23.3) 17.2 (9.8, 30.4) 
HAdV 104 (1.3) 80 (5.3) 52.6 (42.2, 65.4) 47.6 (34.9, 64.9) 58.3 (42.8, 79.5) 
WU-PyV 101 (1.2) 60 (3.9) 39.3 (30.5, 50.6) 16.5 (9.8, 27.8) 67.6 (50.6, 90.2) 
KI-PyV 168 (2.1) 84 (5.5) 55.7 (45.0, 68.9) 51.6 (38.3, 69.5) 60.4 (44.5, 82.1) 
HBoV-1 137 (1.7) 90 (5.9) 59.6 (48.5, 73.3) 47.8 (35.1, 65.2) 73.8 (55.9, 97.4) 
Any virusd 2,646 (32.7) 1,520 (18.8) 978 (930, 1029) 794 (736, 856) 1206 (1127, 1290) 
Co-detectionsd 275 (3.4) 237 (15.6) 147 (130, 168) 117 (96, 142) 184 (155, 219) 
aincludes co-detections; b666 HRV (28.5%) positive samples could not be sequenced primarily because of low viral loads; cThe rate of HRV new VDEs and the 
mean incidence of HRV new VDEs may equal or exceed the total rate of all new VDEs depending on the denominator after all swabs with cycle-threshold values 
>38 are excluded; ddays at risk were not removed from the denominator as an infant could be at risk of being positive for other viruses in every swab. Abbreviations: 
HRV: human rhinovirus, INFV: influenza virus, PIV: parainfluenza virus, RSV: respiratory syncytial virus, HCoV; human coronavirus, HMPV: human 
metapneumovirus, HAdV: human adenovirus, WU-PyV: WU polyomavirus, KI-PyV: KI polyomavirus, HBoV-1: human bocavirus-1; VDE: virus detection episode 
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Virus-positive ARIs and asymptomatic episodes 
When considering virus-positive ARIs and asymptomatic episodes, we retained 346 virus-
positive swabs with ERV Ct values >38, but removed a further 244 swabs with missing 
symptom data, to give a final dataset of 8,202 swabs from 151 participants (3 participants 
submitted swabs, but no symptom data before withdrawing early in the study) (Table 14, 
Table 15, Table 16). 
Of 8,202 swabs, 3,894 (47·5%) were taken during symptomatic periods and 4,308 
(52·5%) from asymptomatic periods. Of all swabs taken anytime during symptomatic 
periods, 1,903/3,894 (48·9%) were positive for a virus, and 1,120/3,894 (28·8%) were new 
VDEs. Overall, 984/4,308 (22·8%) swabs taken during asymptomatic periods were 
positive for a virus, of which 562 (57·1%) were new VDEs and 491/562 (87.4%) were new 
single virus detections (Table 14 and Table 15). 
Table 14 shows that for new VDEs involving only single virus detections, HRV-A, HRV-C, 
INFV-A, PIV-1, PIV-3, RSV-A, RSV-B, HCoV-OC43, HCoV-NL63, HMPV, and HAdV had 
statistically significant, positive AFE values, indicating they were significantly more often 
associated with ARI episodes than asymptomatic periods. 
In contrast, HRV-B, HCoV-229E, HCoV-HKU1, WU-PyV and KI-PyV, and HBoV-1 were 
frequently detected in asymptomatic periods and had low point estimates for AFE, 
indicating they were less likely to have caused the ARI. 
Of the total 1,641 ARIs, 111 (6·8%) did not have swabs submitted during an ARI episode, 
including swabs taken seven days before or seven days after the last day of the illness. 
Of the remaining 1,530 ARIs, 1,154 (75·4%) ARIs (935 (81%) URTI, 219 (19.0%) LRTI) 
had ≥1 swabs with a virus detected during this period.  
RSV and HMPV were more strongly associated with LRTI than asymptomatic detections 
(Table 15), with higher risk ratios than other viruses. While significant, the association 
between LRTI and HRV-C, HCoV-OC43 and PIV-3 detection was weaker. Interestingly, 
co-detected specimens had amongst the strongest AFE values for both ARIs and LRTIs 
(Table 14, Table 15), with HRV the most frequently detected virus, usually in combination 
with DNA viruses (Table 17). 
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Table 14: Acute respiratory infections and asymptomatic single new virus detections, adjusted risk ratios and attributable 
fractions by respiratory virus in 151 children from the ORChID birth cohort (n=8,202). 
Virus ARI-associated single 
new virus detections 
N=3,894 swabs 
Asymptomatic single 
new virus detections 
N=4,308 swabs 
Adjusted risk ratioa 
(95% CI); p value 
 
Attributable fraction 
in the exposed  
(%, 95% CI) 
Single new detections n (%) n (%)   
All HRV 679 (17.4)c 328 (7.6) 1.5 (1.4, 1.6); <0.001 34 (29, 38) 
HRV-A 289 (7.4) 122 (2.8) 1.5 (1.4, 1.6); <0.001 34 (28, 39) 
HRV-B 49 (1.3) 41(1.0) 1.2 (0.9, 1.4); 0.17 14 (-6, 30) 
HRV-C 328 (8.4) 137 (3.2) 1.5 (1.4, 1.7); <0.001 35 (30, 40) 
INFV-A 9 (0.2) 2 (0.0) 1.7 (1.3, 2.3); <0.001 42 (23, 57) 
INFV-B 2 (0.1) 2 (0.0) 1.1 (0.4, 2.8); 0.90 6 (-150, 64) 
PIV-1 6 (0.2) 1 (0.0) 1.8 (1.3, 2.5); <0.001 45 (26, 59) 
PIV-2 3 (0.1) 0 (0.0) n/c n/c 
PIV-3 32 (0.8) 11 (0.3) 1.5 (1.3, 1.9); <0.001 35 (21, 46) 
RSV-A 29 (0.7) 14 (0.3) 1.4 (1.2, 1.7); <0.001 30 (16, 42) 
RSV-B 19 (0.5) 3 (0.1) 1.8 (1.5, 2.2); <0.001 46 (35, 54) 
HCoV-OC43 26 (0.7) 8 (0.2) 1.6 (1.3, 2.0); <0.001 38 (25, 50) 
HCoV-NL63 27 (0.7) 8 (0.2) 1.6 (1.3, 2.0); <0.001 37 (21, 49) 
HCoV-229E 3 (0.1) 4 (0.1) 0.9 (0.4, 2.2); 0.83 -10 (-161, 54) 
HCoV-HKU1 12 (0.3) 10 (0.2) 1.2 (0.8, 1.7); 0.42 14 (-24, 40) 
HMPV 12 (0.3) 4 (0.1) 1.6 (1.2, 2.1); 0.001 37 (16, 53) 
HAdV 28 (0.7) 16 (0.4) 1.4 (1.1, 1.7); 0.008 29 (12, 42) 
WU-PyV 16 (0.7) 15 (0.3) 1.1 (0.8, 1.6); 0.62 9 (-31, 36) 
KI-PyV 23 (0.6) 34 (0.8) 0.9 (0.6, 1.2); 0.37 -17 (-65, 17) 
HBoV-1 35 (0.9) 31 (0.7) 1.1 (0.9, 1.4); 0.30 11 (-12, 29) 
Any virus 961 (24.6) 491 (11.4) 1.5 (1.4, 1.6); <0.001 35 (31, 38) 
New co-detectionsd     
≥ 2 viruses 168 (4.3) 62 (1.4) 1.6 (1.4, 1.7); <0.001 37 (30, 42) 
aadjusted for repeated measures within children using sandwich estimators; bconfidence intervals for attributable fractions were calculated from confidence intervals for 
corresponding risk ratios; cindividual HRV species do not add up to ‘All HRV’ detections because of a combination of more than one HRV species detected within the 
same ARI episode, or single new virus detection episodes where HRV positive specimens could not be sequenced; dincludes 219 (160 symptomatic) new co-detections 
and another 11 co-detections with two and three viruses co-detected respectively where at least one co-detected virus was a new detection. Abbreviations: ARI: acute 
respiratory infection; n/c: not calculable, no cases in the asymptomatic group. HRV: human rhinovirus, INFV: influenza virus, PIV: parainfluenza virus, RSV: respiratory 
syncytial virus, HCoV; human coronavirus, HMPV: human metapneumovirus, HAdV: human adenovirus, WU-PyV: WU polyomavirus, KI-PyV: KI polyomavirus, HBoV-1: 
human bocavirus-1.  
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Table 15: Lower respiratory tract infections and asymptomatic single new virus detections, adjusted risk ratios and 
attributable fractions by respiratory virus in 151 children from the ORChID birth cohort (n=5,267 swabs). 
Virus LRTI-associated single  
new virus detections 
N=959 swabs 
Asymptomatic single  
new virus detections 
N=4,308 swabs 
Risk ratioa 
(95% CI); p-value 
 
Attributable fraction in the 
exposed (%, 95% CI)b 
 
Single detections n (%) n (%)   
All HRV 126 (13.1)c 328 (7.6) 1.1 (1.0, 1.2); 0.22 8 (-5, 20) 
HRV-A 57 (6.0) 122 (2.8) 1.2 (1.0, 1.5); 0.11 17 (-4, 34) 
HRV-B 8 (0.8) 41(1.0) 0.8 (0.4, 1.5); 0.43 -31 (-157, 33) 
HRV-C 68 (7.1) 137 (3.2) 1.3 (1.1, 1.6); 0.01 22 (5, 36) 
INFV-A 2 (0.2) 2 (0.0) 1.6 (0.4, 5.7); 0.50 36 (-131, 82) 
INFV-B 0 (0.0) 2 (0.0) 0.0 (0.0, 0.0); <0.001 0 (0, 0) 
PIV-1 2 (0.2) 1 (0.0) 2.5 (0.8, 7.8); 0.13 59 (-28, 87) 
PIV-2 1 (0.1) 0 (0.0) n/c n/c 
PIV-3 10 (1.0) 11 (0.3) 2.0 (1.2, 3.3); 0.006 50 (18, 70) 
RSV-A 15 (1.6) 14 (0.3) 3.0 (2.1, 4.5); <0.001 67 (51, 78) 
RSV-B 8 (0.8) 3 (0.1) 3.2 (1.8, 5.5); <0.001 68 (45, 82) 
HCoV-OC43 9 (0.9) 8 (0.2) 2.3 (1.4, 3.8); 0.001 56 (29, 73) 
HCoV-NL63 7 (0.7) 8 (0.2) 1.7 (0.9, 3.3); 0.10 42 (-10, 70) 
HCoV-229E 1 (0.1) 4 (0.1) 1.2 (0.2, 7.7); 0.83 19 (-407, 87) 
HCoV-HKU1 2 (0.2) 10 (0.2) 0.8 (0.2, 2.9); 0.71 -28 (-376, 66) 
HMPV 6 (0.6) 4 (0.1) 3.2 (1.7, 6.1); <0.001 69 (43, 83) 
HAdV 5 (0.5) 16 (0.4) 1.0 (0.4, 2.5); 0.96 -2 (-156, 59) 
WU-PyV 5 (0.5) 15 (0.3) 1.4 (0.6, 3.5); 0.48 28 (-80, 71) 
KI-PyV 8 (0.8) 34 (0.8) 1.2 (0.7, 2.2); 0.55 17 (-53, 56) 
HBoV-1 10 (1.0) 31 (0.7) 1.3 (0.8, 2.2); 0.33 24 (-30, 55) 
Any virus 217 (22.6) 491 (11.4) 1.4 (1.2, 1.5); <0.001 27 (18, 35) 
New co-detectionsd     
≥ 2 viruses 58 (6.0) 62 (1.4) 2.2 (1.7, 3.0); <0.001 55 (41, 66) 
aadjusted for repeated measures within children using sandwich estimators; bconfidence intervals for attributable fractions were calculated from confidence intervals for 
corresponding risk ratios; cindividual HRV species do not add up to ‘All HRV’ detections because of a combination of more than one HRV species detected within the same LRTI 
episode, or single new virus detection episodes where HRV positive specimens could not be sequenced; dincludes 110 (51 symptomatic) new co-detections and another 10 co-
detections with 2 and 3 viruses co-detected respectively where at least one co-detected virus was a new detection. Abbreviations: LRTI: lower respiratory tract infection; n/c: not 
calculable as there were no cases in the asymptomatic group. HRV: human rhinovirus, INFV: influenza virus, PIV: parainfluenza virus, RSV: respiratory syncytial virus, HCoV; 
human coronavirus, HMPV: human metapneumovirus, HAdV: human adenovirus, WU-PyV: WU polyomavirus, KI-PyV: KI polyomavirus, HBoV-1: human bocavirus-1.
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Viruses and association with risk factors   
Independent risk factors associated with symptomatic rather than asymptomatic VDEs, 
included increasing age, particularly after 6 months, and virus infections during non-summer 
seasons (Table 16). The regression model revealed childcare attendance was also 
independently associated with higher rates of VDEs, both symptomatic and asymptomatic, 
but no other risk factors were found to be associated with asymptomatic VDEs.
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Table 16: Number of children, child-months, virus-associated symptomatic and asymptomatic episodes and association between 
participant characteristics and acute respiratory infections in 151 children. 
Risk factor  
Children 
(N) 
Child-
months 
(N) 
Symptomatic new VDE 
Odds Ratio (95% CI); p-value 
Asymptomatic new VDE  
Odds Ratio (95% CI); p-value 
n Unadjusted Adjusteda n Unadjusted Adjusted 
Age (months)         
   0-<3 151 423.3 60 Referent rate Referent rate 58 Referent rate Referent rate 
   3-<6 142 398.0 92 1.6 (1.2, 2.3); 0.003 1.7 (1.2, 2.4); 0.003 90 1.7 (1.2, 2.3); 0.003 1.5 (1.0, 2.2); 0.03 
   6-<12 135 715.4 354 3.5 (2.6, 4.6); 
<0.001 
3.6 (2.4, 5.4); 
<0.001 
146 1.5 (1.1, 2.0); 0.01 1.2 (0.8, 1.8); 0.46 
   12-<24 117 1250.6 627 3.5 (2.7, 4.6); 
<0.001 
3.1 (2.0, 4.7); 
<0.001 
270 1.6 (1.2, 2.1); 0.001 1.2 (0.7, 1.8); 0.54 
Sex         
   Male 74 1255.1 481 Referent rate Referent rate 262 Referent rate Referent rate 
   Female 77 1532.2 652 1.1 (1.0, 1.4), 0.17 1.1 (0.9, 1.3); 0.33 302 1.0 (0.8, 1.2); 0.79 0.9 (0.7, 1.2); 0.53 
Type of delivery         
   Vaginal 103 1876.3 802 Referent rate Referent rate 387 Referent rate Referent rate 
   Caesarean 48 910.9 331 0.8 (0.7, 1.0); 0.12 0.8 (0.7, 1.0); 0.09 177 0.9 (0.7, 1.2); 0.64 1.0 (0.8, 1.3); 0.94 
Gestational age at birth         
   Term (39w0d-41w6d) 117 2219.1 937 Referent rate Referent rate 446 Referent rate Referent rate 
   Late pre-term/early 
term  
   (36w0d-38w6d) 
34 568.1 196 0.8 (0.7, 1.1); 0.17 0.9 (0.7, 1.2); 0.48 118 1.1 (0.8, 1.5); 0.58 1.1 (0.8, 1.5); 0.40 
Season         
   Summer 140 678.8 196 Referent rate Referent rate 138 Referent rate Referent rate 
   Autumn 138 702.0 290 1.4 (1.2, 1.7); 
<0.001 
1.4 (1.2, 1.7); 
<0.001 
135 0.9 (0.7, 1.2); 0.64 1.0 (0.8, 1.2); 0.75 
   Winter 138 706.6 350 1.7 (1.4, 2.1); 
<0.001 
1.6 (1.3, 1.9); 
<0.001 
142 1.0 (0.8, 1.3); 0.93 0.9 (0.7, 1.2); 0.67 
   Spring 142 699.9 297 1.5 (1.2, 1.8); 
<0.001 
1.4 (1.2, 1.7); 
<0.001 
149 1.1 (0.8, 1.3); 0.68 1.1 (0.8, 1.4); 0.56 
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Risk factor  
Children 
(N) 
Child-
months 
(N) 
Symptomatic new VDE 
Odds Ratio (95% CI); p-value 
Asymptomatic new VDE  
Odds Ratio (95% CI); p-value 
n Unadjusted Adjusteda n Unadjusted Adjusted 
Family history         
   None present for 
asthma/eczema 
73 1289.6 533 Referent rate Referent rate 286 Referent rate Referent rate 
   Either parent 
asthma/eczema 
75 1447.3 582 1.0 (0.8, 1.2); 0.93 1.0 (0.8, 1.2); 0.85 264 0.8 (0.7, 1.1); 0.16 0.9 (0.7, 1.1); 0.22 
   1st degree relative 
asthma/eczemab 
78 1497.7 600 1.0 (0.8, 1.2); 0.80 1.0 (0.8, 1.2); 0.71 278 0.9 (0.7, 1.1); 0.22 0.9 (0.7, 1.1); 0.36 
Tobacco smoke 
exposure 
   No exposure 129 2383.4 973 Referent rate Referent rate 472 Referent rate Referent rate 
   Either parent smokes 17 307.4 127 1.0 (0.7, 1.4); 0.86 0.9 (0.6, 1.1); 0.29 75 1.2 (0.8, 1.7); 0.42 1.1 (0.8, 1.7); 0.51 
Household size         
   No other children in 
household 
99 1864.9 723 Referent rate Referent rate 350 Referent rate Referent rate 
   >1 child in household 52 922.4 410 1.1 (0.9, 1.4); 0.28 1.1 (0.9, 1.4); 0.17 214 1.3 (1.0, 1.7); 0.05 1.4 (1.0, 1.7); 0.04 
Maternal education 
status 
        
   High school 14 246.7 113 1.1 (0.8, 1.6); 0.56 1.0 (0.8, 1.4); 0.81 62 1.4 (0.9, 2.1); 0.11 1.4 (0.9, 2.1); 0.17 
   Diploma/Certificate 36 650.2 245 0.9 (0.7, 1.1); 0.37 0.9 (0.7, 1.1); 0.25 149 1.2 (0.9, 1.6); 0.29 1.2 (0.9, 1.6); 0.15 
   University/higher 
university degree 
95 1828.3 750 Referent rate Referent rate 346 Referent rate Referent rate 
Mode of feeding         
   Formula 142 2281.5 1039 Referent rate Referent rate 484 Referent rate Referent rate 
   Breastmilk 145 505.5 94 0.4 (0.3, 0.5); 
<0.001 
1.2 (0.9, 1.7); 0.28 80 0.7 (0.6, 0.9); 0.01 0.9 (0.6, 1.3); 0.47 
Childcare attendance         
   No childcare 150 1423.6 423 Referent rate Referent rate 242 Referent rate Referent rate 
   Informal childcare only 47 389.5 117 1.2 (0.9, 1.5); 0.13 0.8 (0.6, 1.1); 0.16 93 1.3 (1.0, 1.7); 0.10 1.3 (0.9, 1.7); 0.16 
   Formal and/or informal 
childcare 
90 973.8 593 2.2 (1.9, 2.5); 
<0.001 
1.5 (1.3, 1.9); 
<0.001 
229 1.4 (1.1, 1.7); 0.002 1.4 (1.0, 1.8); 0.03 
VDE: virus detection episode. aadjusted for age, sex, type of delivery, gestational age, season, family history, tobacco smoke exposure, household size, maternal 
education status, mode of feeding, and childcare attendance; bmother, father or sibling.   
 112 
 
Table 17: Number of symptomatic and asymptomatic new virus co-detection episodesa (n=219). 
 
a does not include 11 co-detections with 3 viruses each specimen; HRV: human rhinovirus; INFV: influenza virus; PIV: parainfluenza virus; RSV: respiratory syncytial 
virus; HCoV: human coronavirus; HMPV: human metapneumovirus; HAdV: human adenovirus; HPyV: human polyomavirus; HBoV-1: human bocavirus-1. 
HRV INFV- A INFV- B PIV-1 PIV-2 PIV-3 RSV A RSV B
HCoV- 
OC43
HCoV- 
NL63
HCoV-
229E
HCoV-
HKU1
HMPV HAdV
WU-
HPyV
KI-HPyV HBoV-1
Total 
asym
HRV 0 0 0 0 3 3 0 1 0 1 1 0 6 9 13 3 40
INFV-A 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
INFV-B 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
PIV-1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
PIV-2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1
PIV-3 8 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 3
RSV A 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2
RSV B 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
HCoV-OC43 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1
HCoV-NL63 5 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1
HCoV-229E 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 2
HCoV-HKU1 0 0 0 0 0 2 0 0 0 0 0 0 0 2 1 0 3
HMPV 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
HAdV 29 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 2
WU-HPyV 17 0 0 0 0 0 3 0 0 1 0 0 0 2 1 1 2
KI-HPyV 24 1 0 0 0 1 1 0 4 1 0 1 0 0 4 2 2
HBoV-1 32 0 0 0 0 0 1 0 0 0 0 2 0 2 2 1 59
Total sym 128 1 0 0 0 3 7 1 4 2 0 3 0 4 6 1 160 219
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DISCUSSION 
Healthy children in the ORChID community-based birth cohort experienced an 
incidence rate of 978 new VDEs per 100 child-years during the first two years of life, 
with HRV playing a dominant role. This high rate of viral events equated to almost 10 
new viral detection episodes per year and includes both ARI episodes and episodes 
of asymptomatic virus shedding. Overall, respiratory viruses were detected by PCR in 
regular weekly swabs at least once during 75% of ARIs, while in asymptomatic periods 
23% of weekly nasal swabs were positive by PCR for respiratory viruses, accounting 
for 33% of all new VDEs. We demonstrated evidence of attribution for ARIs by RNA 
viruses, which included HRV-A, HRV-C, INFV-A, PIV-1, PIV-3, RSV-A, RSV-B, HCoV-
OC43, HCoV-NL63, and HMPV; and HAdV as the single DNA virus representative. All 
these viruses were detected significantly more often in children with an ARI than during 
asymptomatic periods and had statistically significant positive AFEs. The strongest 
associations with LRTI were observed for RSV and HMPV. Increasing age ≥6 months, 
non-summer months, and childcare attendance were independent risk factors for 
symptomatic VDEs. Age as a risk factor for symptomatic infection independent of 
childcare attendance is also noted in other studies (229), and is presumably due to 
protection afforded by maternal transplacental and breastmilk antibodies in the very 
young (292). Environmental risk factors of season and childcare attendance for ARIs 
may be related to the intensity and opportunity for exposure in these settings 
experienced by young children (147, 299). 
The virus-specific attribution of ARIs was quantified by identifying VDEs during 
asymptomatic periods and calculating the virus-specific AFE, an infrequently reported 
metric for helping to determine the relative causal roles of different viruses at a 
population level. A limitation of the AFE approach is that it cannot inform on the 
aetiology at an individual level: in individual cases it does not differentiate between 
those with a true positive test identifying the virus responsible for the ARI and those 
with a false positive result from asymptomatic virus shedding. Nevertheless, knowing 
the AFE for respiratory viruses can help inform clinicians on the likely clinical 
significance of detecting one or more viruses in nasal swab specimens taken from 
infants or young children during an ARI episode, by assigning the group aetiological 
fraction for viruses detected in that child. Importantly, AFE estimates can be applied 
to studies of ARIs in different settings to estimate the true burden of disease in the 
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community, thus informing which viruses should be prioritised in future public health 
policies and interventions. 
Most previous studies have overestimated AFE values by using odds ratios, rather 
than risk ratios, in calculations (22, 151, 182, 296). Odds ratios overestimate the effect 
size when the event is not rare, as occurs with ARIs in children. These studies are 
principally cross-sectional, hospital-based, and often have poorly matched controls. 
Consequently our estimates of AFE being lower than reported elsewhere is not 
surprising, and, we believe, are likely to provide more accurate estimates of the ARI 
and LRTI burden attributable to these viruses in the broader paediatric population. 
The proportion of asymptomatic infections in our study highlights the risks of 
extrapolating hospital-based data from sick children to the community setting. 
Previously, the significance of detecting viruses by PCR was tempered by concerns 
that this may be from an incubating or unrelated subclinical infection or represent 
continued virus nucleic acid shedding from a recent ARI that has resolved. The 
intensive longitudinal specimen and symptom sampling from our cohort, as well as the 
definitions of VDEs and symptomatic VDEs used, helped identify nascent and 
subclinical infections. In this context, our observations emphasise the frequency of 
subclinical infections by respiratory viruses in young children, who when otherwise 
well, may act as important ‘silent’ reservoirs of infection. Similar observations and 
conclusions were reported recently in a household study involving both child and adult 
contacts of symptomatic cases of laboratory-confirmed influenza (102). Nevertheless, 
in addition to influenza, established viruses, such as HRV, PIV-3, RSV, and HMPV are 
also important community respiratory pathogens, especially the latter two viruses and 
potential candidates for vaccine and other therapeutic interventions (300). This 
contrasts with the novel DNA viruses, HPyVs and HBoV-1, which have low AFEs 
calculated for both ARIs and LRTIs, despite their higher detection rates (202, 301). 
However, as suggested by this cohort, synergy may exist between multiple viruses 
causing ARIs. This involved mostly HRV and DNA viruses and warrants further study. 
Strengths and limitations 
The 78% of expected child-days and 68% of expected swab returns was a very good 
retention rate given the intensive and prolonged nature of the study for participating 
families. Analysis of incidence rates of ARI in participants that withdrew from the study 
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at different periods showed no clear association between time of drop-out and ARI 
incidence. Regular parent-collected nasal swabs avoids the need for home visits by 
research staff or clinic attendance during an ARI, minimising possible biased estimates 
of ARI events and specimen availability from losing families failing to seek healthcare. 
Moreover, regular weekly nasal swab collections increase the likelihood of virus 
detections during an ARI episode rather than relying simply upon results from a single 
specimen. Our previous work found that with sensitive PCR techniques, parent-
collected nose or nose-throat swabs sent to the laboratory by standard mail had 
comparable sensitivity to nasopharyngeal swabs obtained by healthcare workers (246, 
256, 302). Longitudinal data collection also allows assessment of asymptomatic status 
by considering past and future illness history, as some viruses are detectable days 
before and after ARI symptoms develop (303), and are therefore less likely to yield 
false positive findings.  
There are also some important limitations to consider. To reduce the chances of false 
negative test results (249), we excluded from analysis 2,679 (23.9%) swabs where the 
internal control for human DNA, ERV-3, was either undetected or present at very low 
levels. We excluded both virus-positive and -negative swabs to avoid over-estimating 
our incidence and prevalence rates. In addition, some viruses were detected rarely, in 
particular influenza, a finding reflected in other community studies (3), but 
nevertheless limiting our ability to provide precise AFE estimates for these agents. We 
also excluded co-detections in individual virus assessments as multiple aetiological 
agents make individual contributions of each agent difficult to ascertain, but analysed 
them separately to look at the association patterns of individual viruses. Symptom 
information, other than doctor-diagnosed otitis media and pneumonia, captured by 
daily diaries was not validated. To maximise accuracy, parents were trained to 
recognise symptoms before commencing the study. While healthcare worker-
validated symptoms would be ideal, a study of this scale is logistically challenging 
without parent participation. This study design has been used previously (302) and 
with others have shown that parents can be trained to recognise symptoms of interest 
(302), often as reliably as health professionals (284, 285). Our rates of ARI, including 
those associated with wheeze, are comparable with other community studies (233, 
237). 
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Finally, as is common for these types of studies, families in our cohort were from more 
advantaged backgrounds and ARI episodes were predominantly of a mild-moderate 
nature (6). While many children in our study were first-born and from advantaged 
families, factors thought to decrease the rate of ARIs, secular changes in Australia 
have led to an increased proportion of children from these families attending childcare 
at an earlier age than other sectors of the population. A slightly higher proportion (80–
85%) of our cohort attended some form of care by the age of 15–24 months, compared 
to 74% of children in the Australian population, with childcare attendance an 
independent risk factor for ARIs (299). Moreover, the incidence of ARIs in the ORChID 
cohort (6) is comparable to other reports in this age group (28, 230, 233) and RSV and 
HRV-associated ARIs approximate other community-based studies conducted in more 
temperate climates of Australia (Perth) and Europe (2, 220, 222). Our findings for this 
cohort remain valid and provide important estimates on community respiratory virus 
exposures and ARIs in Australian children in a subtropical, urban setting. 
 
Conclusions 
Respiratory viruses, particularly HRV, were detected with remarkable frequency in 
healthy Australian children in the first two years of life, with at least one-third of new 
VDEs unaccompanied by symptoms. With molecular methods used increasingly to 
detect respiratory viruses in young children, our study provides insights into supporting 
attribution for virus-specific ARIs in this age group managed within the community. 
The established RNA respiratory viruses and HAdV were more strongly associated 
with symptomatic than asymptomatic infections, while no such associations were 
found for the newly described DNA viruses, HPyVs and HBoV-1. These data 
emphasise the high community levels of HRV circulating amongst young children. 
Importantly, they also provide evidence to suggest that the current clinical trials of 
candidate RSV and HMPV vaccines seeking to protect infants against severe disease 
and hospitalisation might also deliver substantial health benefits for all young children 
within the community (300). 
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Chapter 6: Timing of first respiratory virus detections in infants: a 
community-based birth cohort study 
This chapter is presented as a published original article. 
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ABSTRACT 
Introduction: 
Determining timing of first virus detection episodes (fVDEs) for different respiratory 
viruses in infants identifies risk periods and informs preventive interventions, including 
vaccination. We describe the ages and nature of fVDEs in an infant birth cohort and 
explore factors associated with increased odds of symptomatic fVDEs. 
Methods: 
The Observational Research in Childhood Infectious Diseases (ORChID) study is a 
community-based birth cohort describing acute respiratory infections in young children 
until their second birthday. Parents recorded daily symptoms and collected nose 
swabs weekly, which were batch-tested using polymerase chain reaction assays for 
17 respiratory viruses. 
Results: 
One hundred fifty-eight children participated in ORChID. The median age for fVDEs 
was 2.9 months for human rhinovirus (HRV) but was ≥13.9 months for other respiratory 
viruses. Overall, 52% of HRV fVDEs were symptomatic, compared with 57%-83% of 
other fVDEs. Respiratory syncytial virus and human metapneumovirus fVDEs were 
more severe than HRV fVDEs. Older age and the winter season were associated with 
symptomatic episodes. 
Conclusions: 
Children do not always experience respiratory symptoms with their fVDE. 
Predominance of early HRV detections highlights the need for timing any intervention 
early in life. fVDEs from other respiratory viruses most commonly occur when maternal 
vaccines may no longer provide protection. 
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INTRODUCTION 
Despite better living conditions, improved nutrition, and greater access to healthcare 
and vaccine programs, ARIs remain the most common illness experienced by people 
of all ages (1). Viruses are the most frequent cause of ARIs and the highest incidence 
rates occur during the first two years of life where on average young children 
experience 6-8 episodes per annum (5, 6). While only 3-5% of all children are 
hospitalised for viral ARIs (269), they are responsible for 25% of all hospitalisations in 
this age group imposing a major burden and cost to the health system for children (9). 
With the overwhelming majority of cases managed solely in the community (6), ARIs 
in young children also levy considerable additional costs upon families and society 
(10, 11). 
Much of our recent understanding of the epidemiology of viral ARIs in young children 
relies upon hospital-based studies (21, 22). These emphasize RSV as the 
predominant cause of bronchiolitis and the most common reason for infants to be 
hospitalised in the first year of life (70, 71), and seasonal INFVs, which also have high 
hospitalisation rates in this age group (71, 89). Importantly, the highest hospitalisation 
rates for ARIs associated with both viruses are during the first six months of life (89, 
304-306). However, hospital-based surveillance systems capture only the most severe 
illnesses and under-estimate the substantial burden of disease within the community 
caused by these and other respiratory viruses in older infants and young children (23-
25). Indeed, community-based birth cohort studies of infants at high-risk of asthma 
have instead identified HRVs, ahead of RSV and INFVs as the major upper and lower 
respiratory pathogens in the first year of life (2). Moreover, those with HRV-induced 
wheezing from an early age are also at increased risk of developing asthma, especially 
if already sensitised to aeroallergens (123, 124, 307). 
Although evidence is limited, first infections with respiratory viruses, particularly those 
caused by RSV, are thought to be almost always symptomatic (308) and by implication 
more likely to be brought to medical attention. As a large disease burden may be 
missed by hospital-based studies, understanding community epidemiology is essential 
when planning effective control measures. Consequently, in light of the 
aforementioned studies it is important to determine the timing different respiratory 
viruses are first detected in otherwise healthy young infants. This will help identify 
120 
 
when risk periods commence and to inform future public health interventions, including 
maternal and infant immunisation strategies for this age group. 
Recently, we reported that healthy, term-born infants participating in a community-
based birth cohort study had an average 0.25 (95% CI 0.18, 0.34) respiratory virus 
detection episodes in the first 28 days of life, of which 72% were HRV, with 45% of 
these being asymptomatic (309). In view of this early exposure to respiratory viruses, 
we now report findings for virus detection during the first two years of life by describing 
the ages at which each of nine respiratory virus groups, comprising 17 different 
species and subtypes, were first detected in this birth cohort and in a setting where 
influenza vaccines are not part of the national infant immunisation program. For each 
of the nine viruses, we determined: the nature of the respiratory symptoms associated 
with their first detection, including virus shedding characteristics and healthcare use; 
and whether sociodemographic and seasonal factors were associated with increased 
odds of developing respiratory symptoms at the time of the first detection episode. 
 
MATERIALS AND METHODS 
Details of the study population, demographic and symptom data collection, the ARI 
burden diary, classification of ARIs, anterior nasal swab sample collection, transport, 
processing, and testing have been outlined in Chapter 2. 
 
Definitions 
fVDE: when a respiratory virus not detected previously was first found in an infant’s 
weekly nasal swab specimen. 
Symptomatic fVDE: when respiratory symptoms were reported within seven days 
either side of first detecting the virus of interest in the weekly nasal swab. 
Symptomatic fVDEs were sub-categorized hierarchically as LRTI or URTI episodes 
respectively. 
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Definition of symptom duration for an ARI episode associated with the first 
detection of a respiratory virus. 
If symptoms began within seven days of first detecting the virus, the commencement 
of the ARI episode was marked from the day of symptom onset and its duration 
counted until the day the ARI symptoms ceased and the infant remained symptom free 
for at least the next three days.  
If ARI symptoms began more than seven days before detecting a new positive virus 
swab, the beginning of the episode associated with the virus was judged to be either 
seven days before its detection or up to the time of the previous swab collection 
irrespective of its result (i.e. negative or positive for a different virus or virus species), 
whichever time interval was the shorter. Alternatively, if no prior swabs had been taken 
since the symptomatic ARI episode began, the timing of the episode was from the day 
of symptom onset and continued until symptoms ceased. Similarly, if following a 
positive swab, subsequent specimens were not taken during the same ARI episode, 
the duration of the episode was determined by when symptoms ceased. However, if 
during a single continuous symptomatic ARI episode additional viruses were co-
detected sequentially in successive weekly samples, the symptoms were attributed 
equally to each virus until seven days after the virus was no longer detected or the 
symptoms settled, whichever came sooner. This was done to avoid over-estimating 
the episode length attributed to the virus that was detected initially. 
 
Analysis 
Summary statistics are presented as medians (25th – 75th percentile) for continuous 
variables and frequency (percentage) for categorical variables. First analysed 
separately, HRV, RSV, PIV, INFV, HCoV and HPyV subtypes and species were then 
grouped for additional analyses. The time-to-fVDE and symptomatic fVDE for each 
virus were calculated using life tables with the day of birth as study entry time. Children 
were censored at either the date of the last swab submitted if the next swab was not 
returned for more than 30 days, or at 730 days, whichever came sooner. The 
association between symptomatic/asymptomatic fVDEs and both the Ct value and 
length of shedding were compared using Mann-Whitney tests. For clinical 
characteristics of fVDEs, associations between virus types and symptoms were 
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compared using absolute risk differences for binary outcomes, and median regression 
for continuous outcomes. In all cases HRV was the reference virus. Thus, the risk 
differences were the proportion of children with first viral detection episodes with, for 
e.g., RSV who had symptoms of ARI divided by the proportion of children with first 
viral detection episodes with HRV who had symptoms of ARI. The association 
between potential risk factors (age, sex, season, breastfeeding, childcare attendance, 
number of children in the household) and symptomatic fVDEs was examined for the 
nine respiratory virus groups using logistic regression. Risk factors were categorised 
as: age (0-<3 months; 3-<6 months; 6-<12 months, and 12-24 months); sex (male, 
female); season (winter (June to August); spring (September to November); summer 
(December to February); fall (March to May)); breastfeeding (exclusively breastfed for 
≥4 months, exclusively breastfed for <4 months or never breastfed); childcare 
attendance (no childcare, any form of childcare); number of children in the household 
(no other children, at least one other child). Both univariable and multivariable models 
were constructed. Multivariable models were adjusted for all variables listed above. 
Data were analysed using Stata v12·1 (StataCorp, TX, USA). 
 
RESULTS 
Cohort characteristics 
Of 891 potential participants approached, 165 (18·5%) eligible infants from 163 
families were enrolled, with seven subsequently excluded for protocol breaches 
(Figure 10). The remaining 158 children provided 11,192 swabs (68.3% of maximum 
expected; median 84·5, range 1-104). Subsequently, 1,327 swabs were censored due 
to a gap of >30 days between successive swabs, as were another 67 swabs submitted 
after the child’s second birthday, leaving 9,798 swabs to be included in the full analysis 
(Figure 10, Figure 11). A further 204 swabs without corresponding symptom data were 
excluded from the analysis leaving 9,594 swabs describing the association between 
symptoms and fVDEs. Compared to the general population, study children were from 
smaller families of more advantaged backgrounds (Table 18). 
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Figure 10: Number of nasal swabs submitted by participants of the 
Observational Research in Childhood Infectious Diseases Study. 
 
 
 
  
152 participants with 9,594 swabs 
where symptomatic status could be 
ascertained.  
Data used in Figure 12 (symptomatic 
first virus detection episodes),  
Table 20 - Table 29 
165 (18.5%) eligible participants 
enrolled 
7 enrolled participants excluded 
 1 ineligible (delivered <36 weeks 
gestation) 
 6 did not provide swabs 
158 participants provided  
11,192 swabs 
• 67 swabs received after 730 
days 
• 1,327 swabs from 64 participants   
censored as swab >30 days after 
previous swab 
158 participants with 9,798 swabs 
Data used in Figure 11, Table 18,  
Table 19, Figure 12 (total first viral 
detection episodes) 
204 swabs without corresponding 
symptom data 
891 potentially eligible participants 
approached 
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Figure 11: Kaplan-Meier curve of proportion of children contributing swabs to 
time to first virus detection episode analysis in the Observational Research in 
Childhood Infectious Diseases Study (N=158). 
  
 
Footnote: Children left the study when they did not return a swab for more than 30 days, or at age two 
years, whichever was sooner. 
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Table 18: Characteristics of children enrolled in the Observational Research in 
Childhood Infectious Diseases Study. 
Characteristic No. of children (%) 
N=158 
No. of swabs (%)a 
N=9,798 
Sex (male) 75 (47·5%) 4,366 (44.6%) 
First-born child in 
household 
106 (67·1%) 6,596 (67.3%) 
Smoke exposure at birth   
 Mother (n=156) 5 (3·2%) 184 (1.9%) 
 Other householder 
 (n=155) 
17 (11·0%) 
 
971 (9.9%) 
Maternal educational status 
(n=157) 
  
 Primary school 5 (3.2%) 150 (1.5%) 
 High school 15 (9·6%) 822 (8.4%) 
 Diploma/Certificate 38 (24·2%) 2,244 (22.9%) 
 University degree or 
 higher  99 (63.1%) 
6,582 (67.3%) 
Exclusive breastfeeding   
 At 4 months (n=143)b 84 (58.7%) 5,924 (60.8%) 
Childcarec   
 At 12 months (n=115) 72 (62.6%) 6,180 (65.1%) 
achildren were censored at either the date of the last swab submitted if the next swab was not 
returned for more than 30 days, or at 730 days, whichever came sooner; b15 participants withdrew 
from the study before four months; cformal and/or informal childcare. 
 
  
126 
 
First virus detection episodes  
At least one virus was detected in 2,542/9,798 (25.9%) swabs, while co-detections of 
two or more viruses were observed in 241 (2.5%) specimens. HRV was the earliest 
and most commonly detected virus (present in 1,964/2,542 (77.3%) positive swabs). 
Table 19 and Figure 12 show that HRV-C (found in 98% of children) and HRV-A (94%) 
were more frequently detected than HRV-B (56%) by age two years and at a younger 
age (median age of fVDEs was 6.7, 6.1, and 19.6 months for each HRV species, 
respectively). HRV was detected as early as two days of life and by age three months 
50% of the cohort had HRV detected at least once.  
Other respiratory viruses were not detected as often in the first six months of life (Table 
19 and Figure 12). However, by their second birthday, 50%-60% of the cohort had 
experienced their fVDEs by RSV, PIV-3 and HAdV species, and 70-77% of cohort 
subjects had HCoV, HPyV KI/WU, and HBoV-1 virus species detected on at least one 
occasion. Influenza virus, PIV-1, and PIV-2 were detected in <11% of the cohort. 
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Table 19: Time to first detection of respiratory viruses collected from 158 children in the first two years of life in the 
Observational Research in Childhood Infectious Diseases (ORChID) birth cohort (n=9,798 swabs). 
Virus Virus positive 
swabsa 
N=9,798 
Age at first virus 
detection  
(months)b 
First virus detection proportions 
 
n (%) 
Median 
(25th, 75th centile) 
 
(cumulative % by age in months) 
   6 12 18 24 
HRV combinedc 1,964 (20.0) 2·9 (1·6, 5·1) 81·1 96·3 99·1 99·1 
HRV-A 652 (6.7) 6.7 (3.7, 10.7) 42.4 79.5 92.2 94.4 
HRV-B 150 (1.5) 19.6 (7.7, -) 18.9 34.7 45.4 63.0 
HRV-C 599 (6.1) 6.1 (3.5, 10.1) 48.8 86.4 98.1 98.1 
RSV combined 88d (0.9) 19.4 (11.2, -) 8.5 27.7 48.6 58.4 
RSV-A 67 (0·7) - (13·3, -) 7·0 21·6 39·7 46·8 
RSV-B 22 (0·2) - (-, -) 2·4 8·7 14·6 21·7 
PIV combined 71 (0.7) 23.2 (12.4, -) 9.4 24.7 37.3 58.2 
PIV-1 6 (0·1) - 0·0 1·8 3·9 6·9 
PIV-2 3 (0·0) - 0·8 0·8 0·8 3·7 
PIV-3 62 (0·6) 23·9 (14·2, -,) 8·7 22·1 33·9 55.7 
INFV combinedd 11 (0.1) - 2.2 5.8 8.0 10.9 
INFV-A 8 (0·1) - 0·8 4·4 6·7 8·0 
INFV-B 3 (0·0) - 1·4 1·4 1·4 2·9 
HMPV 24 (0·2) - 0·7 8·6 15·4 21·1 
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Virus Virus positive 
swabsa 
N=9,798 
Age at first virus 
detection  
(months)b 
First virus detection proportions 
 
n (%) 
Median 
(25th, 75th centile) 
 
(cumulative % by age in months) 
   6 12 18 24 
HCoV combined 138 (1.4) 17.2 (9.1, -) 11.5 33.4 52.9 72.2 
HCoV-OC43 43 (0·4) - (19·7, -) 5·3 14·2 20·6 31·6 
HCoV-NL63 52 (0·5) - (16·8, -) 2·9 15·1 27·1 40·2 
HCoV- 229E 10 (0·1) - 2·0 2·0 4·3 7·2 
HCoV-HKU1 33 (0·3) - (22·7, -) 2·0 7·4 18·8 27·2 
HAdV 95 (1·0) 23·5 (11·0, -) 8·0 28·7 44·9 51·3 
HPyV combined 250e (2.6) 13.9 (9.3, 23.9) 6.4 39.4 60.6 76.6 
HPyV-KI  157 (1.6) 19·2 (10·6, -) 4·8 28·0 46·9 55·0 
HPyV-WU   98 (1·0) - (15·1, -) 1·6 13·5 30·9 48.9 
HBoV-1 138 (1·4) 16·0 (9·2, 21·3) 4·7 41·2 63·7 75·4 
aincludes co-detections; children were censored if a swab was not returned for more than 30 days;  
bage at which 50% (25%, 75%) of the cohort have had their first detection with the virus; a dash in the median (25th centile, 75th centile) space reflects fewer than 
50% (25%, 75%) of children were infected with this virus; 
c562 isolates were not able to be typed, 1 swab extract missing and not sequenced; d includes 1 RSV-A/RSV-B co-detection; e includes 5 HPyV-KI/HPyV-WU co-
detections. 
dInfluenza vaccines are not part of the Australian National Immunisation Program; 28 (17.7%) mothers of children in the ORChID cohort had the influenza vaccine 
during their pregnancy, and just seven children received the influenza vaccine in the first two years of life [3]. 
Abbreviations: HAdV, human adenovirus; HBoV-1, human bocavirus-1; HCoV, human coronavirus; HMPV, human metapneumovirus; HPyV, human 
polyomavirus; HRV, human rhinovirus; INFV, influenza virus; PIV, parainfluenza virus; RSV, respiratory syncytial virus. 
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Figure 12: Time to first respiratory virus detection episode by virus and subtype/species. 
   
   
   
   
   
   
Solid line represents all censored first detections for that respiratory virus or virus sub-type; dashed lines represent all censored symptomatic first detections; 
Abbreviations: HCoV: human coronavirus; HPyV: human polyomavirus; HRV: human rhinovirus; INFV: influenza virus; PIV: parainfluenza virus; RSV, 
respiratory syncytial virus. 
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Nature of first virus detection episodes 
While fVDEs for HRV were symptomatic 52% of the time, infections with the other 
RNA viruses and HAdV had symptoms for 69-83% of these episodes (Table 20, Table 
21). fVDEs with other DNA viruses, HBoV-1, and HPyV WU and KI, were symptomatic 
57-66% of the time. Symptomatic fVDEs with RSV and HBoV-1 had significantly lower 
Ct values (higher viral loads) in their nasal swabs than corresponding asymptomatic 
fVDEs (Table 20). No such associations were observed with Ct values for the other 
viruses and no differences in virus shedding duration was seen between symptomatic 
and asymptomatic fVDE groups. 
Table 21 shows that children with RSV and HMPV fVDEs had the highest proportions 
of LRTIs (46.3% and 50.0% respectively). Compared with HRV, RSV, PIV, HMPV, 
HCoV, and HAdV fVDEs were significantly more likely to be symptomatic and for 
HAdV and HPyV symptomatic fVDEs to last longer. Overall, 128 of 527 (24.3%) fVDEs 
resulted in medical visits and antibiotics were prescribed in 63 (49.2%) of these illness 
episodes. Compared with HRV, those with RSV, PIV, HMPV, HCoV, HAdV and HBoV-
1 symptomatic fVDEs were significantly more likely to seek medical advice and for 
those with RSV, INFV, HAdV, HPyV and HBoV-1 to receive antibiotics. While family 
physician consultations were common, children were infrequently taken to the ED or 
hospitalised, and there were no deaths in the cohort.  
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Table 20: Number of symptomatic and asymptomatic first respiratory virus detection episodes, virus-specific median cycle 
threshold values, and median duration of virus shedding, in the first two years of life in 152 children participating in the ORChID 
birth cohort (n=9,594 swabs). 
  First respiratory virus detection episodes   
  Symptomatic episodes Asymptomatic episodes   
Virus  
(No.) 
Children 
with 
single 
positive 
swab, %a 
Children 
(No.) 
Median (range) 
Ct value 
 
Median 
(range) 
virus 
shedding  
(weeks)a 
Children 
(No.) 
Median (range) 
Ct value 
 
Median 
(range) virus 
shedding  
(weeks)a 
p-
valueb 
p-
valuec 
HRV(130) 47.7 68 29.2 (18.8, 39.8) 1.5 (1, 9) 62 29.2 (20.6, 39.1) 2 (1, 11) 0.5 0.4 
RSV (54) 83.3 42 29.3 (22.3, 37.3) 1 (1, 3) 12 36.0 (27.4, 39.6) 1 (1, 3) 0.003 0.5 
PIV (52) 94.2 37 31.0 (22.0, 38.5) 1 (1, 2) 15 31.4 (26.0, 38.3) 1 (1, 1) 0.3 0.3 
INFV (11) 100.0 8 31.9 (29.5, 38.2) 1 (1, 1) 3 30.2 (29.6, 30.3) 1 (1, 1) 0.2 n/c 
HMPV (18) 83.3 15 33.7 (23.8, 39.2) 1 (1, 2) 3 34.4 (34.0, 35.5) 1 (1, 1) 0.5 0.4 
HCoV (67) 74.6 47 29.3 (21.5, 38.9) 1 (1, 3) 20  28.8 (21.4, 38.5) 1 (1, 2) 0.8 0.06 
HAdV (52) 76.9 36 31.3 (18.6, 39.4) 1 (1, 7) 16 33.6 (24.4, 39.1) 1 (1, 2) 0.7 0.05 
HPyV (70)  37.1 40 27.5 (19.0, 39.1) 2.5 (1, 7) 30 32.2 (18.4, 39.3) 2 (1, 5) 0.1 0.2 
HBoV-1 (73)  56.2 48 28.0 (16.9, 38.4) 2 (1, 4) 25 31.6 (18.1, 38.9) 1 (1, 4) 0.001 0.3 
aNasal swabs collected weekly by parents. b Mann-Whitney test comparing median Ct values for the two groups.c Mann-Whitney test comparing median shedding 
duration for the two groups. Abbreviations: HAdV, human adenovirus; Ct, cycle threshold; HBoV-1, human bocavirus-1; HCoV, human coronavirus; HMPV, human 
metapneumovirus; HPyV, human polyomavirus; HRV, human rhinovirus; INFV, influenza virus; N/c, not calculable; No., number; PIV, parainfluenza virus; RSV, 
respiratory syncytial virus.   
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Table 21: Clinical characteristics of the first respiratory virus detection episodes in the first two years of life in 152 children 
participating in the ORChID birth cohort (n=9,594 swabs). 
Virusa  No. of 
children 
ARI 
episodes  
 URTI/ 
LRTI,b 
% 
Risk 
differencec  
for ARI 
episodes,  
% (95%CI) 
Median 
ARI 
symptom 
duration, 
days (IQR) 
Median  
difference of 
ARI episode 
duration,  
days 
(95%CI)d 
Medical 
visits 
FP/ED/ 
Hospitalisede 
% 
Risk 
difference 
for medical 
visits,  
% (95%CI) 
Antibiotics 
after any 
medical 
visitf  
(%) 
Risk 
difference 
for 
antibiotics  
%, (95%CI) 
HRV 130   46.2/ 6.2 0.0 (ref) 5.5 (3, 10) 0.0 (ref) 13.1/ 0.0/ 0.8 0.0 (ref) 23.5 0.0 (ref) 
RSV 54 31.5/ 46.3 25.5  
(11.4, 39.5) 
9 (7, 11) 1.8  
(-0.2, 6.2) 
37.0/ 5.6/ 1.9 24.0 
(9.8, 38.1) 
55.0 34.4 
(4.4, 64.4) 
PIV 52 50.0/ 21.2 18.8  
(3.8, 33.9) 
9 (4, 14) 1.8 
(-0.4, 6.4) 
26.9/ 1.0/ 0.0 15.8 
(2.2, 29.4) 
35.7 12.2  
(-20.0, 44.4) 
INFV 11 54.5/ 18.2 20.4 
(-7.3, 48.1) 
11 (7, 16.5) 1.9 
(-0.2, 12.2) 
36.4/ 0.0/ 0.0 23.3 
(-5.7, 52.3) 
75.0 51.5 
(4.5, 98.5) 
HMPV 18 33.3/ 50.0 31.0 
(11.8, 50.2) 
9 (6, 11) 1.3 
(-1.7, 7.7) 
33.3/ 5.6/ 0.0 20.3 
(1.7, 25.9) 
33.3 9.8 
(-33.0, 52.6) 
HCoV 67 46.3/ 23.9 17.8 
(3.9, 31.8) 
9 (3, 13) 1.9  
(-0.1, 6.1) 
25.4/ 4.4/ 0.0 13.8 
(1.7, 25.9) 
50.0 26.5 
(-4.2, 57.1) 
HAdV 52 44.2/ 25.0 16.9 
(1.7, 32.1) 
10 (5, 13.5) 2.9 
(1.6, 8.4) 
32.7/ 0.0/ 0.0 19.6 
(5.6, 33.6) 
58.8 35.3 
(4.4, 66.2) 
HPyV 70 41.4/ 15.7 4.8 
(-9.7, 19.3) 
11 (4, 17.5) 3.0  
(1.7, 8.3) 
15.7/ 0.0/ 0.0 4.1 
(-6.5, 14.6) 
66.6 43.1 
(9.7, 76.6) 
HBoV-1 73 50.7/ 15.1 13.4 
(-0.4,27.3) 
9 (5, 14) 1.9 
(-0.1, 8.0) 
26.0/ 2.7/ 0.0 13.0 
(1.3, 24.6) 
57.9 34.4 
(4.4, 64.4) 
aDetected in nasal swabs collected weekly by parents. bMutually exclusive hierarchical classification of ARI episodes (LRTI>URTI). c Risk difference is the proportion of children with first 
viral detection episodes with a virus who had symptoms of ARI divide by the proportion of children with first viral detection episodes with HRV (reference) who had symptoms of ARI. 
dMedian difference of ARI episode duration calculated by quantile regression technique. eMedical visits were not mutually exclusive categories as an infant may have more than one 
medical encounter in different settings during a single ARI episode. fMedical visits and antibiotic information were derived from the ARI burden diary triggered in 223/233 (95.7%) eligible 
recorded ARI episodes. Abbreviations: HAdV, human adenovirus; ARI, acute respiratory infection; asym, asymptomatic; ED, Emergency Department; FP, family physician; HBoV-1, 
human bocavirus-1; HCoV, human coronavirus; HMPV, human metapneumovirus; HPyV, human polyomavirus; HRV, human rhinovirus; INFV, influenza virus; IQR, interquartile range; 
LRTI, lower respiratory tract infection; No., number; PIV, parainfluenza virus; ref, reference; RSV, respiratory syncytial virus; URTI, upper respiratory tract infection.
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Because virus co-detections may confound individual virus contributions to ARI symptoms, 
analyses of Ct values, shedding duration and clinical characteristics were repeated for single 
only fVDEs (Table 22 and Table 23). Overall, these gave similar results, although DNA rather 
than RNA virus fVDEs were significantly more likely to have virus co-detections (risk ratio 
2.15 (95%CI 1.62, 2.78). A separate analysis found that single fVDEs with DNA viruses were 
consistently less likely to be symptomatic than corresponding fVDEs when other viruses 
were also present, reaching statistical significance for HPyV-KI and HBoV-1 (Table 24).  
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Table 22: Number of symptomatic and asymptomatic single first respiratory virus detection episodes, virus-specific median 
cycle threshold values, and median duration of virus shedding, in the first two years of life in 152 children participating in 
the ORChID birth cohort (n=9,594 swabs). 
  Single first respiratory virus detection episodes   
Virus  
(No.) 
 Symptomatic episodes Asymptomatic episodes   
 Children 
with 
single 
positive 
swab, %a 
Children 
(No.) 
Median (range) 
Ct value 
 
Median 
(range) virus 
shedding  
(weeks)a 
Children 
(No.) 
Median (range) 
Ct value 
 
Median (range) 
virus shedding  
(weeks)a 
p-
valueb 
p-
valuec 
HRV(128) 47.7 67 29.2 (18.8, 39.8) 2 (1, 9) 61 29.2 (20.6, 39.1) 2 (1, 11) 0.5 0.4 
RSV (43) 83.7 34 29.3 (22.3, 37.3) 1 (1, 3) 9 36.3 (29.4, 39.6) 1 (1, 3) 0.003 0.8 
PIV (35) 97.1 26 31.1 (22.0, 37.5) 1 (1, 2) 9 31.4 (30.1, 38.3) 1 (1, 1) 0.3 0.6 
INFV (10) 100.0 7 31.4 (29.5, 38.2) 1 (1, 1) 3 30.2 (29.6, 30.3) 1 (1, 1) 0.4 N/c 
HMPV (13) 76.9 11 33.7 (23.8, 36.4) 1 (1, 2) 2 34.2 (34.0, 34.4) 1 (1, 1) 0.9 0.4 
HCoV (55) 76.4 39 29.2 (21.5, 38.9) 1 (1, 3) 16 28.0 (21.4, 38.5) 1 (1, 2) 0.8 0.05 
HAdV (29) 75.9 17 31.5 (18.6, 39.4) 1 (1, 7) 12 31.8 (24.4, 38.9) 1 (1, 2) 0.7 0.09 
HPyV (39)  46.2 18 27.5 (22.0, 34.9) 2 (1, 7) 21 31.3 (18.4, 37.9) 1 (1, 4) 0.1 0.2 
HBoV-1 (46)  63.0 25 28.7 (16.9, 38.1) 1 (1, 4) 21 32.7 (26.6, 38.9) 1 (1, 4) 0.004 0.2 
 
aNasal swabs collected weekly by parents. b Mann-Whitney test comparing median Ct values for the two groups. c Mann-Whitney comparing median shedding 
duration for the two groups. Abbreviations: HAdV, human adenovirus; Ct, cycle threshold; HBoV-1, human bocavirus-1; HCoV, human coronavirus; HMPV, 
human metapneumovirus; HPyV, human polyomavirus; HRV, human rhinovirus; INFV, influenza virus; N/c, not calculable, No., number; PIV, parainfluenza 
virus; RSV, respiratory syncytial virus.   
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Table 23: Clinical characteristics of the single first respiratory virus detection episodes in the first two years of life in 152 
children participating in the ORChID birth cohort (n=9,594 swabs). 
Virus  No. of 
childre
n 
ARI 
episodes  
 URTI/ 
LRTI,b 
% 
Risk 
difference  
for ARI 
episodes,  
% (95%CI) 
Median 
ARI 
symptom 
duration, 
days 
(IQR)c 
Median  
difference for 
ARI episode 
duration,  
days (95%CI)  
Medical 
visits 
FP/ED/ 
hospitalisedd,
e 
% 
Risk 
difference 
for medical 
visits,  
% (95%CI) 
Antibiotics 
after any 
medical 
visite  
(%) 
Risk 
difference 
for 
antibiotics  
%, (95%CI) 
HRV 128  46.9 / 5.5 0.0 (ref) 5 (3, 10) 0.0 (ref) 12.5 / 0.0 / 0.8  0.0 (ref) 18.8 0.0 (ref) 
RSV 43  37.2 / 
41.9 
26.7 
(11.8, 41.6) 
9 (7, 11) 2.3 
(0.5, 7.5) 
34.9 / 7.0 / 2.3 20.1 
(4.9, 35.2) 
42.9 24.1 
(-8.1, 56.3) 
PIV 35  54.3 / 
20.0 
21.9 
(5.1, 38.8) 
9 (4, 13) 2.6 
(1.2, 8.8) 
28.6 / 2.9 / 0.0 18.9 
(2.5, 35.3) 
18.2 1.3 
(-30.1, 32.6) 
INFV 10 50.0 / 
25.0 
17.7 
(-12.0, 47.3) 
10 (5, 14) 1.5 
(-1.6, 11.6) 
40.0 / 0.0 / 0.0 27.5 
(-3.4, 58.4) 
75.0 56.3 
(9.7, 102.8) 
HMPV 13  38.5 / 
46.2 
32.3 
(10.8, 53.7) 
9 (6, 11) 1.5 
(-1.4, 9.4) 
38.5 / 7.7 / 0.0 26.0 
(-1.1, 53.0) 
20.0 1.3 
(-38.7, 41.2) 
HCoV 55  49.1 / 
21.8 
18.6 
(3.8, 33.4) 
7 (3, 14) 1.2 
(-1.3, 5.3) 
21.8 / 3.6 / 0.0 11.1 
(-1.4, 23.7) 
61.5 42.8 
(10.2, 75.4) 
HAdV 29  48.3 / 
10.3 
6.3 
(-13.6, 26.2) 
7 (5, 15) 0.9 
(-2.5, 6.5) 
31.0 / 0.0 / 0.0 18.5 
(0.7, 36.3) 
77.8 59.0 
(25.8, 92.2) 
HPyV 39  35.9 / 
10.3 
-6.2 
(-24.1, 11.7) 
9 (3, 17) 2.3 
(0.6, 9.4) 
7.7 / 0.0 / 2.6 -2.2 
(-13.4, 8.9) 
100.0 81.3 
(62.1, 100.4) 
HBoV-1 46  39.1 / 
15.2 
2.0 
(-14.8,18.8) 
9 (5, 14 2.0 
(0.1, 7.9) 
26.1 / 2.2 / 0.0 13.6 
(-0.3, 27.5) 
58.3 39.6 
(5.8, 76.4) 
aDetected in nasal swabs collected weekly by parents. bMutually exclusive hierarchical classification of ARI episodes (LRTI>URTI). cMedian difference of ARI 
episode duration calculated by quantile regression technique. dMedical visits were not mutually exclusive categories as an infant may have more than one 
medical encounter in different settings during a single ARI episode. eMedical visits and antibiotic information were derived from the ARI burden diary triggered 
in 223/233 (95.7%) eligible recorded ARI episodes. 
Abbreviations: HAdV, human adenovirus; ARI, acute respiratory infection; asym, asymptomatic; ED, Emergency Department; FP, family physician; HBoV-1, 
human bocavirus-1; HCoV, human coronavirus; HMPV, human metapneumovirus; HPyV, human polyomavirus; HRV, human rhinovirus; INFV, influenza virus; 
IQR, interquartile range; LRTI, lower respiratory tract infection; No., number; PIV, parainfluenza virus; ref, reference; RSV, respiratory syncytial virus; URTI, 
upper respiratory tract infection.  
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Table 24: Association between (i) single first detection of the DNA viruses, adenoviruses, human polyomaviruses KI and 
WU, and human bocavirus-1, and (ii) when other respiratory viruses were present at the time these DNA viruses were first 
detected; and respiratory symptoms. 
Virus Single first virus detection episode First virus detection episode with 
other respiratory viruses presenta 
Risk ratiob 
(95%CI) 
 Symptoms Asymptomatic  Symptoms Asymptomatic  
 n % n % n % n %  
HAdV (n=52) 17 58.6 12 41.4 19 82.6 4 17.4 0.71 (0.50, 1.02) 
HPyV-KI (n=55) 17 53.1 15 46.9 19 82.6 4 17.4 0.63 (0.43, 0.91) 
HPyV-WU (n=41) 9 42.9 12 57.1 12 60.0 8 40.0 0.77 (0.43, 1.43) 
HBoV-1 (n=73) 25 54.3 21 45.7 23 85.2 4 14.8 0.63 (0.48, 0.83) 
 
a HAdV: 20 first detections had one other virus present ( 16 HRV; 2 HCoV; 2 HPyV-WU) and three first detections had two other viruses present (HRV and 
HPyV-KI; 2 RSV and HPyV-KI).  
HPyV-KI: 21 first detections had one other virus present (14 HRV; 1 RSV; 3 HCoV; 2 HPyV-WU; 1 HBoV-1) and two first detections had two other co-
detected viruses (HRV and HAdV; HRV and HCoV). 
HPyV-WU: 19 first detections had one other virus present (10 HRV, 1 RSV, 1 PIV; 2 HCoV; 4 HPyV-KI) and one first detection had two other co-detected 
viruses (HRV and RSV). 
HBoV-1: 27 first detections had one other virus present (22 HRV, 1 RSV, 1 HCoV, 1 HPyV-KI, 2 HPyV-WU). 
b Risk ratio represents the relative risk of an infant developing ARI symptoms associated with a single fVDE by a DNA virus compared to an fVDE by the 
same DNA virus when other viruses are co-detected in the nasal swab specimen. 
Abbreviations: HAdV, human adenovirus; ARI, acute respiratory infection; fVDE, first virus detection episode; HBoV-1, human bocavirus-1; HCoV, human 
coronavirus; HPyV, human polyomavirus; HRV, human rhinovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus. 
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Factors associated with symptomatic first virus detection episodes 
After adjusting for potentially confounding variables, characteristics associated with 
symptomatic fVDEs included the winter season, as opposed to summer for HRV and spring 
and summer for HPyV, while age between 6-<12 months was identified for PIV-3. No 
sociodemographic or seasonal factors were identified for symptomatic fVDEs for the other 
respiratory viruses (Table 25–Table 29).
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Table 25: Association between selected participant characteristics and symptomatic first virus detection episodes for 
human rhinoviruses and respiratory syncytial viruses (n=9,594 swabs). 
Risk factor Human rhinoviruses Respiratory Syncytial Viruses 
N Symptomatic  
n (%) 
Unadjusted 
OR  
(95% CI) 
Adjusted 
ORa  
(95% CI) 
N Symptomatic 
n (%) 
Unadjusted 
OR  
(95% CI) 
Adjusted ORa 
(95% CI) 
Total cases 130 68 (52.3%)   54 42 (77.8%)   
Age (months)         
  0-<3 70 36 (51.4%) Reference Reference 3 2 (66.7%) 0.7 (0.1, 8.7) 1.4 (0.0, 64.3) 
  3-<6 40 18 (45.0%) 0.8 (0.4, 1.7) 0.7 (0.3, 1.7) 8 6 (75.0%) 1.0 (0.2, 6.3) 0.3 (0.0, 2.9) 
  6-<12 17 11 (64.7%) 1.7 (0.6, 5.2) 1.6 (0.5, 5.7) 19 16 (84.2%) 1.8 (0.4, 8.3) 2.2 (0.3, 17.2) 
  12-<24 3 3 (100.0%) n/c n/c 24 18 (75.0%) Reference Reference 
Sex         
  Male 62 29 (46.8%) Reference Reference 27 19 (70.4%) Reference Reference 
  Female 68 39 (57.4%) 1.5 (0.8, 3.1) 1.8 (0.8, 3.9) 27 23 (85.2%) 2.4 (0.6, 9.3) 2.5 (0.4, 13.7) 
Season         
  Winter 25 17 (68.0%) Reference Reference 13 10 (76.9%) Reference Reference 
  Spring 25 12 (48.0%) 0.4 (0.1, 1.4) 0.2 (0.1, 0.9) 4 3 (75%) 0.9 (0.1, 12.2) 1.9 (0.1, 42.7) 
  Summer 33 12 (36.4%) 0.3 (0.1, 0.8) 0.2 (0.1, 0.7) 10 8 (80.0%) 1.2 (0.2, 9.0) 0.4 (0.1, 6.1) 
  Fall 47 27 (57.4%) 0.6 (0.2, 1.76) 0.4 (0.1, 1.2) 27 21 (77.8%) 1.1 (0.2, 5.1) 0.6 (0.1, 4.5) 
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Risk factor Human rhinoviruses Respiratory Syncytial Viruses 
N Symptomatic  
n (%) 
Unadjusted 
OR (95% CI) 
Adjusted 
ORa (95% CI) 
N Symptomatic 
n (%) 
Unadjusted 
OR (95% CI) 
Adjusted ORa 
(95% CI) 
Total cases 130 68 (52.3%)   54 42 (77.8%)   
Breastfeeding         
Exclusively 
breastfed  
53 28 (52.8%) Reference Reference 22 14 (63.6%) Reference Reference 
<4 months/never  
breastfed 
Exclusively 
breastfed >4 
months 
76 39 (51.3%) 0.9 (0.5, 1.9) 1.0 (0.4, 2.3) 32 28 (87.5%) 4.0 (1.0, 15.6) 5.8 (1.0, 33.1) 
Childcare attendanceb        
  No childcare 40 22 (55.0%) Reference Reference 16 11 (68.8%) Reference Reference 
  Formal and/or 
informal 
childcare 
80 41 (51.3%) 0.9 (0.4, 1.8) 1.1 (0.5, 2.4) 37 30 (81.1%) 2.0 (0.5, 7.4) 2.4 (0.4, 13.8) 
No. children in 
household 
       
  No other 
children 
84 49 (58.3%) Reference Reference 32 22 (68.8%) Reference Reference 
  One/more 
children 
46 19 (41.3%) 0.5 (0.2, 1.0) 0.7 (0.3, 1.5) 22 20 (87.0%) 4.5 (0.9, 23.3) 4.7 (0.7, 32.9) 
aadjusted for age, sex, season, breastfeeding, childcare and number of siblings in household;  
bchildcare attendance at 12 months;  
Abbreviations: n/c: not calculable; OR: odds ratio; CI: confidence interval  
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Table 26: Association between selected participant characteristics and symptomatic first virus detection episodes for 
parainfluenza and influenza viruses. 
Risk factor Parainfluenza viruses Influenza viruses 
N Symptomatic  
n (%) 
Unadjusted OR 
(95% CI) 
Adjusted ORa 
(95% CI) 
N Symptomatic 
n (%) 
Unadjusted 
OR (95% CI) 
Adjusted 
ORa (95% 
CI) 
Total cases 52 37 (71.2%)   11 8 (72.7%)   
Age 
(months) 
        
  0-<3 7 4 (57.1%) 0.8 (0.1, 4.3) 0.5 (0.1, 4.7) 2 1 (50.0%) n/c n/c 
  3-<6 6 3 (50.0%) 0.6 (0.1, 3.5) 0.5 (0.1, 4.0) 1 1 (100%) n/c n/c 
  6-<12 17 16 (94.1%) 9.1 (1.1, 82.4) 14.0 (1.1, 181) 4 3 (75.0%) 0.3 (0.0, 11.9) n/c 
  12-<24 22 14 (63.6%) Reference Reference 4 3 (75.0%) Reference Reference 
Sex         
  Male 28 20 (71.4%) Reference Reference 4 3 (75.0%) Reference Reference 
  Female 24 17 (70.8%) 1.0 (0.3, 3.2) 1.7 (0.3, 8.8) 7 5 (71.4%) 0.8 (0.1, 13.6) n/c 
Season         
  Winter 8 7 (87.5%) Reference Reference 6 6 (100%) Reference Reference 
  Spring 29 19 (65.5%) 0.3 (0.0, 2.5) 0.2 (0.0, 4.3) 4 2 (50.0%) n/c n/c 
  Summer 12 8 (66.7%) 0.3 (0.0, 56.9) 0.5 (0.0, 12.0) 1 0 (0.0%) n/c n/c 
  Fall 3 3 (100.0%) n/c n/c 0 0 (0.0%) n/c n/c 
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Risk factor Parainfluenza viruses Influenza viruses 
N Symptomatic  
n (%) 
Unadjusted 
OR (95% CI) 
Adjusted ORa 
(95% CI) 
N Symptomatic 
n (%) 
Unadjusted 
OR (95% CI) 
Adjusted 
ORa (95% CI) 
Total cases 52 37 (71.2%)   11 8 (72.7%)   
Breastfeedin
g 
     
Exclusively 
breastfed  
21 16 (76.2%) Reference Reference 4 2 (50.0%) Reference Reference 
<4 months /never  
breastfed 
Exclusively 
breastfed >4 
months 
31 21 (67.7%) 1.1 (0.3, 3.8) 0.5 (0.1, 2.6) 7 6 (85.7%) 6.0 (0.3, 107.4) n/c 
Childcare attendanceb       
  No childcare 15 8 (53.3%) Reference Reference 3 2 (66.7%) Reference Reference 
  Formal 
and/or 
informal 
childcare 
36 28 (77.8%) 2.6 (0.7, 9.2) 4.3 (0.8, 24.1) 8 6 (75.0%) 1.5 (0.1, 26.9) n/c 
No. children in 
household 
       
  No other 
children 
34 24 (70.6%) Reference Reference 6 4 (66.7%) Reference Reference 
  One/more 
children 
18 13 (72.2%) 1.1 (0.3, 3.9) 0.6 (0.1, 3.3) 5 4 (80.0%) 2.0 (0.1, 32.0) n/c 
aadjusted for age, sex, season, breastfeeding, childcare and number of siblings in household;  
bchildcare attendance at 12 months;  
Abbreviations: n/c: not calculable due to small number of detections; OR: odds ratio; CI: confidence interval  
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Table 27: Association between selected participant characteristics and symptomatic first virus detection episodes for 
human metapneumoviruses and human coronaviruses. 
Risk factor Human metapneumovirus Human coronaviruses 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa  
(95% CI) 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa (95% CI) 
Total cases 18 15 (83.3%)   67 47 (70.1%)   
Age (months)         
  0-<3 1 1 (100.0%) n/c n/c 10 5 (50.0%) 0.4 (0.1, 1.8) 0.2 (0.0, 1.3) 
  3-<6 0 0 (0.0%) n/c n/c 6 3 (50.0%) 0.4 (0.1, 2.4) 0.4 (0.0, 3.2) 
  6-<12 9 8 (88.9%) 2.7 (0.2, 36.8) n/c 23 19 (82.6%) 1.9 (0.5, 7.4) 1.5 (0.3, 6.8) 
  12-<24 8 6 (75.0%) Reference Reference 28 20 (71.4%) Reference Reference 
Sex         
  Male 7 6 (85.7%) Reference Reference 28 18 (64.3%)  Reference Reference 
  Female 11 9 (81.8%) 0.8 (0.1, 10.2) n/c 39 29 (74.4%) 1.6 (0.6, 4.6) 2.4 (0.6, 8.7) 
Season         
  Winter 9 7 (71.4%) Reference Reference 32 26 (81.3%) Reference Reference 
  Spring 6 5 (83.3%)   1.4 (0.1, 20.4) n/c 17 10 (58.8%) 0.3 (0.1, 1.2) 0.4 (0.1, 1.6) 
  Summer 0 0 (0.0%) n/c n/c 9 5 (55.6%) 0.3 (0.1, 1.4) 0.2 (0.0, 1.3) 
  Fall 3 3 (100.0%) n/c n/c 9 6 (66.7%) 0.5 (0.3, 2.4) 0.5 (0.1, 4.3) 
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Risk factor Human metapneumovirus Human coronaviruses 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa  
(95% CI) 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa (95% CI) 
Total cases 18 15 (83.3%)   67 47 (70.1%)   
Breastfeeding        
Exclusively 
breastfed  
4 2 (50.0%) Reference Reference 30 20 (66.7%) Reference Reference 
<4 months /never breastfed 
Exclusively 
breastfed >4 
months 
13 12 (92.3%) 12 (0.7, 203.1) n/c 37 27 (73.0%) 1.3 (0.5, 3.8) 0.9 (0.3, 3.2) 
Childcare attendanceb        
  No childcare 3 2 (66.7%) Reference Reference 40 25 (62.5%) Reference Reference 
  Formal 
and/or informal 
childcare 
14 12 (85.7%) 3.0 (0.2, 50.8) n/c 27 22 (81.5%) 1.7 (0.6, 5.2) 3.0 (0.7, 
12.2) 
No. children in household        
  No other 
children 
10 9 (90.0%) Reference Reference 40 26 (65.0%) Reference Reference 
  One/more 
children 
8 6 (75.0%) 0.3 (0.0, 4.5) n/c 27 21 (77.8%) 1.9 (0.6, 5.8) 2.1 (0.3, 7.3) 
aadjusted for age, sex, season, breastfeeding, childcare and number of siblings in household;  
bchildcare attendance at 12 months;  
Abbreviations: n/c: not calculable due to small number of detections; OR: odds ratio; CI: confidence interval 
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Table 28: Association between selected participant characteristics and symptomatic first virus detection episodes for 
human adenovirus and human polyomaviruses. 
Risk factor Human adenoviruses Human polyomaviruses 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa (95% 
CI) 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa (95% CI) 
Total cases 52 36 (69.2%)   70 40 (57.1%)   
Age (months)         
  0-<3 0 0 n/c n/c 0 0 (0.0%) n/c n/c 
  3-<6 9 4 (44.4%) 0.5 (0.1, 2.3) n/c 8 2 (25.0%) 0.2 (0.0, 1.0) 0.1 (0.0, 0.9) 
  6-<12 24 20 (83.3%) 2.9 (0.7, 12.1) n/c 35 20 (57.1%) 0.7 (0.2, 1.9) 0.4 (0.1, 1.3) 
  12-<24 19 12 (63.2%) Reference Reference 27 18 (66.7%) Reference Reference 
Sex         
  Male 24 15 (62.5%) Reference Reference 32 19 (59.4%) Reference Reference 
  Female 28 21 (75.0%) 1.8 (0.5, 5.9) n/c 38 21 (55.3%) 0.8 (0.3, 2.2) 1.5 (0.4, 3.9) 
Season         
  Winter 23 14 (60.9%) Reference Reference 17 14 (82.4%) Reference Reference 
  Spring 10 7 (70.0%) 1.5 (0.3, 7.4) n/c 28 13 (46.4%) 0.2 (0.0, 0.8) 0.1 (0.0, 0.6) 
  Summer 6 4 (66.7%) 1.3 (0.2, 8.5) n/c 15 6 (40.0%) 0.1 (0.0, 0.7) 0.1 (0.0, 0.7) 
  Fall 13 11 (84.6%) 3.5 (0.6, 19.8) n/c 10 7 (70.0%) 0.5 (0.1, 3.1) 0.4 (0.1, 3.1) 
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Risk factor Human adenoviruses Human polyomaviruses 
N Symptomatic  
n (%) 
Unadjusted 
OR 
(95% CI) 
Adjusted 
ORa  
(95% CI) 
N Symptomatic  
n (%) 
Unadjusted OR 
(95% CI) 
Adjusted 
ORa (95% CI) 
Total cases 52 36 (69.2%)   70 40 (57.1%)   
Breastfeeding        
Exclusively 
breastfed  
24 16 (66.7%) Reference Reference 31 19 (61.3%) Reference Reference 
<4 months /never breastfed 
Exclusively 
breastfed >4 
months 
28 20 (71.4%) 1.3 (0.4, 4.1) n/c 39 21 (53.8%) 0.7 (0.3, 1.9) 0.4 (0.1, 1.4) 
Childcare attendanceb        
  No childcare 17 10 (61.9%) Reference Reference 21 10 (47.6%) Reference Reference 
  Formal and/or 
informal childcare 
34 25 (74.2%) 1.9 (0.6, 6.7) n/c 48 30 (62.5%) 1.8 (0.7, 5.2) 2.5 (0.7, 8.7) 
No. children in 
household 
       
  No other 
children 
30 23 (76.7%) Reference Reference 52 28 (53.8%) Reference Reference 
  One/more 
children 
22 13 (59.1%) 0.4 (0.1, 1.5) n/c 18 12 (66.7%) 1.7 (0.6, 5.3) 2.3 (0.6, 8.7) 
aadjusted for age, sex, season, breastfeeding, childcare and number of siblings in household;  
bchildcare attendance at 12 months;  
Abbreviations: n/c: not calculable due to small number of detections; OR: odds ratio; CI: confidence interval  
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Table 29: Association between participant characteristics and symptomatic first virus detection episodes for human 
bocavirus-1. 
Risk factor Human bocavirus-1 
N Symptomatic  
n (%) 
Unadjusted OR 
(95% CI) 
Adjusted ORa  
(95% CI) 
Total cases 73 48 (65.8%)   
Age (months)     
  0-<3 1 0 (0.0%) n/c n/c 
  3-<6 5 2 (40.0%) 0.2 (0.0, 1.6) 0.1 (0.0, 1.4) 
  6-<12 39 25 (64.1%) 0.6 (0.2, 1.7) 0.5 (0.2, 1.6) 
  12-<24 28 21 (75.0%) Reference Reference 
Sex     
  Male 31 22 (71.0%) Reference Reference 
  Female 42 26 (61.9%) 0.7 (0.2, 1.8) 0.7 (0.3, 2.2) 
Season     
  Winter 37 26 (70.3%) Reference Reference 
  Spring 11 8 (72.7%) 1.1 (0.3, 5.1) 1.5 (0.3, 7.8) 
  Summer 8 4 (50.0%) 0.4 (0.1, 2.0) 0.9 (0.1, 5.6) 
  Fall 17 10 (58.8%) 0.6 (0.2, 2.0) 0.7 (0.2, 2.6) 
Breastfeeding    
Exclusively breastfed 30 18 (60.0%) Reference Reference 
<4 months /never breastfed 
Exclusively breastfed 
 >4 months 
43 30 (69.8%) 1.5 (0.6, 4.1) 1.3 (0.5, 3.9) 
Childcare attendanceb     
  No childcare 22 13 (59.1%) Reference Reference 
  Formal and/or informal 
childcare 
51 35 (68.6%) 1.5 (0.5, 4.3) 1.9 (0.6, 6.2) 
No. children in household     
  No other children 52 36 (69.2%) Reference Reference 
  One/more other children 21 12 (57.1%) 0.6 (0.2, 1.7) 0.6 (0.2, 2.1) 
aadjusted for age, sex, season, breastfeeding, childcare and number of siblings in household; bchildcare attendance at 12 months; 
Abbreviations: n/c: not calculable due to small number of detections; OR: odds ratio; CI: confidence interval. 
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DISCUSSION 
In this community cohort of healthy Australian children, we detected respiratory viruses early 
in life, with HRV playing a dominant role from birth, and other viruses detected generally 
after six months of age. Although only about half of the HRV fVDEs were associated with 
respiratory symptoms, 70-83% of fVDEs with other respiratory RNA viruses were 
symptomatic. While 57-69% of fVDEs with HAdV, HPyV KI/WU and HBoV-1 DNA viruses 
had symptoms, this decreased to 43-59% when these were the sole detected agents. High 
viral loads for RSV and HBoV-1 were associated with symptoms, but shedding duration was 
independent of symptom status. Overall, RSV and HMPV fVDEs were most likely to be 
associated with LRTIs and to result in medical visits where antibiotics were commonly 
prescribed irrespective of the virus or viruses detected around the time of presentation. The 
winter season was an independent risk factor for symptomatic HRV and HPyV fVDEs, and 
age >6 months was a risk factor for symptomatic PIV fVDEs. No risk factors were identified 
for other common viruses. 
First respiratory virus infections are believed to be almost invariably symptomatic and, in the 
case of RSV, to result in more severe disease because of the infant’s immature immune 
system and small airways, with re-infections thought to have a lower risk of illness (74, 308). 
Our data show that during their fVDEs children do not always experience respiratory 
symptoms. The cumulative proportion of children in our cohort with fVDEs from viruses other 
than HRV increased steadily after age six months. The delayed appearance of these other 
viruses may be from the protective effects of maternal antibodies and reduced exposure, as 
attendance at childcare centres is less common in this age group (6, 310).  
Our findings differ from the Houston Family study, which relying heavily upon serology, 
reported 68% of infants had RSV by age 12 months and virtually all were infected by their 
second birthday. However, studies from Asia, Europe and Latin America observed RSV 
seroprevalence rates of 36-70% by age two years (75-77, 311, 312), while in Kenya a birth 
cohort project similar in design to the Houston study found 73% had RSV by two years of 
age (79). These results are more in keeping with our own and possible explanations for our 
lower incidence of RSV fVDEs during the first two years of life than in the Houston study 
include variations in intensity and duration of seasonal exposure (313), fewer subjects with 
older siblings to introduce RSV into the household (79, 314), and relying upon PCR rather 
than serology to detect the virus. The Houston study also enrolled families that lived 
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throughout the metropolitan area and were representative of low income groups (315), in 
contrast to the ORChID cohort. 
Hospital-based studies are skewed towards those with the most severe infections and 
represent <5% of the infant population (269). While RSV predominates in hospitalised 
infants aged <6 months with LRTIs, HRV is the most common virus detected in older infants 
and young children admitted with wheezing illnesses, which are often recurrent and 
associated with a subsequent increased risk of asthma (123, 124, 307, 316). In contrast, 
community-based studies like our own find symptomatic fVDEs with HRV occurring by age 
4-6 months, and with RSV and other viruses appearing on average beyond this age (2, 79, 
226). Viruses such as RSV, PIV, INFV and HMPV are more likely than other viruses to be 
associated with respiratory symptoms (22), and consequently, although less commonly 
exposed to these viruses than HRV at a young age, it is thought that young infants 
hospitalised with more severe disease have pre-existing smaller airways, immature immune 
systems and/or are lacking protective maternal antibodies (15, 317). As these infants 
become older and their airways grow and immune systems mature, the symptoms of 
infections by these other viruses lessen (74, 79).  
While wheezing illnesses following early exposure to HRV are associated with a greater 
likelihood of developing asthma in high-risk cohorts (123, 124, 307), the role of early 
asymptomatic HRV infections has received less attention. A recent report suggested that 
HRV detection in the first four weeks of life, even if asymptomatic, may help program 
immune memory with an exaggerated Th2 (rather than Th1) mucosal immune response and 
impaired anti-viral responses (291). This suggests a potential pathway for the later 
development of asthma and allergic sensitization in susceptible individuals. If true, 
interventions seeking to reduce HRV infections in high-risk infants will need to be introduced 
early. Although maternal vaccines to protect infants from early respiratory virus infections is 
an active area of research, especially for RSV and influenza viruses (310), our study 
emphasises the predominance of early HRV detections, the long-term effects of which 
remain uncertain in healthy infants. It also highlights that for many in our study population, 
their first infection from non-HRV viruses occurs at an age when maternal vaccines may no 
longer be protective (310).  
The fVDEs by DNA viruses were significantly more likely than RNA viruses to have additional 
viruses co-detected during this episode. In part, this might be explained by most HRV fVDEs 
occurring during the first six months of life where other viruses were detected uncommonly. 
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When sole fVDEs by these DNA viruses were examined they were found to be similar to 
HRV fVDEs in that about 50% of episodes were associated with symptoms, although 
symptomatic episodes with HPyV and HBoV-1 were significantly more prolonged than those 
associated with HRV. These findings indicate that while common, these viruses often cause 
mild or no ARI symptoms, even after a fVDE (22, 202, 301). Interestingly, HBoV-1 viral load 
was associated with the presence of ARI symptoms, a metric along with HBoV-1 capsid 
mRNA that has been reported previously to be associated with disease severity (202). 
The ORChID cohort spanned multiple seasons and its strengths include the comprehensive 
surveillance provided by regular weekly nasal swab collections and daily symptom diary 
recordings by parents. The return rate of 68% of expected swab is noteworthy given the 
project’s intensive and prolonged nature. Potential limitations include parents missing very 
mild symptoms. However, we minimised reporting inaccuracy by training parents on 
symptom recognition and diary completion before they commenced the study and included 
only doctor-diagnosed episodes of otitis media and pneumonia (6). This study design has 
been used successfully before where parents were trained to recognize respiratory 
symptoms (256). Another limitation is parents having a suboptimal nasal swabbing 
technique (249). However, sensitive molecular detection methods combined with mailed 
parent-collected nasal swabs provide comparable results with nasopharyngeal swabs 
collected by health professionals (246, 256, 318). For logistical reasons we did not include 
other respiratory viruses, such as INFV-C or PIV-4, in our assays, although 17 viruses still 
provide a comprehensive survey of early life exposures. Additionally, 29% of HRV-positive 
specimens were unable to be typed, mainly due to low viral loads, a finding comparable with 
other community-based cohort studies (150). We may have under-estimated virus shedding 
duration because of missing swabs or swabs being collected only weekly. Similarly, 
ascribing symptoms to viruses when swab collection was not always done weekly or if other 
viruses were detected during the fVDE could compromise accuracy, although sub-analyses 
of sole fVDEs were reassuring. It is also likely we were unable to identify risk factors 
associated with symptomatic non-HRV fVDEs because of a lack of power, as numbers for 
some sub-categories were small. As is common with cohort studies, our families were from 
more advantaged backgrounds, but our findings for infections rates, such as RSV, 
approximate recent studies (79, 308, 312) and provide an insight into respiratory viruses 
affecting children from a developed country in a subtropical, urban setting.  
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In conclusion, respiratory viruses are detected early in life, with HRV playing a dominant role 
from birth. The onset of fVDEs for other respiratory viruses increased after age six months, 
with RSV and HMPV having the more severe symptoms, but identifiable sociodemographic 
and seasonal factors were not consistently associated with symptomatic fVDEs in our 
cohort. Whether early fVDEs, particularly from HRV, are important or preventable and have 
adverse long-term effects on some individuals warrants further study.  
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Chapter 7 – General Discussion and Conclusions 
 
Summary of findings 
For my PhD I undertook analysis of data collected from the ORChID cohort study. The 
findings presented in Chapters 3–6 offer insights into respiratory virus epidemiology and 
respiratory illness in a community cohort of healthy Australian infants and young children less 
than two years of age from the subtropical urban environment of the city of Brisbane. 
My work has resulted in four chapters in the form of published papers. The key findings, as 
they relate to the hypotheses outlined in Chapter 1, are: 
a) ARIs are a frequent and common cause of early childhood morbidity in the community. 
They are, for the most part, mild illnesses with few hospitalisations. However, almost 
50% of ARI episodes lead to primary care consultations when they involve more than 
simple nasal discharge or congestion, or an isolated dry cough. 
b) Diverse respiratory virus species are detected from a very early age. HRV detections 
dominate throughout, but especially in the first six months of life. Despite their 
dominance, only 34% of HRV detections were associated with symptoms. While my 
typing studies were limited to the neonatal period, diverse HRV genotypes were 
identified, with serial detections often reflecting sequential infections with new HRV 
strains. 
c) Several RNA viruses, including various HRV, INFV, PIV, RSV, HMPV, and HCoV 
species and subtypes, were associated with an increased risk of ARI symptoms when 
found in respiratory secretions of an infant. Support for causality was strongest for 
RSV and HMPV in children with LRTIs. Of the three HRV species, HRV-C was 
associated with an increased risk of LRTIs. 
d) Contrary to the view that first infections with viruses are almost always symptomatic, 
particularly with RSV (74), and more likely to result in more severe disease and 
therefore to require medical care, first detections of respiratory viruses did not always 
result in illness. HRV fVDEs were detected early (median of 2.9 months of age), in 
contrast with all other respiratory viruses, which were first detected later (median >13.9 
months). 
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What this research adds 
In the last two decades, several prospective studies have been conducted in cohorts of both 
healthy infants and young children, and in infants deemed to be at high risk of asthma and/or 
atopy. These studies have sought to examine the contribution of individual respiratory 
viruses to respiratory illness using molecular testing techniques. While several new human 
viruses have been discovered in patients with respiratory illness, they and other respiratory 
viruses have also been detected in asymptomatic subjects. The lack of well-designed 
longitudinal epidemiological studies in healthy community cohorts has meant the clinical 
significance of these detections remains unclear. The frequent detection of HRV in 
respiratory specimens without subsequent sequence-based typing to distinguish between 
species and genotypes has made the aetiology of HRV difficult to ascertain. The role of 
HRV-C species in LRTI and wheezing illness has also been the subject of ongoing debate.  
The ORChID study findings provide a wealth of information about the relationship between 
respiratory virus infection and symptoms of respiratory illness. The study builds on historic 
community-based studies of respiratory virus epidemiology, which established the 
conceptual framework for the community epidemiology of respiratory virus infection. 
However, the ORChID study uses modern molecular-based techniques over four respiratory 
seasons to address questions about respiratory virus acquisition and infection, the only study 
reported to date to sample intensively over this length of time in a healthy cohort. 
The ORChID data highlight the differences in epidemiological profiles displayed by hospital 
and community cohorts, and the risk of extrapolating hospital-based data to the community 
setting. Hospital-based studies are skewed towards those with the most severe disease and 
represent a minority of infants and infections. In contrast to hospitalised cohorts, HRVs are 
the predominant viruses circulating in the community and infants are exposed to the virus in 
the first few weeks of life. Fortunately, most illnesses are mild, and although HRVs do not 
play a large attributable role for ARIs, they are nevertheless major contributors to respiratory 
illness burden because of their greater prevalence. 
In contrast, studies have reported that RSV, and to a much lesser extent, seasonal INFV, 
are the most common reasons for infants to be hospitalised in the first year of life (70, 71, 
89). RSV is considered to be more virulent than HRV as detection of RSV in young children 
is more likely to be associated with respiratory symptoms, as observed in other studies (22), 
and from our own observations (319). Although less commonly exposed to RSV than HRV, 
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it is thought that otherwise well infants hospitalised with RSV have more severe disease and 
represent a subset with pre-existing smaller airways, immature immune systems, and/or lack 
protective maternal antibodies (15, 317). As infants and young children become older and 
their airways grow and immune systems mature the symptoms of initial RSV infection lessen.  
Studies in community-based, high-risk cohorts, however, have shown that HRV is the 
predominant virus in the first year of life associated with wheezing illness (2, 120, 121). In 
hospital-based studies, infants hospitalised with HRV-associated wheezing or LRTIs are 
older and are more likely to have a prior history of wheezing (320). HRV is the most common 
virus detected in older infants and young children admitted with wheezing illnesses. These 
infections are often recurrent and associated with a subsequent increased risk of asthma 
(122), (123, 124, 307, 316).  
The ORChID data analysis also underlines the early and frequent interaction of diverse 
HRVs (symptomatic and asymptomatic) at a time when the immune system is not fully 
developed. HRVs are known to alter innate immune responses, and have been suggested 
as contributing to more severe disease in asthmatics and those genetically predisposed to 
allergic phenotypes (321, 322). These impaired innate immune responses to HRV may 
increase susceptibility to HRV-induced wheezing and asthma (321). A recent study of the 
Danish asthma birth cohort (COPSAC2010) showed that HRV infection in the first four weeks 
of life, even if asymptomatic, induced an exaggerated type-2 mucosal immune response in 
some infected neonates (291). Asymptomatic presence of HRVs in the neonatal airway was 
a potent activator of the local mucosal immune response. Thus, early HRV exposure may 
trigger aberrant immune programming in susceptible individuals and promote subsequent 
development of asthma and allergic sensitisation (124, 291). It has been suggested HRVs 
play a role as early life ‘educators’ of the immune system in healthy children through normal 
virus-host interactions, which in atopic children take on the role of a ‘miseducator’ (323).  
Finally, the ORChID study findings show that, while relatively common (319), the frequency 
of RSV infection in early life is also less than identified in some previous studies. The seminal 
Houston study showed 97% of children had culture or serological evidence of at least one 
RSV infection by the same age (74). Subsequently, most serologically-based studies have 
not been able to replicate such high levels of RSV infection in the first two years of life. While 
most show high seroprevalence by the age of three years, many have had methodological 
limitations (small numbers, cross-sectional design), differences in age categories, and 
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seasonal variations in the incidence of RSV infection. The most robust of these studies and 
similar in design to the Houston study was the community study conducted in Kenya, which 
recorded 73% of children with serological evidence of prior RSV infection by the age of two 
years (79).  
The ORChID study findings are more in keeping with other recent studies (75-77, 79, 311, 
312) showing a lesser likelihood of RSV infection early in childhood. There are several 
reasons for this finding, including population, geographic, temporal, sociodemographic, and 
technical factors. The use of weekly PCR instead of serology may have missed some 
infections. However, the median age at first detection in our cohort was at 19.4 months (25th 
centile 11.2 months), and by 24 months of age, only 58% of the cohort had experienced a 
first RSV infection. Variations in intensity and duration of seasonal exposure (313) may also 
have resulted in a lower incidence of RSV fVDEs than observed in the Houston study. RSV 
activity varies in severity from year to year. In cities like Houston with high annual rainfall, 
activity can be prolonged (324). Queensland Health data show in the two years involving 
2012 and 2013, the mid-point period of the study, RSV activity in South-east Queensland 
was below average (https://www.health.qld.gov.au/clinical-practice/guidelines-
procedures/diseases-infection/surveillance/reports/flu).  
In addition, 67% of children in our cohort were first born and thus were less likely to have 
older siblings to transmit RSV into the household in the first few months before attending 
childcare (79, 325). Cohort subjects also had low exposure to environmental tobacco smoke, 
including maternal smoking during pregnancy and while breastfeeding and less crowded 
households, factors known to be associated with hospitalisation (308). Further community-
based studies in cohorts of low socioeconomic status and high disadvantage, in high-risk 
groups such as Indigenous populations, are warranted to examine if symptomatology in 
these groups is more frequent or severe than urban infants from small families.  
However, if these findings are confirmed in other studies, the ‘delayed’ appearance of first 
RSV infections in our study has important implications for immunisation strategies such as 
antenatal maternal immunisation. Less than 10% of the ORChID cohort experienced an RSV 
first infection by the age of six months, an age after whichpassive maternal antibodies may 
no longer be protective. Thus, while an antenatal RSV vaccine may reduce the 
hospitalisation rate of RSV infections in infants in the first few months of life (of which only 
~2% are hospitalised in the first year of life), it may not have as great an impact upon the 
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community burden of RSV infection. . 
It is also pertinent to place the ORChID study in a broader context with other longitudinal 
studies conducted in non-atopic/allergic populations at high risk of ARIs. Similar to the 
ORChID study, a study in healthy Aboriginal and non-Aboriginal children (326), as well as a 
study conducted among children with LRTI of similar age in the PNG highlands (327), both 
employing sensitive molecular techniques, identified a diversity of respiratory viruses in the 
first two years of life, with early dominance by HRV. The Kalgoorlie study also showed 
sequential infections were a result of HRV serotype replacement, similar to what we have 
noted with sequential HRV positive specimens during the neonatal period.  
However, in contrast to the ORChID study, where HRV-C was associated with LRTI 
symptoms, the Kalgoorlie study found HRV-C was associated with upper respiratory 
symptoms in all children. HRV of any individual species was also not associated with LRTI 
in the PNG study (327). Instead, LRTI was associated with detection of the DNA viruses 
adenovirus B and C, influenza A, and RSV. HRV-A and HRV-C were also associated with 
carriage of respiratory bacteria (326). Respiratory viruses, including HRV, have been shown 
to exacerbate nasopharyngeal bacterial load in another birth cohort study in Aboriginal 
children in the Northern Territory (13). 
As well as differences in viral aetiology, there were also differences in the seasonality of 
virus circulation, and other environmental and social risk factors. HRV-A was found to be 
more common in summer in Aboriginal children, thought to be due to increased social 
interaction (326). In non-Aboriginal children, childcare attendance and exclusive 
breastfeeding at age 6-8 weeks were associated with the detection of HRV-A. Gestational 
smoking was positively associated with HRV-C detection among non-Aboriginal but not 
Aboriginal children. A decreased risk of HRV detection was associated with larger non-
Aboriginal households. These findings suggest that further community studies are warranted 
in diverse settings to gain a greater understanding of the mechanistic role of respiratory 
viruses in early childhood, including modulation of viral load and frequency from seasonal 
and environmental factors, and their interaction with respiratory bacteria in these 
environments. 
Strengths 
Notable features of the ORChID study design included the relatively large size, being 
community based, enrolment from birth, and prospective intensive specimen sampling and 
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symptom data collection irrespective of illness. This last feature allowed assessment of 
asymptomatic status with consideration of past and future illness history. This has in turn 
enabled the calculation of a population-level attributable fraction for individual respiratory 
viruses in healthy children (Chapter 5). 
Recruitment over two years and data collection over four years accounted for seasonality and 
year-to-year variability in respiratory virus circulation within the community. An extensive 
panel of real-time PCR assays was used, with sequencing to species level able to be 
performed on 73% of HRV-positive swabs, a proportion comparable with other community-
based studies (118, 145, 150).  
Parental participation in obtaining regular nasal swabs avoided the need for home visits by 
research staff or clinic attendance during an ARI. The requirement for home visits by 
research staff in other studies may have led to a loss of families or incomplete specimen 
collection during ARIs, potentially resulting in biased estimates of ARI events and specimen 
availability. The sensitivity of this method of collection was compared in some of our previous 
work, which found that parent-collected nose or nose-throat swabs sent to the laboratory by 
regular mail had comparable sensitivity to nasopharyngeal swabs obtained by healthcare 
workers (256). 
These attributes of the ORChID study design have several advantages that cross-sectional 
study designs cannot address. The community-based design has captured the non-
hospitalised disease burden in young children and allowed for more accurate estimates of the 
burden of community ARI. Recruitment through GP clinics alone would have underestimated 
disease burden by more than a factor of three. 
Limitations 
The ORChID cohort study design also presented some challenges. Given the size of the 
study, the decision to involve parents in the data collection process was made for 
methodological, logistical, and cost considerations. A study of this magnitude would have 
been cost intensive had we employed research staff to collect information on every ARI and 
undertake visits on a weekly basis. Specimen quality resulting from poor swabbing technique 
and accuracy in recognising respiratory symptoms were large considerations in this study. 
We tried to minimise these limitations by training parents at the beginning of the study, which 
has been shown to be successful in other settings (284, 285). 
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The symptom card used in the ORChID study was one modified from a previous study on 
seasonal INFV vaccine effectiveness and used in another cohort study successfully in 
Melbourne (3). It included both respiratory and systemic signs and symptoms, intended to 
capture INFV-like symptoms in older children. We restricted the ARI definition to include only 
respiratory symptoms in these analyses, given the age of the children, to increase reliability. 
Symptom information, other than doctor-diagnosed AOM and pneumonia, captured by daily 
diaries was not validated. We tried to minimise inaccuracy of reporting by training parents 
how to recognise symptoms and complete the diary before they commenced the study. A 
parental questionnaire such as the Canadian Acute Respiratory Flu Scale has been available 
since the beginning of this century, but they are not suitable for home-based parent collection 
on a recurring basis (328). There is a need for a simple, recurrent, validated tool for the 
collection of respiratory illness symptoms in children.  
Besides controlling for specimen quality at the beginning of the study, we also incorporated 
internal controls for the amount of human DNA present on nasal swabs. Low or absent levels 
indicated poor quality samples taken with a sub-optimal swabbing technique containing few 
host epithelial cells, resulting in a decreased odds of detecting viruses (249). Parents were 
also contacted when specimens of poor quality were observed. We reinforced good 
swabbing techniques with additional instructions on these occasions. We may also have 
underestimated virus shedding duration because of missing swabs or swabs being collected 
only weekly.  
Analysis of ERV-3 positive and respiratory virus positive specimens showed that ERV-3 
positive sample rates increased with age and varied by season (249), with ERV-3 positive 
rates in the first six months of age as a reference. It is possible, therefore, that swab quality 
was not as good as when children were first recruited compared to later, and this might bias 
identification of virus versus another. 
As mentioned earlier, 27% of sequences from HRV detections either failed to align with HRV 
reference prototype sequences or could not be typed to species level. These combined 
limitations would result in a ‘minimum estimate’ and an under-estimation of species-specific 
incidence rates. Furthermore, some viruses, such as INFV, HMPV, and some PIVs, were 
detected in small numbers in this cohort limiting the ability to draw conclusions about these 
viruses in the community, and so, interpretation of results has been much more circumspect 
given relatively small numbers. 
158 
 
My analysis also excluded co-detections in individual virus assessments as multiple 
aetiological agents make individual contributions of each agent difficult to ascertain. Instead, 
I analysed viruses separately to look at the association patterns of individual viruses. 
However, multiple respiratory viruses do co-circulate at any one time and a comprehensive 
metagenomics study in the future that includes the respiratory virome will need to take into 
consideration multiple concurrent virus-virus, virus-bacteria, and virus-host interactions. We 
also observed arbitrary rules when assigning illness duration with mixed detections. 
Finally, as is common for these types of studies, families in the ORChID cohort were from 
more advantaged backgrounds. Longitudinal cohort studies of this intensity and duration are 
often over-represented with households from higher income brackets (2, 230). Recruitment 
of families with lower than average mean household income presents a challenge for 
researchers with this study design. Targeting recruitment efforts in the Melbourne study to 
lower socioeconomic areas (3) did not significantly improve representation from low income 
households. However, the effect of families with higher socioeconomic status can be 
complex. While these factors are thought to decrease the rate of ARIs, secular changes in 
Australia have led to an increased proportion of children from these families attending 
childcare at an earlier age than other sectors of the population. The majority of children in 
the ORChID study were first born (67%) compared to 41% of families with one child in the 
Brisbane urban area recorded in the 2011 Census (329), and this would impact on the rate 
of ARI in children in the household. Like other studies, we have shown the presence of 
siblings to be a risk determinant for ARIs (47).  
Clinical implications 
The development of more sensitive, specific, and rapid assays of respiratory specimens is 
increasingly being used in the diagnosis and clinical management of patients. Methods such 
as MassTag PCR have been developed for differential diagnosis of respiratory infections 
(330), where multiplex primer sets were designed to identify up to 22 respiratory pathogens 
in a single reaction. Assay kits will allow for rapid screening and are more likely to be used 
in the future as antiviral therapies become available. While vaccines have only been 
developed against INFV so far, there are good prospects of an imminent vaccine against 
RSV, currently entering Phase II trials (331), and vaccines in development against several 
other respiratory viruses (300). Rapid identification of the aetiological cause of an ARI could 
improve patient management and antibiotic stewardship. Timely detection of viral pathogens 
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by PCR would reduce the risk of unnecessary antibiotic use in those with a compatible 
clinical illness. 
However, the use of PCR to test swabs taken during symptomatic and asymptomatic periods 
in the ORChID study has increased the appreciation of a wide clinical spectrum of respiratory 
virus impact, ranging from subclinical infections to mild to severe infections requiring 
hospitalisation. Calculations of the attributable fraction have highlighted the relative 
importance of RSV, HMPV, and PIV, in LRTIs in children in the community. While recent 
molecular detection assays using multiplex quantitative RT-PCR have good sensitivity, 
negative predictive value, and have been optimised to detect a panel of respiratory viruses, 
findings from the ORChID study challenge the notion of specificity and positive predictive 
value for some viruses with high rates of asymptomatic detection, such as HRV and HAdV. 
Attempts to link viruses with clinical disease are confronted by the high rates of recovery 
from asymptomatic individuals for some viruses, as well as concurrent viral infections in 
some specimens. Distinguishing incidental and unrelated asymptomatic viral shedding from 
symptomatic disease due to the virus will require other methods of analysis such as querying 
the host response (see ‘Future research’, page 162). 
Public health implications 
Quantitative estimates of the relative proportion of virus-associated ARIs in the community 
yield important insights for prioritising public health interventions. The strong association 
of RSV and HMPV with LRTIs in young children managed within the community indicates 
successful development of vaccines against these two viruses should provide substantial 
health benefits. Findings on the timing of first VDEs of individual viruses are important in 
identifying at-risk groups and determining the optimal timing of maternal and infant 
immunisation strategies. Evidence from this thesis shows that, along with other data on 
burden and healthcare costs, virus-specific data are required to populate models for the cost 
effectiveness of any potential therapeutic treatment or vaccine to be considered.  
The high prevalence of HRV compared with other respiratory viruses, and its possible role 
in immunological programming and asthma in susceptible individuals, presents a challenge 
when developing an HRV vaccine, particularly with multiple genotypes and little evidence of 
cross-protective immunity between genotypes. 
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Future research 
Emerging evidence indicates infections early in life, along with other environmental insults 
to developing airways in susceptible children, may contribute to later development of chronic 
respiratory conditions such as asthma in childhood and COPD in adults (18, 19, 332-334). 
Children who participated in the ORChID study have been enrolled in a follow-on study (the 
Early Life Lung Function Study) exploring the impact of respiratory viral infections in the first 
two years of life and respiratory health in later childhood (3–7 years of age) as measured by 
lung function measurements. The relative impact and role of each of the viral pathogens 
tested, the frequency of infection, and severity of illness will also be recorded. Additional 
studies will also examine the role of common respiratory bacterial pathogens (Streptococcus 
pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) and their interactions with 
the 17 respiratory viruses, including the effect of these interactions on airway epithelial cells 
ex vivo and upon their immune recognition in vivo. Outcomes from this research could inform 
interventions made at a critical time in lung development to attenuate or even prevent loss 
of lung function.  
Whether early fVDEs are important or preventable and have adverse long-term effects on 
some individuals warrants further study. The ORChID study findings have highlighted the 
extremely frequent interaction between HRV and the immature immune system. The concept 
of HRV as an early ‘educator’ of the immune system fits well with an emerging view that one 
of the key functions of the infant’s microbiome is education of the immune system. This is a 
growing area of research (335, 336). Greater understanding of the mechanistic role of 
viruses in early childhood in both healthy children and in those at risk of atopy/asthma would 
help inform public health strategies such as immunisation and identify at risk groups.  
Future studies need to examine not only the composition, but also the functioning, of complex 
microbial communities in the upper airways and their relationship to health and disease. 
Emerging evidence indicates that pathobiological processes such as bronchiolitis involve a 
complex interplay among viruses, airway microbiome, and host immunity (337-339), with the 
suggestion that microbiota form the mediator between early-life environmental risk factors 
for and susceptibility to LRTI over the first year of life (340). The ORChID study was not 
designed to specifically address these important questions, focusing as it did on viruses.  
Many aspects of HRV epidemiology, immunobiology, strain characterisation, and clinical 
impact remained poorly addressed. Few data have tracked strains from year-to-year, 
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reported if strains recur each year, if homotypic strains re-infect and if so, how long protective 
immunity lasts. There are no data that convincingly identify a distinct clinical outcome for any 
single HRV subtype, and whether some subtypes are more virulent than others (117). Many 
studies have detected some strains more or less frequently, but they do not seek all likely 
microbial causes or even span sufficient time to encompass commonly circulating HRV 
strains (117). The heterogeneity of HRVs hinders the significance of detecting the virus on 
clinical respiratory PCR panels, with the result that repeated detections cannot distinguish 
between reinfection with a new subtype versus prolonged shedding. 
There is also a current need for a validated, parent-collection tool for respiratory symptoms. 
The swabs used in this study, with the VTM-soaked sponge, are no longer manufactured. 
Flocked swabs for anterior nasal swabbing would be useful, but at present, no system free 
of frank liquid is available that would allow their transport through surface mail in Australia. 
Given the high background rate of PCR positivity in asymptomatic individuals, approaches 
to better define ‘infection’ or more appropriate analytical approaches have been proposed. 
One option to better define infection is to query the host response. Several groups have 
investigated host gene expression in peripheral blood leukocytes and shown differences in 
response to viral versus bacterial infection or in response to symptomatic versus 
asymptomatic infection (341, 342). Proteomics and metabolomics provide alternative paths 
for evaluating host response and interactions with local microbial communities. Evidence of 
active replication and transcription (188), or host gene expression assays and biomarkers of 
anti-viral responses to identify respiratory virus infections have also been explored (343). An 
approach that combines pathogen detection with characterisation of host response may yield 
a test or tests that could inform clinicians of the likelihood of a bacterial or mixed viral-
bacterial infection and the need to start antibiotic therapy. Clinicians could withhold 
antibiotics when bacterial infection was unlikely, lessening the overuse of antibiotics to treat 
viral respiratory infections (344). 
Finally, the ORChID study also captured information on time off work, missed childcare and 
missed activities. A future cost analysis will evaluate the economic and social impact of ARIs 
in these Australian families. 
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Conclusions 
Through analysis of the ORChID study data and by compilation of these publications and 
this thesis, I have made important, original contributions to understanding respiratory virus 
epidemiology in healthy children in the community. My work complements other research on 
respiratory illness in hospital and vulnerable populations, such as children with underlying 
chronic respiratory disorders. Future metagenomics studies linked with high density 
sampling of an ORChID-type study to determine the biological mechanisms of health and 
respiratory disease, and to identify diagnostic, therapeutic and vaccine targets, would be 
beneficial not only to the child and their family, but for future adult respiratory health and 
society.  
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Appendix 2: Koch’s modified postulates 
(i) A nucleic acid sequence belonging to a putative pathogen should be present in most 
cases of an infectious disease. Microbial nucleic acids should be found preferentially in 
those organs or gross anatomic sites known to be diseased (i.e., with anatomic, histologic, 
chemical, or clinical evidence of pathology) and not in those organs that lack pathology.  
(ii) Fewer, or no, copy numbers of pathogen-associated nucleic acid sequences should 
occur in hosts or tissues without disease.  
(iii) With resolution of disease (for example, with clinically effective treatment), the copy 
number of pathogen-associated nucleic acid sequences should decrease or become 
undetectable. With clinical relapse, the opposite should occur.  
(iv) When sequence detection predates disease, or sequence copy number correlates with 
severity of disease or pathology, the sequence-disease association is more likely to be a 
causal relationship. 
(v) The nature of the microorganism inferred from the available sequence should be 
consistent with the known biological characteristics of that group of organisms. When 
phenotypes (e.g., pathology, microbial morphology, and clinical features) are predicted by 
sequence-based phylogenetic relationships, the meaningfulness of the sequence is 
enhanced. 
(vi) Tissue-sequence correlates should be sought at the cellular level: efforts should be 
made to demonstrate specific in situ hybridization of microbial sequences to areas of tissue 
pathology and to visible microorganisms or to areas where microorganisms are presumed 
to be located. 
(vii) These sequence-based forms of evidence for microbial causation should be 
reproducible.” 
Reference: Fredricks DN and Relman DA. Sequence-based identification of microbial pathogens: a 
reconsideration of Koch’s postulates. Clinical Microbiology Reviews 1996;9:18-33
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